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functions  such  as motor  control,  reward  and  cognition.  In  the work  presented  here,  organotypic 
brain  slice  co‐cultures  of  (a)  the  mesostriatal  and  (b)  the  mesocortical  dopaminergic  projection 
systems  consisting  of  tissue  sections  of  the  ventral  tegmental  area/substantia  nigra  (VTA/SN),  in 
combination with  the  target  regions  of  (a)  the  striatum  (STR)  or  (b)  the  prefrontal  cortex  (PFC), 
respectively,  were  used  to  evaluate  different  approaches  to  stimulate  neurite  outgrowth: 
(i) inhibition of cAMP/cGMP turnover with 3’,5’ cyclic nucleotide phosphodiesterase inhibitors (PDE‐
Is), (ii) blockade of calcium currents with nimodipine, and (iii) the co‐cultivation with bone marrow‐
derived mesenchymal  stromal/stem  cells  (BM‐MSCs).  The neurite  growth‐promoting properties of 
the  tested  substances and  cell populations were analyzed by neurite density quantification  in  the 
border  region between  the  two brain slices, using biocytin  tracing or  tyrosine hydroxylase  labeling 
and  automated  image  processing  procedures.  In  addition,  toxicological  tests  and  gene  expression 
analyses were conducted. 
(i)  PDE‐Is were  applied  to VTA/SN+STR  rat  co‐cultures.  The quantification of neurite density  after 
both biocytin  tracing and  tyrosine hydroxylase  labeling  revealed a growth promoting effect of  the 
PDE2A‐Is  BAY60‐7550  and  ND7001.  The  application  of  the  PDE10‐I  MP‐10  did  not  alter  neurite 
density in comparison to the vehicle control. 





Egr1,  Egr2,  Egr4,  Fos  and  JunB),  glial  fibrillary  acidic  protein,  and myelin  components  (Mal, Mog, 
Plp1) were not significantly changed (with the exception of Egr4) by the treatment with 0.1 µM and 
1 µM nimodipine. 
(iii)  Bulk  BM‐MSCs  that  were  classically  isolated  by  plastic  adhesion  were  compared  to  the 
subpopulation Sca‐1+Lin‐CD45‐‐derived MSCs (SL45‐MSCs). The neurite growth‐promoting properties 
of both MSC populations were quantified  in VTA/SN+PFC mouse co‐cultures. For  this purpose,  the 
MSCs  were  seeded  on  glass  slides  that  were  placed  underneath  the  co‐cultures.  A  significantly 
enhanced neurite density within the co‐cultures was induced by both bulk BM‐MSCs and SL45‐MSCs. 




































































Axonal  projections  can  get  lost  as  a  consequence  of  (i)  brain  injury  (e.g.  traumatic  brain  injury), 
(ii) the  occurrence  of  cell  death  in  neurodegenerative  diseases,  such  as  Parkinson’s  disease,  and 
(iii) the  malformation  of  neuronal  processes  during  development.  The  loss  of  these  projections 
results  in  the  impairment  of  the  basic  organization  of  neuronal  circuits.  To  date,  there  are  no 
adequate  therapy  strategies  available  that  would  lead  to  the  complete  regeneration  of  these 
neuronal circuits after injury or with the onset of neurodegenerative diseases.  








Taking  into  account  the  considerable  consequences  of  disturbances  of  dopaminergic  neuronal 
projections and regrowth failures after injury and/or in neurodegenerative diseases, there is a strong 
need  for  experimental  models,  in  which  these  projections  are  reproduced.  These  experimental 
models would attempt to accelerate development, as well as the characterization and the selection 
of  effective  neurite  outgrowth‐promoting  substances.  Organotypic  brain  slice  co‐cultures  that 
reconstruct dopaminergic projections could be such an experimental model.  
To fully understand the scale of the problem, there will be an introduction into the anatomy and the 
(patho)physiological  characteristics of  the dopaminergic projection  system, as well as  into general 
mechanisms of neurite  regeneration. Next,  the history and principles of dopaminergic organotypic 
co‐cultures will be looked at. Finally, the particular substances and cells that have been characterized 
with  regard  to  their  (neuroregenerative)  effects  in  organotypic  brain  slice  co‐cultures  will  be 
introduced.  
1.1 The dopaminergic system 
The catecholamine dopamine (DA, Fig. 1A)  is a neuromodulator that  is  involved  in the regulation of 
the diverse functions of the CNS. Among these functions are motor control, reward and cognition. 
The  five  DA  receptors  (D1‐D5)  that  have  been  described  so  far  belong  to  the  family  of  seven 
transmembrane domain G‐protein coupled receptors (Fig. 1B). The DA receptors are divided into two 
subfamilies:  the D1‐like  (D1, D5) and  the D2‐like  (D2, D3, D4) DA  receptors  (1). While  the  former 
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interact  with  a  stimulatory  Gs‐protein,  the  stimulation  of  the  latter  leads  to  the  activation  of 
inhibitory Gi‐proteins as reviewed in more detail in (2). This means that the DA can be an activating 




Fig. 1(A)  The  catecholamine neurotransmitter dopamine  (DA).  (B)  The  structure of  the DA  receptor  (D1‐
subtype). Seven transmembrane helices are indicated (1‐7). Potential phosphorylation sites are represented 
on the intracellular loop and the intracellular COOH‐terminal tail. Potential glycosylation sites are indicated 








forebrain with a  topography organized  in  three planes: dorso‐ventral, medial‐lateral and  anterior‐
posterior  (10).  Among  them,  the  three  main  pathways  are  the  mesostriatal  (also  termed 
nigrostriatal), mesocortical and mesolimbic dopaminergic pathways (11) (Fig. 2). The mesolimbic DA 
pathway is involved in reward and emotions and is comprised of dopaminergic projections from the 
ventral portions of the SNc and  the VTA to  the  limbic  forebrain  (including e.g. nucleus accumbens, 
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Fig.  2(A)  Scheme  of  dopaminergic  projections  in  a  rodent’s  brain  arising  in  the  ventral  tegmental 
area/substantia  nigra‐complex  (VTA/SN).  It  was  not  attempted  to  distinguish  VTA  and  SN,  because  of 







VTA/SN  indicating  the  localization  of  VTA,  SN  pars  compacta  (SNc)  and  SN  pars  reticulata  (SNr).  (C‐E) 
Location of dopaminergic neurons of the VTA/SN projecting to (C) the PFC and ACg, (D) the STR and (E) the 
NAc. (A) adapted from (14); (B‐E) adapted from (9,15) 
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1.1.1.1 Mesostriatal Projections 
The  mesostriatal  pathway  arises  from  the  ventral  and  intermediate  sheets  of  the  SNc  and  the 
ventrolateral VTA and projects to the dorsal striatum (STR), which contains caudate and putamen (9). 
This pathway  is  important  for motor planning  and  the  execution of movement  (11). Moreover,  it 
seems to be involved in non‐motor functions, such as cognition (16).  
dopaminergic  fibers  of  this  particular  projection  have  been  shown  to  innervate  patch  structures 











frequent  varicosities  (0.4‐1.0 µM), giving  them a  crinkled appearance  (12). Additionally,  they have 
been  shown  to be negative  for  the  28kDa  calcium binding protein  (now  referred  to  as  calbindin‐
D28k), in contrast to those innervating matrix structures of the STR (21).  
The  STR  is  the major  input  structure of  the basal  ganglia,  receiving projections  from  the  cerebral 
cortex,  the  brainstem,  and  the  thalamus.  Among  the  projections  from  the  brainstem  are  the 
mesostriatal  projections  that  modulate  two  distinct  pathways  within  the  complex  basal  ganglia 
circuits:  the direct  and  the  indirect pathway. Dopaminergic projections  from  the  SNc  activate  the 




The mesocortical  projections  arise  in  the  dorsal  tier  of  SNc  and  VTA  and  project  to  the  anterior 
cingulate cortex, the entorhinal cortex, perirhinal cortex and the PFC (23,24). These pathways play a 
prominent  role  in  concentration  and  the  executive  functions,  such  as  the  working  memory 
(16,25,26).  
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receive  the dopaminergic  inputs, are mainly pyramidal  cells  in  the deeper  layers  (V,VI) of  the PFC 
(32,33).  They  conduct  excitatory  signals  to,  for  example,  the  VTA  by  mainly  using  the 








Parkinson’s  disease.  The  degeneration  of  dopaminergic  neurons  in  the  SNc  entails  a  reduction  of 
dopaminergic projections  to  the dorsal  STR, which  leads  to  the dysregulation of  the basal ganglia 
motor circuit. The cardinal motor symptoms of Parkinson’s disease  ‐  tremor, rigidity and akinesia  ‐ 
highlight the importance of DA projections for movement control (22,37,38).  
Depression.  Disturbances  in  neurotransmission  are  believed  to  present  the  molecular  basis  of 
depression.  Among  them  is  the  deficiency  of  the  mesolimbic  DA  transmission  that  results  in 
(i) reduced DA levels in the ventral STR, including the nucleus accumbens, and (ii) the dysfunction of 
the  closely  connected  reward  system.  These  particular  disturbances  are  expected  to  cause 
anhedonia,  a  frequent  symptom  of  depression  (16,39). Moreover,  lower  extracellular  DA  in  the 
dorsal  STR  has  been  associated  with motor  retardation  in major  depression  disorder  (40).  New 
approaches  targeting  the dopaminergic system are of high  interest, considering  the current  lack of 
therapy options that could reverse these effects. 
Schizophrenia. Much  evidence  suggests  that  schizophrenia  is  a neurodevelopmental disorder with 
genetic  and  environmental  factors,  which  can  cumulatively  lead  to  different  developmental 
trajectories  (41).  The  reduced  elaboration  of  inhibitory  interneuron  activity,  and  the  exceeded 
pruning of the excitatory pathways cause an  imbalance in the  inhibitory and excitatory pathways  in 
the PFC  (42). The  impairment of DA  transmission  in  the PFC  is associated with deficits  in working 
memory  ‐a  core dysfunction  in  schizophrenia  (25,26). Additionally, deficient DA  function  results  in 
the hypostimulation of D1 receptors in the PFC. It has been suggested that this reduced stimulation 
INTRODUCTION - The dopaminergic system
6
can play a  role  in  the development of  the “negative”  symptoms and cognitive  impairments of  the 
disease (43). 





Following brain  injury, membrane resealing at  the  transection site of  the severed axons  is  the  first 
prerequisite  for  survival  of  the  neuron.  Another  requirement  for  regeneration  after  mechanical 
lesions  is  the  growth  cone  formation  and  extension.  It  has  been  demonstrated  that  high  calcium 





CNS  is  inhibited by extrinsic and  intrinsic mechanisms. Extracellular growth‐inhibitory mechanisms 
include (i) repellent guidance cues that are important during development and upregulated following 
injury, for example ephrins and their receptors (46–48). Additionally, (ii) myelin proteins like Nogo‐A, 
myelin‐associated  glycoprotein  (MAG)  and  oligodendrocyte  myelin  glycoprotein  (OMgp)  present 
growth‐inhibitory factors. Furthermore, (iii) the glial scar  impedes the regrowth of severed axons. It 
consists of activated astrocytes and  the secreted extracellular matrix components, e.g. chondroitin 
sulfate proteoglycan,  (as reviewed  in more detail by  (49,50)). A  therapeutic approach  to overcome 
this non‐permissive environment  is  the neutralization of growth‐inhibitory  factors  like Nogo‐A with 
specific  antibodies  (51–53),  and  the  enzymatic  digestion  of  chondroitin  sulfate  proteoglycan  by 
chondroitinase ABC (53,54). 
Despite these extrinsic factors that impede axon regrowth, spontaneous axon regeneration has been 
observed under certain circumstances  (55,56) as reviewed  in  (57). These observations suggest  that 
there must be  intrinsic mechanisms  that enable  the  regenerating axon  to overcome  the  inhibitory 
environment,  which  is  created  by  the  above  mentioned  factors.  Examples  of  the  intrinsic 
mechanisms,  which  lead  to  growth  cone  formation  and  extension,  are  the  activation  of  gene 
expression, local protein synthesis and microtubule assembly (57). These processes are regulated by 
intracellular signaling pathways  including the MAPK/ERK pathway and the PI3K/Akt pathway. These 
pathways  interact with  each  other  and with  other  signaling  cascades  in  a  complex manner  that 











Organotypic  brain  slice  co‐cultures  present  an  experimental model  that  provides  some  important 
advantages,  in contrast to single‐cell culture or  in vivo models. The complex cytoarchitecture of the 
brain  tissue  is preserved within  these models. For example, Snyder‐Keller et al. demonstrated  that 
the  complex  striatal matrix‐patch organization  can be  found  in  striatal  slice  cultures after ex  vivo‐
cultivation  and,  to  an  even  greater  extent,  in mesostriatal  co‐cultures  (VM+STR)  (61). Moreover, 





The  ex  vivo  cultivation  and  the  characterization of  explants of  the VM  can be  traced back  to  the 
1970s (68,69). In the first study of co‐cultures, tissue explants of the midbrain and the STR (caudate 
nucleus), derived from the brains of newborn dogs, were combined (70). In this study, the outgrowth 
of  catecholamine  containing  fibers  from  the midbrain portion  into  the  striatal  slice was observed. 
This  target‐oriented  fiber  growth,  with  plexiform  nerve  terminals  in  the  STR,  was  confirmed  in 
mesostriatal  rat  co‐cultures  (63).  The  combination  of  VM  slices  with  slices  of  (a)  STR,  (b) 
hippocampus  or  (c)  cerebellum  clearly  demonstrated  that  the  ex  vivo  observed  target‐oriented 
neurite outgrowth correlates with  the projections, which are built  in vivo during  the development. 
While  there was  significant  ingrowth  into  STR, which  represents  a major  target of mesencephalic 
dopaminergic neurons, only a few neurites grew  into the hippocampal slice, a minor target region. 
No  ingrowth of dopaminergic  fibers was observed  in co‐cultures with  the cerebellum, a non‐target 
region  for mesencephalic DA neurons  (64). These  findings were confirmed  in a  later study working 
with  triple  cultures  containing  (a)  cerebral  cortex+SN+STR  or  (b)  cerebral  cortex+VTA+STR, 
respectively  (71).  This  study  further  demonstrated  the  specific  innervation  of  (a)  the  STR  by 







explants  (72).  Furthermore,  the  importance  of  the  striatal  tissue  donor’s  age  in  nigrostriatal  co‐
cultures has been demonstrated: dopaminergic fibers originating from the VM are only attracted to 
the STR at  late embryonic (i.e. E19+) and early postnatal stages (i.e. <P4)  (64,73). Triple cultures of 
the VM,  the  STR  and  a  cortical part,  revealed  a  rather moderate  innervation of  the  cortex, when 
compared to the STR (66,71).  
Two principle  cultivation  techniques have become prevalent  in  recent decades and both methods 
consider the major requirements of organotypic cultivation. The necessary conditions are as follows: 
sufficient oxygenation,  stable attachment  to a  substrate, and an appropriate culture medium  (74). 
(i) The  roller  tube  technique has been proven  to  allow  the organotypic  growth of neuronal  tissue 
explants  (75,76).  However,  there  is  a  non‐physiological  flattening  to  quasi‐monolayers,  which  is 
preferable when optimal  optical  conditions  are  required  (74).  (ii) If  the maintenance of  the  semi‐
three‐dimensional  structure  is desired,  the membrane  interface  technique would be  the preferred 









on a neonatal rat brain. The regions containing ventral  tegmental area/substantia nigra  (VTA/SN) and  the 
prefrontal  cortex  (PFC)  are  highlighted  in  dark  and  bright  red,  respectively.  The  region  containing  the 
striatum (STR)  is highlighted  in blue. (B) Coronal sections of the rat brain. Additional cuts are  indicated by 
dashed  lines to  isolate PFC  (*), VTA/SN  (#) and the STR  (*), respectively.  (C) Coronal sections were placed 
side by side on membrane  inserts as co‐cultures. During  the ex vivo cultivation, co‐cultures were  treated 
with  nimodipine  or MSC  populations  (VTA/SN+PFC)  or with  different  PDE‐Is  (VTA/SN+STR),  respectively. 
(A,B) adapted from (79). 
1.4 Promising substances and cells to enhance neuroregeneration 
As  discussed  above  (see  section  1.2),  the  regrowth  of  neurites  after mechanical  lesions  is  a  very 
complex process. Many  intrinsic  and  extrinsic  factors  influence  the  regrowth  capacities of  injured 
neurites. These  factors provide a wide  range of molecular  targets  for  therapeutical approaches  to 




3’,5’‐cyclic‐nucleotide  phosphodiesterases  (PDEs,  EC  3.1.4.17)  are  enzymes  that  hydrolyze  the  3’ 
cyclic  phosphate  bond  of  the  second messenger molecules  cAMP  and/or  guanosine  3’,  5’  cyclic 










methylxanthines, were  found  (82,83). These early PDE‐inhibitors  (PDE‐Is) were used as  therapeutic 










PDE2 has been detected  in  the brain  in unique neuronal populations.  Its activity has,  for example, 
been shown in striatal cells (86). It regulates cGMP levels in neurons, and is believed to be involved in 
long‐term memory  (81). BAY60‐7550  is one example of potent and highly selective PDE2‐Is.  It was 
shown  in an  in vivo mouse model that treatment with this PDE‐I enhances memory and  learning by 
enhancing synaptic plasticity (87). 
PDE10 is highly expressed in the STR of the rodent brain (88). Thus, its involvement in the modulation 
of  striatonigral  and  striatopallidal  pathways  has  been  suggested  (89).  Within  the  STR,  PDE10  is 
expressed in medium spiny neurons, where it is supposed to regulate the metabolism of both cAMP 
and  cGMP  (89).  The  selective  inhibition  of  PDE10  is  discussed  as  a  possibility  to  treat  psychosis, 
because  studies  have  demonstrated  its  efficacy  in  behavioral models  predictive  of  antipsychotic 
activity (90). Moreover, with regard to the corticostriatal projections, PDE10‐Is could  improve some 
of  the  cognitive  symptoms  of  schizophrenia  by  increasing  the  activity  of  the  GABAergic  striatal 













distribution  volume  in  the  brain.  However,  when  using  it  as  a  therapeutic  agent,  low  oral 
bioavailability, short half‐life and high protein binding have to be considered (94). Nimodipine’s low 
adverse  effect profile has been  confirmed  in  numerous  clinical  trials  and  is  advantageous  for  the 
clinical application of the substance (95–97). 
In  the early eighties nimodipine was regarded as a vasodilatory agent with a preferential effect on 






suggested  (104,105).  However,  the  clinical  application  of  nimodipine  was  mainly  related  to  its 
beneficial effects when applied after subarachnoid hemorrhage. In this clinical situation, nimodipine 
reduces  the  deleterious  effects  of  related  delayed  cerebral  vasospasm  (106).  Nevertheless,  later 
research discovered other fields of application. Experimental studies in animal models demonstrated 
the  neuroregenerative  effects  of  nimodipine  after  mechanical  peripheral  nerve  injury  (107,108). 
Moreover, clinical studies have demonstrated improved nerve function after vestibular schwannoma 
surgery, especially when nimodipine was applied  intravenously before, during and after the surgery 





for  cell  therapies  in  regenerative  medicine.  Currently,  clinical  trials  are  ongoing,  applying  bone 
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marrow  (BM)‐derived MSCs  to  treat  a  variety  of  disorders:  neurodegenerative  disorders  such  as 
multiple sclerosis and Parkinson’s disease, disorders of the locomotor system, like osteoarthritis and 
injury of  the  articular  cartilage,  and others, e.g.  acute  respiratory distress  symptoms,  chronic  and 
ischemic stroke, liver failure and spinal cord injury (http://www.clinicaltrials.gov/ 2015‐03‐03). 
In addition to the BM, MSCs have been isolated from nearly every adult tissue (as reviewed by (110)), 
mainly  due  to  their  presence  in  the  perivascular  region  (111,112). However,  the main  sources  of 
MSCs are adult BM (113,114), adipose tissue (115), and umbilical cord blood (116).  
MSCs  are  classically  characterized  by  their  ability  to  adhere  to  plastic  surfaces  and  to  undergo 
sustained  proliferation.  Their  trilineage  differentiation  capacity  into  adipocytes,  chondrocytes  and 
osteoblasts in vitro has been first described by Pittenger (117) and became an important criterion for 
the  definition  of  MSCs  (118).  Moreover,  for  human  MSCs,  cell  surface  expression  of  cluster  of 
differentiation  (CD)73, CD90  and CD105  as well  as  the  absence of hematopoietic  lineage markers 
such as CD11b, CD14, CD19 or CD34, CD45 or CD79 are required, to refer to the cells as MSCs (118). 
The characteristics  for murine MSCs overlap partly with  those described  for human MSCs, but are 
generally less well defined (119). 
With  regard  to  the  development  of  new  strategies  for  the  treatment  of  neurological  and 
neurodegenerative disorders, (i)  it was assumed that MSCs would replace  lost cells  in the damaged 
tissue.  In addition  to  their  trilineage potential,  the  transdifferentiation  into  cells of other  lineages, 
such as neurons, has been described  in several studies (e.g. (120,121)). However, the experimental 
approach to characterize the neuronal phenotype, varies between the different laboratories and the 
validity of  the  results  is  controversial  (as discussed by  (122)).  (ii)  Immunomodulatory mechanisms 
have been described. MSCs limit stress response/inflammation and apoptosis following injury (123–
125).  (iii)  The  capacity  of MSCs  to  produce  and  secrete  neurotrophic  factors  and,  in  addition,  to 
induce  growth  factor  secretion  in  host  cells  can  be  another  powerful  mechanism,  creating  a 
microenvironment  around  a  lesion  site  that  fosters  the  regeneration  and  repair  of  the  damaged 
tissue, as  it has been shown in preclinical studies (125–127). These paracrine effects are thought to 
contribute  more  significantly  to  the  broad  therapeutic  efficacy  of  MSCs,  as  opposed  to  their 
plasticity, in achieving tissue repair.  
However, the composition of the secreted cytokines and growth factors varies significantly between 
different  MSC  preparations,  because  the  proportions  of  the  respective  subpopulations  of  the 
intrinsically  heterogeneous  MSCs  and  their  biological  activity  strongly  depend  on  isolation  and 
cultivation protocols  (128). As a consequence,  the effect of applied MSCs  in  the context of clinical 
application  is hardly predictable. Some recent advances  in experimentation allowed for attempts to 
isolate defined homogeneous MSC subpopulations. Thus, specific surface markers, in addition to the 
ones  mentioned  above,  have  been  identified. Kucia  et  al.  described  a  multiparameter  sorting 
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method,  yielding a homogeneous murine BM‐derived  cell population  that expresses  the  stem  cell 
antigen‐1 (Sca‐1) and  is hematopoietic  lineage‐depleted and CD45‐negative (Sca‐1+Lin‐CD45‐). These 
cells  expressed  the  pluripotency markers  SSEA‐1,  Oct‐4,  Nanog  and  Rex‐1  (129).  Therefore,  and 
because  of  their  small  size,  the  group  termed  them  “very  small  embryonic‐like  (VSEL)  cells”. 
However,  the pluripotency has not yet been rigorously proven  (130).  In another study,  the surface 
markers, platelet‐derived growth factor receptor‐ߙ (PDGFR‐ߙ), and Sca‐1 were described as suitable 





consequences  of  axon  (re)growth  failures,  especially  within  dopaminergic  projections.  Utilizing 







The  effects  of  the  treatment  with  different  concentrations  of  nimodipine  (0.1 µM‐10 µM) 
were compared. 
 
(iii) Mesenchymal  stromal/stem  cells  (MSCs),  whose  therapeutic  potential  is  supposed  to  be 
based  i.a.  on  the  secretion  of  growth  factors, which  act  extracellularly  on  the  respective 
receptors 
In  the work presented here,  the neurite outgrowth‐enhancing potential of  the prospectively 
isolated  (Sca‐1+Lin‐CD45‐)  murine  MSC  subpopulation  that  we  name  “SL45‐MSC”  was 
compared to murine bulk BM‐MSC, classically isolated through plastic adhesion. 
Being already an established model  for  the analysis of  the neurite growth‐promoting properties of 
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Fig. 5 Work program.  (A) The  treatment of each  study  is  indicated.  (B) The projection  systems  that have 
been used for the respective study are represented as schemes. As  indicated  in the  left and middle panel, 
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tyrosine hydroxylase-positive fibers indicated a significant 
increase after treatment with BAY60-7550 and nerve growth 
factor in relation to dimethyl sulfoxide. Additionally, a dose-
dependent increase of intracellular cGMP levels in response 
to the applied PDE2-Is in PDE2-transfected HEK293 cells was 
found. In summary, our findings show that PDE2-Is are able 
to significantly promote axonal outgrowth in organotypic 
slice co-cultures, which are a suitable model to assess 
growth-related effects in neuro(re)generation. 
 Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 Axonal projections and the basic organization of mid-
brain dopaminergic (DAergic) neurons are the subject of 
interest when studying human neurological disorders, e.g. 
Parkinson’s disease  [1] , schizophrenia  [2] , and drug abuse 
or addiction  [3, 4] . The mesencephalon as a region of com-
plex anatomical organization, and projection patterns of 
the DAergic neurons are divided into the retrorubral area 
 Key Words 
 Axonal outgrowth   Biocytin   Development   
Dopaminergic system   Organotypic slice co-culture   
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 Abstract 
 The development of appropriate models assessing the po-
tential of substances for regeneration of neuronal circuits is 
of great importance. Here, we present procedures to analyze 
effects of substances on fiber outgrowth based on organo-
typic slice co-cultures of the nigrostriatal dopaminergic sys-
tem in combination with biocytin tracing and tyrosine hy-
droxylase labeling and subsequent automated image quan-
tification. Selected phosphodiesterase inhibitors (PDE-Is) 
were studied to identify their potential growth-promoting 
capacities. Immunohistochemical methods were used to vi-
sualize developing fibers in the border region between ven-
tral tegmental area/substantia nigra co-cultivated with the 
striatum as well as the cellular expression of PDE2A and 
PDE10. The quantification shows a significant increase of fi-
ber density in the border region induced by PDE2-Is (BAY60-
7550; ND7001), comparable with the potential of the nerve 
growth factor and in contrast to PDE10-I (MP-10). Analysis of 
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(A8 cell group), substantia nigra (SN; A9 cell group), and 
the ventral tegmental area (VTA; A10 cell group)  [5–7] . 
Tract-tracing techniques have revealed three projections 
to forebrain targets, namely the mesolimbic, the mesocor-
tical, and the nigrostriatal pathways (for references, see 
 [8] ). The trajectories from the SN and VTA target all in-
trinsic nuclei of the basal ganglia while exhibiting prefer-
ential concentrations of terminals in the dorsal and ven-
tral striatum (STR)  [1, 8] . The balance between these pro-
jections is thought to be regulated by afferent DAergic 
signals from the VTA and SN pars compacta, acting on 
differentially distributed D1 and D2 dopamine (DA) re-
ceptors, e.g. on striatal medium spiny neurons. The activa-
tion of D1 receptors leads to an intracellular accumulation 
of cyclic adenosine 3  ,5  -monophosphate (cAMP) via the 
adenylyl cyclase and following activation of cAMP-depen-
dent protein kinase. Otherwise, DA inhibits the adenylyl 
cyclase via D2 receptors (for references, see  [9] ).
 It is well known that disruption of DAergic cell activ-
ity and the loss of ascending projections to the basal gan-
glia results in the emergence of fundamental pathological 
features. Due to the necessity for therapeutic strategies 
promoting neuro(re)generation, there is a clear need to 
develop appropriate test systems to assess the potential of 
different substances regarding regeneration and repair of 
neuronal circuits. Over the last years, we established ex 
vivo models of organotypic slice co-cultures of the DA-
ergic system  [10–12] . Parts of this system were recon-
structed using tissue slices from the VTA/SN and STR or 
the prefrontal cortex, respectively, to analyze the cytoar-
chitectural organization of the VTA/SN and the innerva-
tions of the target regions by DAergic fibers. Our results 
demonstrated that tyrosine hydroxylase (TH)-immu-
nopositive neurons are also able to develop their charac-
teristic innervation patterns in organotypic slice co-cul-
tures  [10] . A number of intracellular and extracellular 
molecules are involved in the regulation of neuronal dif-
ferentiation. Using our model system, we were able to 
identify a trophic support in axonal outgrowth after pu-
rinergic stimulation  [11, 12] . Moreover, second messen-
gers cAMP and cyclic guanosine 3  ,5  -monophosphate 
(cGMP), formed from the triphosphates ATP and GTP, 
appear to play prominent roles in regulating neuronal 
differentiation and neuroplasticity  [13, 14] . Elevated in-
tracellular levels of the cyclic nucleotides are important 
for axon regeneration, even beyond the required increase 
in cAMP levels needed to respond to most factors that 
support cell survival  [15] . Cyclic nucleotide phosphodies-
terases (PDEs) comprise a superfamily of metallophos-
phohydrolases that specifically cleave the 3  ,5  -cyclic 
phosphate moiety of cAMP and/or cGMP and terminate 
the action of cyclic nucleotide signaling  [16] . Eleven indi-
vidual PDE subfamilies (PDE1–PDE11) with varying se-
lectivity for cAMP or cGMP have been identified in 
mammalian tissues based on sequence similarities, in-
hibitor sensitivity, and biochemical properties. They are 
involved in mediating a range of different functions, in-
cluding cytoskeletal rearrangement, gene transcription, 
and regulation of ion channel function  [17, 18] . Recent 
data have shown that PDE2 and PDE10 are localized in 
the nigrostriatal system and hydrolyze both cAMP and 
cGMP. The inhibition of PDE2 selectively increases cyclic 
nucleotide levels, influencing synaptic plasticity and 
memory formation  [19, 20] . Inhibition of PDE10 modu-
lates neuronal activity within the striatopallidal and ni-
grostriatal pathway and leads to efficacy in behavioral 
models predicting an antipsychotic effect  [21–24] .
 The aim of the present study was to characterize pos-
sible trophic/regenerative properties of selected PDE2 in-
hibitors (PDE2-Is; BAY60-7550 and ND7001) and PDE10-
I (MP-10), as compared to the effect of the neurotrophin 
nerve growth factor (NGF) by using an organotypic slice 
 co-culture model (VTA/SN+STR). To quantify the po-
tential of stimulating fiber growth, density of neuronal 
fibers in the border region of slice co-cultures was de-
termined using both biocytin-tracing technique and
TH immunolabeling, and subsequent automated image 
quantification.
 Materials and Methods 
 Materials/Substances 
 Selected PDE-Is with different subclass specificities were used 
(details, see  table 1 ; structural formula, see  fig. 1 ):  BAY60-7550 
(2-(3,4-dimethoxybenzyl)-7-{(1R)-1-[(1R)-1-hydroxyethyl]-4-
phenyl-butyl}-5-methyl imidazo[5,1-f][1,2,4]triazin-4(3H)-one; 
Alexis Biochemicals, San Diego, Calif., USA), ND7001 (3-(8-meth-
oxy-1-methyl-2-oxo-7-phenyl-2,3-dihydro-1H-benzo[e][1,4]di-
azepin-5-yl)-benzamide), and MP-10 (2-[4-(1-methyl-4-pyridin-
4-yl-1H-pyrazol-3-yl)-phenoxymethyl]-quinoline 3) were syn-
thesized at biocrea (Radebeul, Germany).
 Furthermore, the following substances/factors were applied: 
NGF (Sigma-Aldrich, Taufkirchen, Germany), dimethyl sulfox-
ide (DMSO; AppliChem GmbH, Darmstadt, Germany), artificial 
cerebrospinal fluid (ACSF) of the composition (m M ): 126 NaCl; 
2.5 KCl; 1.2 NaH 2 PO 4 ; 1.3 MgCl 2 , and 2.4 CaCl 2 (pH 7.4; Hospital 
Pharmacy, University of Leipzig, Germany).
 In vitro PDE Assay 
 PDE activity was measured by the conversion of [ 3 H]-cAMP 
and [ 3 H]-cGMP into [ 3 H]-AMP and [ 3 H]-GMP, respectively, as 
described previously  [25] . PDEs 1B, 2A, 3A, 4A, 5A, 7B, 8A, 9A, 
10A, and 11A were generated from full-length human recombi-
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nant clones. PDE6 was isolated from bovine retina as described 
previously  [26] . PDE activity was measured with the preferred 
substrates, in detail, for PDE1B, 2A, 3A, 4A, 7B, 8A, 10A, and 11A 
cAMP was used and for PDE5A, 6, and 9A cGMP, at or below the 
K m value (Michaelis-Menten constant). PDE1B and PDE2A were 
activated by Ca 2+ /calmodulin and by cGMP, respectively. The 
other PDEs did not need any additional activation procedure. In-
hibition of PDE activity was measured using a scintillation prox-
imity assay at varied compound concentrations and optimized 
fixed enzyme concentrations for each enzymatic assay. IC 50 (half 
maximal inhibitory concentration) values were calculated with 
the Hill2 parameter model from at least four independent exper-
iments, done in duplicates.
 Intracellular cGMP Assay 
 The selected PDE-Is BAY60-7550 and ND7001 were tested in 
a cellular test system to analyze the effects on intracellular cGMP 
levels. Human embryonic kidney (HEK) 293 cells, stably trans-
fected with the full-length sequence of human PDE2A 
(NM002599), were cultured in collagen I-coated 96-well plates 
(70,000 cells/well) over night. On the next day, the test com-
pounds were administered at a final DMSO concentration of 0.5% 
and incubated for 30 min at 37  °  C and 5% CO 2 . This was followed 
by incubation with the guanylyl cyclase (GC)-activating agent so-
dium nitroferricyanide(III) dihydrate (sodium nitroprusside, 
SNP, 100   M ; Sigma-Aldrich) for 10 min. Wells incubated without 
test compound in the presence and absence of SNP were used as 
controls for statistical analysis. The level of intracellular cGMP 
was determined with the enzyme-linked immunosorbent assay 
system (cGMP EIA System; GE Healthcare UK Ltd., Little Chalf-
ont, England).
 Animals 
 Neonatal rat pups (WISTAR RjHan, own breed; animal house 
of the Rudolf Boehm Institute of Pharmacology and Toxicology, 
University of Leipzig) of postnatal day 1–5 (P1–5) were used for 
preparation of the organotypic slice co-cultures. The animals 
were housed under standard laboratory conditions, under a 12-
 Fig. 1. Chemical structures of the PDE 
substrates cGMP and cAMP and of the 
PDE-Is BAY60-7550, ND7001, and MP-10. 
Table 1. I C50 values (nM) of the PDE2-Is BAY60-7550 and 
ND7001, and the PDE10-I MP-10 against individual phosphodi-
esterases
PDE BAY60-7550 ND7001 MP-10
hPDE2A 0.18 57 2,630
hPDE1B 426 >5,000 >5,000
hPDE3A >5,000 >10,000 >5,000
hPDE4A 2,130 >10,000 2,230
hPDE5A 516 >10,000 >5,000
bPDE6 2,200 >10,000 >5,000
hPDE7B 1,740 >10,000 >5,000
hPDE8A >5,000 >10,000 >5,000
hPDE9A >5,000 >10,000 >5,000
hPDE10A 1,640 1,460 1.14
hPDE11A >5,000 >10,000 >5,000
O verview of the IC50 values (nM) of the PDE2-Is BAY60-7550 
and ND7001, and the PDE10-I MP-10 against individual human 
(h) PDEs as well as the bovine (b) PDE6.
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hour light/12-hour dark cycle and allowed access to lab food and 
water ad libitum.
 All of the animal use procedures were approved by the Com-
mittee of Animal Care and Use of the relevant local governmental 
body in accordance with the law of experimental animal protec-
tion.
 Preparation of Slice Cultures 
 Slice co-cultures were prepared from P1–5 old rats and culti-
vated according to the ‘static’ culture protocol described by Fran-
ke et al.  [10] (for details, see also  fig. 2 ). Briefly, rat pups were de-
capitated and the brains were removed from the skull under ster-
ile conditions. The brains were apposed to an agar block and fixed 
onto the specimen stage of a slicer (Leica VT 1000S; Nussloch , 
Germany) with cyanoacrylate glue (Histoacryl  ; B. Braun, Tutt-
lingen, Germany). Coronal sections (thickness 300   m)  were cut 
at mesencephalic ( fig. 2 : A) and forebrain levels ( fig. 2 : B). During 
the preparation of organotypic slice cultures of the ventral mes-
encephalon we did not attempt to separate the VTA and the SN. 
For further discussion, this area will be named VTA/SN. After 
preparation of the VTA/SN ( fig. 2 : A’, asterisk) and the STR ( fig. 2 : 
B’, asterisk), respectively, the slices were transferred into petri 
dishes filled with cold (4   °   C) preparation solution (MEM, Mini-
mum Essential Medium, 2 m M glutamine; Invitrogen GmbH, 
Darmstadt, Germany) supplemented with the antibiotic gentami-
cin (50   g/ml; Invitrogen GmbH). Selected sections were placed 
next to each other on moistened translucent membrane inserts 
(0.4   m; Millicell-CM, Millipore, Bedford, Mass., USA) as co-
cultures (VTA/SN+STR) and were put in 6-well plates each filled 
with 1 ml incubation medium (50% MEM, 25% Hank’s Balanced 
Salt Solution, 25% heat inactivated horse serum; glutamine to a 
final concentration of 2 m M ; all from Invitrogen GmbH and with 
0.044% sodium hydrogen carbonate, NaHCO 3 ; Sigma-Aldrich). 
The pH was adjusted to 7.2. The cultures were stored at 37   °   C in 
5% CO 2 and the medium was changed 3 times a week.
 Fixation of the Tissues 
 After 10 days in vitro (DIV), the cultures were fixed in a solu-
tion consisting of 4% paraformaldehyde, 0.1% glutaraldehyde, 
15% picric acid in phosphate buffer (PB, 0.1  M ; pH 7.4) for 2 h and 
subsequently washed with PB intensively. Following fixation, the 
co-cultures were cut into 50-  m thick slices by means of the vi-
bratome.
 Immunohistochemistry 
 (a) Qualitative Characterization of PDEs. Following pre-incu-
bation in 1% H 2 O 2 solution for 25 min as well as in blocking solu-
tion containing 10% normal horse serum in 0.1  M PB for 1 h, re-
spectively, the slices were incubated with goat anti-PDE2A (1: 100; 
Santa Cruz Biotechnology, Inc., Santa Cruz, Calif., USA) or rabbit 
anti-PDE10 (1: 500; FabGennix Inc., Frisco, Tex., USA) for 48 h at 
4  °  C.
 (b) Quantitative Characterization of TH-Positive Fibers. After 
pre-treatment with H 2 O 2 and incubation with blocking solution, 
the slices were incubated with mouse anti-TH (1: 1,000; Chemi-
con, Temecula, Calif., USA) for 48 h at 4  °  C.
 (a, b) After washing with PB, the slices were incubated with 
biotinylated anti-goat, biotinylated anti-rabbit or biotinylated an-
ti-mouse immunoglobulin IgG (H+L) (1: 65; Vector Laboratories, 
Inc., Burlingame, Calif., USA), respectively, for 2 h at room tem-
perature. Afterwards, the avidin-biotin-horseradish peroxidase 
complex (1: 50; ABC-Elite Kit, Vector Laboratories, Inc.) was ap-
plied and visualized by 3,3  -diaminobenzidine hydrochloride 
(DAB; Sigma-Aldrich) as the chromogen. For the TH immunola-
beling, nickel/cobalt-intensified DAB was used. After mounting 
on glass slides, the stained slices were dehydrated in a series of 
graded ethanol, processed through n-butylacetate and cover-










 Fig. 2. Schematic illustration of the preparation procedure to ob-
tain organotypic slice co-cultures of the DAergic system as de-
scribed previously by Franke et al. [10]. Intact brains were re-
moved from 1- to 5-day-old rats. Afterwards, transverse cuts were 
made at the level of A to isolate the mesencephalon and the stria-
tal region (B). Additional horizontal cuts were made indicated by 
the dashed lines to separate the VTA/SN (A’  * ) and the STR (B’  * ). 
In the last step, selected coronal sections (thickness 300   m) were 
placed next to each other on moistened membranes as co-cultures 
as shown in the pictures. 
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 Single Labeling.  After washing with Tris-buffered saline (TBS, 
0.05  M ; pH 7.6) and blocking with TBS containing fetal calf serum 
(FCS, 5%) and Triton X-100 (0.3%), the slices were incubated with 
mouse anti-TH (1: 1,000; Chemicon); mouse anti-  III-tubulin
(1: 400; Promega GmbH, Mannheim, Germany) or mouse anti-
glial fibrillary acidic protein (GFAP, 1: 1,000; Sigma-Aldrich), re-
spectively, for 48 h at 4  °  C. The visualization of the respective pri-
mary antibodies was performed with carbocyanine (Cy)2-conju-
gated goat anti-mouse IgG (1: 400; Jackson ImmunoResearch, 
West Grove, Pa., USA). In addition, slices were stained with the 
nucleic acid probe Hoechst 33342 (Hoe, final concentration 40 μg/
ml; Molecular Probes, Leiden, The Netherlands) to identify the 
cell nuclei.
 Multiple Fluorescence Labeling . After the blocking step, per-
formed as described above, the slices were incubated with an an-
tibody mixture of rabbit anti-microtubule-associated protein-2 
(MAP2, 1: 500; Millipore, Temecula, Calif., USA), mouse anti-
GFAP (1: 1,000; Sigma-Aldrich) and goat anti-PDE2A (1: 100; San-
ta Cruz Biotechnology, Inc.) or mouse anti-MAP2 (1: 1,000; Mil-
lipore), goat anti-GFAP (1: 300; Santa Cruz Biotechnology, Inc.) 
and rabbit anti-PDE10 (1: 500; FabGennix Inc.), respectively, in 
TBS-containing 5% FCS and 0.3% Triton X-100 for 48 h at 4   °   C. 
The simultaneous visualization of the different primary antisera 
was performed with a mixture of secondary antibodies specific 
for the appropriate species IgG (rabbit, mouse, goat; all from Jack-
son ImmunoResearch). In detail, Cy2- (1: 400), Cy3- (1: 1000), and 
Cy5- (1: 100) conjugated IgGs were diluted in TBS supplemented 
with 5% FCS and 0.3% Triton X-100 and the mixture was applied 
for 2 h at room temperature.
 TH-double immunofluorescence was performed using anti-
bodies against mouse anti-TH (1: 1,000; Chemicon) and goat anti-
PDE2A (1: 100; Santa Cruz Biotechnology, Inc.) or rabbit anti-
PDE10 (1: 500; FabGennix Inc.), respectively, in TBS-containing 
5% FCS and 0.3% Triton X-100 for 48 h at 4  °  C. The visualization 
was performed with a mixture of DyLight TM 649-conjugated don-
key anti-mouse IgG (1: 100, color coded in green) and Cy3-conju-
gated donkey anti-rabbit or anti-goat (1: 1,000; Jackson Immu-
noResearch, each). Subsequently, all slices were stained with the 
nucleic acid probe Hoechst as described above.
 After intensive washing and mounting on glass slides, all 
stained sections were dehydrated in a series of graded ethanol, 
processed through n-butylacetate and covered with Entellan.
 Confocal Microscopy 
 Imaging of the fluorescence-labeled specimen was done using 
a confocal laser scanning microscope (LSM 510 Meta; Zeiss, 
Oberkochen, Germany). Excitation wave lengths were 633 nm 
(helium/neon2), 543 nm (helium/neon1), and 488 nm (argon). An 
ultraviolet laser (351/364 nm, Enterprise) was used to evoke the 
Hoechst fluorescence.
 Treatment Procedure 
 According to the treatment procedure described in Heine et 
al.  [12] (for a detailed time schedule, see  fig. 3 ), the slice co-cul-
tures were divided into different experimental groups and were 
treated with the following substances (final concentration): 
BAY60-7550 (10   M ), ND7001 (10   M ), MP-10 (10   M ), and NGF 
(50 ng/ml). The experiments were performed in a blinded fashion, 
i.e. the compound identity was only provided after final data anal-
ysis.
 The substances (except NGF) were dissolved in DMSO, steril-
ized by filters (0.2   m; Sarstedt, Nümbrecht, Germany) and fi-
nally added to 1 ml incubation medium. To exclude influences 
resulting from the solvent DMSO (final concentration 0.1%), an 
additional control group was used, treated only with ACSF (1%). 
The substances were applied at each medium change (4 times 
within the incubation period).
 Tracing Procedure 
 At DIV 8, small biocytin crystals (Sigma-Aldrich) of similar 
size were placed on the VTA/SN part of the co-cultures (accord-
ing to  [10] ) under binocular control (for detailed time schedule, 
see  fig. 3 ). Cultures were left in contact with the crystals for 2 h to 
allow the uptake of biocytin, followed by careful rinsing with 
fresh incubation medium. Then, the cultures were reincubated 
with medium containing the substances to allow for anterograde 
transport of the tracer. After DIV 10, the cultures were fixed as 
described above and cut into 50-  m thick slices by means of the 
vibratome.
 The visualization of the traced axons was performed using a 
previously described protocol  [10] . Briefly, the anterogradely 
transported tracer biocytin was labeled using the ABC-Elite Kit 
(1: 50; Vector Laboratories, Inc.), in combination with nickel/co-
balt-intensified DAB. After mounting on glass slides, all stained 
sections were handled as described above.



















 Fig. 3. A detailed chronological scheme of the experimental pro-
cedure is illustrated. During the incubation period of the cultures, 
the treatment was executed 4 times (ST), starting on DIV 1 using 
the respective substances. At DIV 8, the biocytin tracing was per-
formed as described and, finally, at DIV 10, the co-cultures were 
fixed and analyzed. ST = Substance treatment. 
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 Fig. 4.  a Overview of a DAergic nigrostriatal co-culture (VTA/
SN+STR) using the biocytin-tracing technique in combination 
with DAB labeling. The small biocytin crystals had been placed 
onto the VTA/SN part of the co-culture; afterwards, the antero-
grade tracer was transported from the cell bodies to the outgrow-
ing fibers. The cell bodies (labeled black) of the VTA/SN and the 
respective outgrowing fibers, linking the border region and grow-
ing into the STR, are shown.  b–f Examples of TH immunofluo-
rescence labeling to characterize the expression of the DAergic 
marker in the co-cultures: TH-IR was observed on cell bodies and 
outgrowing fibers within the VTA/SN ( b ,  e ) as well as on fiber 
processes in the border region ( c ,  d ) and the STR ( d ,  f ). In the bor-
der region, strong TH-IR was observed (e.g. arrowhead in  c ,  d ) on 
fibers, but also an increased number of ‘dot-like’ structures (e.g. 
arrows in c ,  d ) was found. Finally, within the STR, a fine network 
of TH-positive fibers and ‘dot-like’ structures is characteristic ( f ). 
 g–i The expression of   III-tubulin- ( g ), GFAP- (astroglial marker) 
( h ), as well as MAP2- (neuronal marker) ( i ) positive fibers in the 
border region is demonstrated, together with the nuclear stain 
Hoechst (Hoe) 33342. Scale bars:  a 10   m;  b–d ,  f 20   m;  e 50   m; 
 g–i 10   m. 
RESEARCH ARTICLES - Phosphodiesterase Inhibitors (PDE-Is)
22
 Phosphodiesterase 2 Inhibitors Promote 
Axonal Outgrowth 
Neurosignals 7
 Automated Image Quantification 
 The quantification of outgrowing biocytin-traced fibers as 
well as of the TH-labeled fibers was performed within the border 
region of the co-cultures, i.e. the part where the two initially sep-
arated brain slices were grown together ( fig. 4 a). The following 
criteria were used for the selection of the biocytin-traced slices: 
(a) the tracer was correctly placed on the VTA/SN; (b) the major 
part of the VTA/SN was characterized by a dense network of bio-
cytin-traced structures, and (c) no traced cell bodies had been 
observed in the target region STR (described in detail in  [12] ).
 The raw images were obtained at 20 ! magnification from the 
whole border region by a usual transmitted light bright field mi-
croscope (Axioskop 50; Zeiss, Oberkochen, Germany) equipped 
with a CCD camera. Due to the usual problems with sensor noise 
and the large amount of light absorption and scattering inside the 
complex tissue structure of the stained co-culture slices, the axo-
nal structures are typically blurred and image quality further suf-
fers from inhomogeneous illumination. The border region is 
composed of both vesicular and fibrous structures (in the follow-
ing only termed fibers) due to the dynamic transport properties 
of the tracer biocytin. Thus, a tailored image analysis pipeline had 
to be designed to quantify the fiber density in an automated man-
ner. This procedure can be roughly split into two parts: image 
pre-processing and fiber detection.
 Pre-Processing of the Images 
 At first, a deconvolution of the images was computed to reduce 
the blur and highlight the expected ‘true’ structures of the fibers. 
Since the real point-spread function of the microscope setup was 
lacking, the convolution kernel was estimated by a general Gauss-
ian function (the width of the Gaussian is empirically set to 2 pix-
els), which is a reasonable guess in the general case of isotropic 
blur. The actual deconvolution was done with a damped least 
squares method (see  [27] ).
 The deconvolution step inevitably leads to an increase in noise. 
Since noisy image structures would lead to a high number of false 
positive hits for subsequent detection of vesicular structures, a 
total variation-based smoothing step was applied to suppress sin-
gle pixel noise in the images while preserving structures of inter-
est  [28] .
 Large-scale blurry structures in the background (due to struc-
tures from out-of-focus structures in the tissue) were subsequent-
ly removed by applying a top-hat transform, image structures 
larger than a given threshold were removed (a cutoff of 40 pixels 
was used here, see  [29] for details).
 Quantification of the Fiber Density 
 After pre-processing, the fiber structures appeared as well-de-
fined bright regions that clearly stood out against the background. 
These regions were then extracted by Otsu thresholding  [30] .
 Subsequently, the image area occupied by the fibers was mea-
sured to obtain a reasonable estimate of the underlying axonal 
density of the analyzed specimen. Precisely, the ratio of the num-
ber of foreground pixels (fibers) against the total number of pixels 
in the images was taken, giving the percentage of area occupied 
by fibers in the focal plane.
 Statistics 
 Statistical analysis of the intracellular cGMP assay was per-
formed using Student’s t test. Statistically significant differences 
were considered at a p level  ! 0.05 ( *  p  ! 0.05,  * *  p  ! 0.01,  * * *  p  ! 
0.001; the error bars indicate the SEM).
 Statistical analysis of the quantitative data, comparing the dif-
ferent treatment groups, was performed using a Wilcoxon Rank 
Sum test. Each individual group was compared to the control 
group DMSO. To correct for multiple pairwise testing between 
groups, a conservative Bonferroni p value correction was applied. 
Statistically significant differences were considered at a p level 
 ! 0.05 ( *  p  ! 0.05,  * *  p  ! 0.01,  * * *  p  ! 0.001). For each group, the 
treatment experiments were repeated for at least three individual 
preparations.
 Results 
 IC 50 Values of Selected PDE-Is 
 The potency and selectivity of BAY60-7550, ND7001, 
and MP-10 were confirmed against individual human 
purified proteins of each PDE family (except for PDE6, 
which was isolated from bovine retina), and the results 
are shown in  table 1 .
 The data of the IC 50 values against PDE2A indicated 
the following ranking: BAY60-7550  1 ND7001  1 MP-10. 
The PDE2-I BAY60-7550 inhibited the target enzyme 
with high potency with an IC 50 value of 0.18 n M , and 
ND7001 was characterized as a PDE2-I with moderate 
affinity (IC 50 = 57 n M ). Both compounds are highly selec-
tive against all other PDE isoforms. MP-10 inhibited the 
activity of PDE10 with high potency (IC 50 = 1.14 n M ) as 
well as high selectivity towards each individual isoform 
of the PDE family. In general, PDE proteins show a high 
degree of sequence homology across different species, es-
pecially within their catalytic domains (for review, see 
 [17, 18] ). Thus, it is very unlikely that PDE-Is show spe-
cies-specific effects with regard to their inhibitory activ-
ity. We have tested, for example, the PDE2-I ND7001 in a 
reference experiment using rat and human PDE2 pro-
teins and could not detect any significant differences in 
their inhibitory activity across species (data not shown).
 Effects of PDE2-Is on Intracellular cGMP Level 
 The PDE2-Is BAY60-7550 and ND7001 had been se-
lected for the cellular cGMP assay. Measurement of 
cGMP levels in HEK293 cells, stably transfected with the 
full-length sequence of human PDE2A, confirmed that 
PDE2-I BAY60-7550 ( fig.  5 a) and ND7001 ( fig.  5 b) in-
creased cGMP levels in a dose-dependent manner. In the 
presence of SNP (100   M ), these compounds significant-
ly increased cGMP levels as compared to the control 
group. These findings suggest that PDE2 may play a ma-
jor role in the degradation of cGMP under conditions of 
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GC stimulations. The numbers of independent experi-
ments per compound were: BAY60-7550, n = 8, and 
ND7001, n = 4, performed in duplicates.
 Characterization of the Organotypic Co-Cultures 
(VTA/SN+STR) 
 In the present study, the VTA/SN and the STR, main 
parts of the DAergic nigrostriatal projection system, were 
prepared from P1–5 old rats, a period during which the 
rat exhibits an adult localization of the neurons, although 
the axonal network is still immature  [31] . Following fixa-
tion of the cultures at DIV 10, the slices were character-
ized using different labeling techniques.
 Biocytin Tracing 
 The morphology of the biocytin-traced cell bodies as 
well as the outgrowth of the fibers were analyzed in treat-
ed as well as untreated control co-cultures. An example 
of an untreated biocytin-traced co-culture is shown in 
 figure 4 a. In general, numerous biocytin-marked fibers 
(labeled in black) originating from the VTA/SN, ramified 
and crossed the border region between the two brain slic-
es. Moreover, their fiber processes were observed to grow 
into the striatal part of the culture. The fiber pathways of 
the VTA/SN+STR co-cultures developed an innervation 
pattern similar to that found in vivo  [10] . These findings 
are in accordance with other studies, showing that the 
projections of axons to their targets follow special stereo-
typical routes during the development of the central ner-
vous system and that selected guidance molecules sup-
port this innervation  [32–34] .
 Immunohistochemistry/Immunofluorescence 
 The expression of TH, a marker for DAergic neurons, 
was shown using immunofluorescence labeling in combi-
nation with confocal laser scanning microscopy. The re-
sults indicate the presence of TH-positive cell bodies and 
fibers in the VTA/SN ( fig. 4 b, e), whereas the expression 
of the marker was restricted to fibers within the border 
region ( fig. 4 c, d) and the STR ( fig. 4 d, f). Fluorescence 
images illustrating the differences in the expression of TH 
immunoreactivity (IR) in the respective anatomical parts 
of the DAergic system are shown in  figure 4 b–d. The pic-
tures especially exemplify the expression of the ‘dot-like’ 
structures in the border region and the target area (also 
observed after biocytin tracing, see  fig. 6 ). Furthermore, 
antibodies against neuronal markers, i.e.   III-tubulin and 
MAP2 and the astroglial marker GFAP, were used to 
prove the existence of neuronal processes and glial cells, 
especially within the border region of the co-cultures. A 
positive IR for all investigated markers was observed in 
VTA/SN and STR. Examples are shown in  figure 4 g–i, 
where the existence of   III-tubulin- ( fig.  4 g), MAP2- 
( fig. 4 i), and GFAP- ( fig. 4 h) labeled fibers spanning the 
border region and, thus, linking the two slices could be 
verified. These results are consistent with the results 
 Fig. 5. Dose-dependent effects of PDE2-Is BAY60-7550 ( a ) and 
ND7001 ( b ) on intracellular cGMP levels in a PDE2-HEK293 cell 
line. BAY60-7550 and ND7001 (in the presence of the GC stimu-
lator SNP) increased the intracellular cGMP level in a dose-de-
pendent fashion. Values are shown in fmol cGMP per well. The 
error bars indicate SEM. The numbers of independent experi-
ments per compound were: BAY60-7550 (n = 8) and ND7001 (n = 
4), performed in duplicates. Differences to SNP were considered 
to be statistically significant according to a p level  ! 0.05 ( *  p  ! 
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found in our previous studies, demonstrating the expres-
sion of neuronal and glial fiber connections within VTA/
SN + prefrontal cortex co-cultures  [12] .
 Further light microscopic and triple immunofluores-
cence labeling studies with specific antibodies directed 
against PDE2A and PDE10 were performed to demon-
strate the expression of these isoforms. Examples are 
shown in  figure 7 .
 The light microscopic data indicated the expression of 
PDE2A on cell bodies and fibrous structures in the STR 
and VTA/SN (data not shown) and correlate with the im-
munofluorescence data. The immunofluorescence label-
ing was predominately found at the plasma membrane as 
well as in the cytoplasm (an example for the STR is given 
in  fig. 7 a–c, arrows). Moreover the co-localization of the 
PDE2A-IR on MAP2-immunopositive cells could be ob-
served (example for VTA/SN;  fig. 7 f–h, arrows). We did 
not find PDE2-positive fibers in the border region (an ex-
ample is shown in  fig.  7 d, e). Double immunofluores-
cence experiments using TH and PDE2A indicated no 
co-expression on cell bodies or fibers in all parts of the 
studied co-cultures, as shown in  figure 7 i–m.
 Light microscopic images also confirmed the evidence 
of PDE10-marked cell bodies and fibers in the STR and 
the VTA/SN. Additional investigations using double im-
munofluorescence labeling with antibodies against TH 
and the PDE10 isoform indicated the expression of PDE10 
on cell bodies and single fibers. On the other hand, no 
co-expression with TH-positive fibers (STR, VTA/SN) or 
the localization on TH-positive neurons (VTA/SN) could 
be found ( fig. 7 n–q).
 The obtained results thus clearly underline the expres-
sion of the investigated isoforms in the VTA/SN+STR co-
cultures during development.
 Treatment of Organotypic Co-Cultures with PDE2- 
and PDE10-Is 
 Qualitative Results of the Fiber Growth (Biocytin 
Tracing) 
 Further co-cultures (VTA/SN+STR) had been used to 
study the influence of selected PDE-Is, with different 
subclass specificities, on fiber growth and sprouting. All 
experiments were performed in a blinded fashion, i.e. the 
compound identity was provided after final data analysis. 
a b c
d e f
 Fig. 6. Results of the biocytin tracing after substance treatments 
are demonstrated within the border region of the co-cultures. 
Compared to control conditions applying ACSF ( a ) and DMSO 
( b ) an increase in biocytin-positive fibers in PDE2-Is-treated co-
cultures using BAY60-7550 ( d ) and ND7001 ( e ) was observed. 
These effects were comparable with the effect evoked by the 
growth factor NGF ( c ). Co-cultures treated with MP-10 ( f ) were 
characterized by few biocytin-traced innervations within the bor-
der region. Scale bar:  a–f 20   m. 
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a b c d e
f g h
i j k l m
n o p q
 Fig. 7. Confocal images of multiple immunofluorescence labeling 
using antibodies against PDE2A ( a–m ) and PDE10 ( n –q ) in com-
bination with MAP2 (neuronal marker), TH (DAergic marker), 
and Hoechst (Hoe) are shown.  a–h PDE2A is expressed in the STR 
and VTA/SN especially on cell bodies (plasma membrane, cyto-
plasm; co-expression with MAP2 is indicated by arrows). No la-
beling was found on fibers in the border region (example given in 
 d ,  e ). The double-labeling experiments with antibodies against 
TH indicated neither co-localization of PDEA2 and TH in the 
STR, VTA/SN, nor in the border region ( i–m ). PDE10 was found 
to be expressed on cell bodies and also on fibers (indicated by ar-
rows in  n–q ), but no co-localization was found with TH-positive 
structures in the studied regions. Scale bars:  a–c 5   m;  d–h 10 
  m;  i 20   m;  j ,  k 20   m;  l–o 10   m;  p ,  q 20   m. 
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As described in the Methods section, the co-cultures 
were treated 4 times with the respective substances, over 
an incubation time of 10 days and, afterwards, the out-
growth of the biocytin-traced fibers in the border region 
was analyzed.
 Differences in fiber outgrowth within the border re-
gion could be observed for the different treatments, and 
examples of these results are illustrated in  figure 6 . An 
increase in biocytin-positive fibers was apparent in 
PDE2-I- (e.g. BAY60-7750,  fig. 6 d) treated co-cultures in 
comparison to control conditions (ACSF,  fig. 6 a; DMSO, 
 fig. 6 b). The growth factor NGF evoked an effect compa-
rable to the PDE2-Is under study ( fig.  6 c). Co-cultures 
treated with MP-10, an inhibitor of the PDE10, were char-
acterized by fewer biocytin-traced innervations within 
the border region compared to the effects induced by the 
PDE2-Is ( fig. 6 f). Furthermore, the ‘dot-like’ structures 
are of particular interest. They could be observed in the 
border region and the target region (STR) after substance 
treatment. This expression was also found after TH label-
ing of outgrowing fibers (see also  fig. 4 ,  8 ). A significant 
increase in the number of puncta was noticeable after 
treatment with BAY60-7550.
 Quantification of Fiber Density (Biocytin Tracing) 
 Starting from light microscopic images, the density of 
the biocytin-positive fibers was measured for all treat-
ment groups in the border region of the co-cultures using 
the automated image quantification described above. The 
respective results of the tested substances are shown as 
box-whisker plots in  figure 9 . A significant increase in 
neuronal fiber outgrowth after application of the PDE2-
Is BAY60-7550 and ND7001 was observed, with BAY60-
7550 exhibiting the strongest effect. These results were of 










































 Fig. 8.  a–d TH-positive fibers after substance treatment ( a ACSF; 
 b NGF,  c DMSO,  d BAY60-7550 solved in DMSO) within the bor-
der region of the co-cultures are shown (scale bar:  a–d 20   m).
 e Results of automated image quantification to measure the den-
sity of the TH-positive fibers in the border region of differently 
treated co-cultures in comparison to control conditions. After 
TH labeling, the fiber density was quantified, taking the ratio of 
the number of foreground pixels (fibers) over the total number of 
pixels in the images to reveal the size of the area occupied by fi-
bers. The box-whisker plots represent the empirical distribution 
of the fiber densities in the different groups (the vertical axis cor-
responds to the percentage of image pixels belonging to labeled 
fibers). Compared with ACSF and DMSO, the growth factor NGF 
induced a significant increase in TH-positive fibers in the studied 
co-cultures. In contrast, the PDE2-I BAY60-7550 evoked only a 
small but significant increase of the number of TH-positive fibers, 
in comparison with the solvent DMSO. The numbers of analyzed 
images per group are: ACSF (n = 8), DMSO (n = 20), NGF (n = 33) 
and BAY60-7550 (n = 94). Differences were considered statisti-
cally significant at a p level  ! 0.05 ( *  p  ! 0.05,  * * *  p  ! 0.001).  
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comparable effect size as for the neurotrophic factor NGF. 
MP-10 (PDE10-I) caused a clearly lower fiber density in 
the border region, akin to the effects observed in the con-
trol groups. Moreover, no significant differences in fiber 
density could be observed between the ACSF and the 
DMSO control group, thus excluding adverse effects re-
sulting from the solvent DMSO. The numbers of ana-
lyzed images per group are: ACSF (n = 22), DMSO (n = 
62), NGF (n = 41), BAY60-7550 (n = 101), ND 7001 (n = 
103), and MP-10 (n = 76).
 Treatment of Organotypic Co-Cultures with PDE2-I 
and NGF – Characterization of DAergic Fibers 
 Qualitative Results of the Fiber Growth (TH 
Immunolabeling) 
 Treatment of the co-cultures with ACSF, NGF, DMSO, 
and BAY60-7550 (solved in DMSO) and immunolabeling 
with antibodies against TH indicated differences in the 
expression of TH-positive fibers in the border region (ex-
amples are shown in  fig. 8 a–d). Especially the effect of 
NGF as trophic factor was clearly visible.
 Quantification of the Fiber Density
(TH Immunolabeling) 
 Moreover, the density of the TH-positive fibers was 
analyzed and quantified for all treatment groups as de-
scribed above. The results are shown in  figure 8 e. The 
growth factor NGF induced a significant increase in TH-
positive fibers in the studied co-cultures as compared to 
ACSF and DMSO. In contrast, the PDE2-I BAY60-7550 
evoked a smaller (in comparison to the biocytin tracing) 
but statistically significant increase in the density of TH-
positive fibers under these conditions (as compared with 
the DMSO group). The observed difference in effect size 
of BAY60-7550 treatment between biocytin tracing and 
TH labeling suggests an involvement of additional neu-
rotransmitter populations, other than the TH-positive 
(DAergic) subgroup. Although small differences between 
DMSO and ACSF exist, they were not found to be statisti-
cally significant.
 The numbers of analyzed images per group are: ACSF 
(n = 8), DMSO (n = 20), NGF (n = 33), and BAY60-7550 
(n = 94). Differences were considered statistically signifi-
cant at a p level  ! 0.05 ( *  p  ! 0.05,  * *  p  ! 0.01,  * * *  p  ! 
0.001).
 Discussion 
 The characterization of determinants of innervation 
patterns and the activities of growth promoting factors 
are of special interest for the development of clinical 
strategies to promote fiber development and, thereby, the 
regeneration of neuronal circuits. Using the ex vivo mod-
el of organotypic slice co-cultures, consisting of the VTA/
SN and the STR, in combination with biocytin tracing, 
TH immunolabeling, and subsequent automated image 
quantification, it was shown that substances with the po-
tential to inhibit PDE2 (BAY60-7550, ND7001) were able 
to increase neuronal fiber outgrowth, in contrast to the 
studied PDE10-I (MP-10) and the control substances 
ACSF and DMSO.
 The data suggest a role for PDE2-Is, possibly mediat-
ed via cGMP, in the induction of fiber outgrowth in the 
nigrostriatal projection system. In PDE2-transfected 
HEK293 cells, a dose-dependent increase of intracellular 
cGMP levels in response to PDE2-Is, the previously de-












































 Fig. 9. Automated image quantification to measure the fiber den-
sity in the border region of different treated co-cultures in com-
parison to control conditions. After biocytin tracing, the fiber 
density was quantified, taking the ratio of the number of fore-
ground pixels (fibers) over the total number of pixels in the im-
ages to reveal the size of the area occupied by fibers. The box-
whisker plots represent the empirical distribution of the fiber 
densities in the different groups (the vertical axis corresponds to 
the percentage of image pixels belonging to traced fibers). The 
analysis revealed a significant increase in neuronal fiber out-
growth after application of PDE2-Is BAY60-7550 and ND7001, 
with effects comparable to the stimulation capacity of NGF. The 
inhibitor of PDE10, MP-10, caused a significantly lower fiber den-
sity in the border region, similar to the results of ACSF and DMSO. 
The numbers of analyzed images per group were: ACSF (n = 22), 
DMSO (n = 62), NGF (n = 41), BAY60-7550 (n = 101), ND7001
(n = 103), and MP-10 (n = 76). Statistically significant differences 
were considered at a p level  ! 0.05 ( * * *  p  ! 0.001). 
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could further be shown. These data indicate that inhibi-
tion of PDE2 results in a dose-dependent augmentation 
of intracellular cGMP levels.
 In vivo studies on rats have shown that DAergic neu-
rons emerged around embryonic day 10, with the first 
nerve fibers appearing in the STR around embryonic 
days 14–15. The innervations are completed at about P15 
 [35] . Thus, the situation in the established ex vivo model 
strongly correlates with the developmental processes of 
physiological neuronal circuits. The observed neurite 
outgrowth pattern is consistent with our own previous 
data obtained under in vivo conditions  [10] .
 PDEs are involved in distinct tasks in the brain, both 
in the mature rat brain and at embryonic as well as post-
natal stages when significant developmental and matura-
tional events are in progress  [19, 20, 36] . An increase
in PDE activity was reported during development of
the brain from fetus to adulthood  [37, 38] . Our data indi-
cate an expression of PDE2A and PDE10 on cells in the 
DAergic co-culture preparations, consequently underlin-
ing a role of these isoenzymes in early development.
 Hydrolyzing PDE families have distinct expression 
patterns within the central nervous system. For instance, 
striatal medium spiny neurons express mRNA for the 
PDE1B, 2A, 4B, 7B, 9A, and 10A isoforms (for references, 
see  [39, 40] ). A prominent PDE2A-IR was found besides 
the STR in the isocortex, hippocampus, and basal gan-
glia. Moreover, a high expression was observed in the SN 
and VTA on cell bodies and terminals  [20, 36] , which is 
supported by the findings presented in this work. PDE10 
mRNA and protein are highly enriched in medium spiny 
neurons in the STR, within the cell bodies and dendrites 
as well as on SN axons  [22, 41, 42] . PDE10A is associated 
with post-synaptic membranes of these medium spiny 
neurons and their dendrites and spines  [43] .
 Under physiological conditions, the dual substrate en-
zyme PDE2(A) plays a critical role in the feedback control 
of cellular cAMP and cGMP levels, resulting in acute and 
long-term changes of neuronal functions. The basal PDE2 
activity in neurons is low, but it is stimulated by an acute 
increase in cGMP following GC activation during signal 
transduction. In detail, a characteristic feature of PDE2 is 
the positive cooperativity with the substrate cGMP due to 
an allosteric cGMP binding site at N-terminal domains 
 [40, 44] . This cyclic nucleotide stimulates cAMP degrada-
tion such that higher concentrations of cGMP inhibit 
cAMP hydrolysis and low levels of cGMP enhance the rate 
of cAMP hydrolysis  [39, 44] . Besides the described fea-
tures of PDE2, also special GAF domains of PDEs 5, 6, 10, 
and 11 bind cGMP and may regulate the catalytic activity 
or protein-protein interactions (for references, see  [45] ). 
As a consequence, inhibition of PDE2 selectively increas-
es cGMP and cAMP in brain active synapses  [19, 44] . In-
cubation of cultured neurons and hippocampal slices 
with the selective PDE2-I BAY60-7550 resulted in in-
creased cGMP levels  [44] . This is in accordance with our 
present data, indicating a dose-dependent increase of in-
tracellular cGMP levels in response to the investigated 
PDE2-Is obtained in the HEK cell line. Inhibition of the 
PDE10A causes also increased levels of cAMP and cGMP 
 [40] , with the difference that the regulation of the two cy-
clic nucleotides by PDE10A is independent  [22] .
 The involvement of cAMP/cGMP during neuronal de-
velopment in synaptic plasticity and memory formation 
has been described  [19, 36, 44] . Recent data suggest a role 
of cAMP (via cAMP-dependent protein kinase) in neuri-
togenesis and synaptogenesis during neuronal differen-
tiation in NG108-15 cells  [14] . The particular role of ex-
change proteins directly activated by cAMP (Epac) will 
be of specific interest for further studies as they are 
known to be involved in mediating cAMP responses. 
These are implicated in various cellular processes such as 
integrin-mediated cell adhesion and cell-cell junction 
formation or influencing, for example, cortical actin cy-
toskeleton (for review, see  [46] ).
 cGMP can regulate directional guidance of growth 
cones  [13, 47] and is involved in the outgrowth of cortical 
neurons during maturation  [32] . The observed trophic 
effects clearly show that inhibitors of PDE2 are able to 
modulate neuronal fiber outgrowth in VTA/SN+STR co-
cultures in contrast to the studied PDE10-I (MP-10), sug-
gesting an involvement of PDE2, via cGMP signaling, in 
synaptic plasticity. Data from Boess et al.  [44] confirm 
that inhibition of PDE2, e.g. by the selective PDE2-I 
BAY60-7550, increases cGMP/cAMP in cultured neurons 
and hippocampal slices, resulting in enhanced long-term 
potentiation of synaptic transmission, which is thought 
to be a key factor implicated in pro-cognitive activity 
without affecting basal synaptic transmission. A role of 
PDE2A activity in memory processes is further support-
ed by the results of Song et al.  [47] and Rutten et al.  [19] 
showing that BAY60-7550 reportedly improves perfor-
mance of rodents in recognition memory tasks.
 Inhibition of PDE10 promotes effects modulating basal 
ganglia function in ways that suggest a particular thera-
peutic utility in the treatment of psychosis in schizophre-
nia  [22, 23, 48] . It has also been shown that PDE10-I
increases phosphorylation of key cAMP-dependent
substrates, such as cAMP response element-binding pro-
tein, extracellular receptor kinase, or, more recently, the 
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AMPA-receptor GluR1 subunit  [48–51] . Sotty et al.  [51] 
further suggest a modulatory role of PDE10A on mesolim-
bic DAergic neurotransmission, via the D1-regulated feed-
back loop controlling midbrain DAergic neuronal activity. 
Therefore, investigating its modulatory role to affect the 
confluence of the corticostriatal glutamatergic and the 
midbrain DAergic pathways will be of particular interest.
 The regulation of cAMP synthesis by DA and other 
neurotransmitter receptors has been extensively studied. 
But the importance of cAMP degradation by PDEs and 
the precise roles of each PDE isoform in DAergic signal-
ing are not yet completely understood, owing to the di-
versity of PDE isoforms expressed in the STR and the 
complexity of their potential regulation (for review, see 
 [24] ). The authors conclude that the inhibition of PDEs 
upregulates cAMP/PKA signaling in three neuronal sub-
types, resulting in (a) the stimulation of DA synthesis at 
DAergic terminals, (b) the inhibition of D2 receptor sig-
naling in striatopallidal neurons, and (c) the stimulation 
of D1 receptor signaling in striatonigral neurons. How-
ever, it should be noted that the striatopallidal system as 
well as the corticostriatal glutamatergic projection are 
not constituents of the organotypic slice co-culture sys-
tem used in the present study – possibly causing the dif-
ferent inhibitory effects of the investigated PDE-Is (espe-
cially for PDE10-I). However, the mechanism of inhibi-
tion responsible for the observed effects of the two kinds 
of PDE-Is needs further experimental investigations, es-
pecially  the role of PDE10 to affect the corticostriatal glu-
tamatergic and the midbrain DAergic pathways.
 Finally, in the present study, the growth-promoting ef-
fect of the PDE-Is was compared with the stimulating ca-
pacity of NGF, which elicited a significant increase in fi-
ber outgrowth intensity. Neurotrophins, like NGFs and 
their receptors, are the major regulators of neuronal sur-
vival during development, after injury or nervous system 
diseases  [52] . NGF promotes neurite extension through a 
cAMP-independent signaling pathway involving Ras, 
PKC, and extracellular signal-regulated protein kinase 
 [53] . It has been shown that cAMP also induces neuronal 
differentiation in PC12 cells and that the co-treatment of 
NGF and dibutyryl cAMP exhibits synergistic effects on 
neurite outgrowth  [54] . Moreover, NGF increases cGMP 
level and activates PDEs in PC12 cells  [55] . Also other 
trophic molecules have been shown to enhance survival 
and neurite outgrowth of mesencephalic DAergic neu-
rons in single cell cultures or slice cultures  [56–58] . Treat-
ment of organotypic slice co-cultures with BDNF result-
ed in enhanced survival of TH-positive neurons and an 
increased growth of TH-positive fibers into the striatal 
tissue  [58] . GDNF has been shown to act as a powerful 
chemoattractant for outgrowing DAergic axons in organ-
otypic co-cultures  [33, 59] as well as under in vivo condi-
tions  [60] . Finally, Thompson et al.  [60] showed that axo-
nal regrowth in the nigrostriatal trajectory can be further 
enhanced by the addition of trophic support by overex-
pression of GDNF in the striatal target.
 In summary, cAMP/cGMP are involved in survival, 
repair, and remodeling in the nervous system both dur-
ing development and after injury, and PDE2 appears to 
act as an important regulator in these processes. In the 
present study, we were able to analyze the specific poten-
tial of PDE-Is in mediating the growth of defined fiber 
connections under controlled conditions, using the ex 
vivo model of organotypic slice co-cultures of the nigro-
striatal system in combination with an automated image 
quantification. Hence, our results strongly support a tro-
phic role of PDE2-Is in shaping interneuronal connec-
tions during the early phase of neuronal development. 
The characterization of the molecular and functional ba-
sis underlying the observed effects of PDE2-Is in regen-
eration and repair of disrupted neuronal circuits will be 
an important next step to foster the development of im-
proved ways for the treatment of neurological disorders.
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a  b  s  t  r  a  c  t
Calcium  ions  (Ca2+) play  important  roles  in neuroplasticity  and  the  regeneration  of  nerves.  Intracellular
Ca2+ concentrations  are  regulated  by  Ca2+ channels,  among  them  L-type  voltage-gated  Ca2+ channels,
which  are  inhibited  by  dihydropyridines  like  nimodipine.  The  purpose  of this  study  was  to investigate  the
effect  of nimodipine  on  neurite  growth  during  development  and  regeneration.  As an  appropriate  model
to  study  neurite  growth,  we chose  organotypic  brain  slice  co-cultures  of the  mesocortical  dopaminergic
projection  system,  consisting  of  the  ventral  tegmental  area/substantia  nigra  and  the  prefrontal  cortex
from  neonatal  rat  brains.  Quantiﬁcation  of  the  density  of  the  newly  built  neurites  in the  border  region
(region  between  the  two  cultivated  slices)  of  the  co-cultures  revealed  a  growth  promoting  effect  of
nimodipine  at concentrations  of  0.1 M and  1 M that was  even  more  pronounced  than  the  effect  of  the
growth  factor  NGF.
This beneﬁcial  effect  was  absent  when  10  M  nimodipine  were  applied.  Toxicological  tests  revealed
that  the  application  of nimodipine  at this  higher  concentration  slightly  induced  caspase  3  activation  in
the  cortical  part of the  co-cultures,  but  did  neither  affect  the  amount  of lactate  dehydrogenase  release  or
propidium  iodide  uptake  nor  the  ratio  of  bax/bcl-2.  Furthermore,  the  expression  levels  of  different  genes
were  quantiﬁed  after  nimodipine  treatment.  The  expression  of  Ca2+ binding  proteins,  immediate  early
RESEARCH ARTICLES - Nimodipinegenes,  glial  ﬁbrillary  acidic  protein,  and  myelin  components  did  not  change  signiﬁcantly  after  treatment,
indicating  that  the  regulation  of  their  expression  is  not  primarily  involved  in  the  observed  nimodipine
mediated  neurite  growth.  In summary,  this  study  revealed  for the  ﬁrst  time  a neurite  growth  promoting
effect  of nimodipine  in  the mesocortical  dopaminergic  projection  system  that  is highly  dependent  on  the
applied  concentrations.
©  2014  ISDN.  Published  by  Elsevier  Ltd.  All  rights  reserved.Abbreviations: ANOVA, analysis of variance; Arc, activity-regulated cytoskeleton-assoc
ide; DIV, days in vitro; Egr, early growth response protein; FCS, fetal calf serum; Fos, p
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yelin and lymphocyte protein; MAP2, microtubule associated protein-2; Mog, myelin o
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itative  reverse transcription polymerase chain reaction; SOM, self-organizing maps; TB
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. Introduction
Nimodipine is a blocker of the L-type voltage-gated Ca2+ chan-
els (LVCC), which regulate the intracellular Ca2+ concentration.
alcium ions (Ca2+) play an important role in neuronal plasticity
Gispen et al., 1988). Their intracellular concentration is crucial
or the regulation of axonal and dendritic growth, guidance during
euronal development and for resprouting of axons after injury
for review see Gomez and Zheng, 2006). It has been shown that
roper neuronal development proceeds when the intracellular Ca2+
s within an optimal range (Fields et al., 1993; Kater and Mills,
991; Kater et al., 1988). Therefore, the modulation of Ca2+ chan-
els such as the LVCC is of special interest, when neurite (re)growth
s desired.
Being one of the examined LVCC blockers, the dihydropyridine
erivate nimodipine has been intensively studied. Its beneﬁcial
ffects have been conﬁrmed in clinical studies (Liu et al., 2011,
cheller and Scheller, 2012) and in diverse experimental studies,
here it has been applied to models of various disorders. These
xperimental studies, analyzing the effect of nimodipine (and other
ihydropyridine LVCC blockers), focused on (i) the neuroprotective
roperties after different kinds of neuronal injury (Harkany et al.,
000; Krieglstein et al., 1996; Lecht et al., 2012; Li et al., 2009; Rami
nd Krieglstein, 1994; Weiss et al., 1994), for example by reducing
he consequent intracellular free Ca2+ overload after e.g. ischemic
njury and excitotoxic lesion (Kobayashi and Mori, 1998) and (ii) the
eurite growth promoting characteristics, mainly investigated in
he peripheral nervous system (Angelov et al., 1996; Lindsay et al.,
010; Mattsson et al., 2001).
LVCC are expressed in a couple of brain regions of the central
ervous system, among them the mesencephalon (Mercuri et al.,
994; Nedergaard et al., 1993; Takada et al., 2001), the cortex, and
he hippocampus (Dolmetsch et al., 2001; Quirion et al., 1985; Tang
t al., 2003). In the cortex, LVCC are located on the entire postnatal
euron including dendrites and axonal processes (Tang et al., 2003).
Although the beneﬁcial outcomes of LVCC modulation by
imodipine are well established, the exact cellular and molecu-
ar mechanisms by which this modulation occurs are still unclear.
evertheless, results of some previously published studies may
n part explain how neurite growth after nimodipine treatment
s accomplished. An upregulation of Ca2+ binding proteins (CBPs,
arvalbumin (Pvalb), S100b, calbindin) has been observed in cor-
ical neurons after nimodipine administration (Buwalda et al.,
994; Luiten et al., 1994). Furthermore, the expression of the
lial ﬁbrillary acidic protein (GFAP) was enhanced following long-
erm nimodipine treatment (Guntinas-Lichius et al., 1997). An
ncrease in myelination was found surrounding the recovering
eurons after unilateral facial crush injury and interestingly also
round neurons located in the contralateral nonlesioned site in
imodipine treated animals (Mattsson et al., 2001). Moreover,
icroglial-mediated oxidative stress and inﬂammatory response
as attenuated by nimodipine (but not by other LVCC block-
rs) in dopaminergic neurons/microglial co-cultures (Li et al.,
009).
In this study, we wanted to investigate whether nimodipine
irectly inﬂuences neurite growth. We  further aimed to elucidate
hich genes are potentially involved in the nimodipine mediated
rowth effects. To address these questions, we determined the neu-
ite density in the border region of organotypic co-cultures of the
esocortical dopaminergic system, which culture together brain
lices of the ventral tegmental area/substantia nigra (VTA/SN) and
refrontal cortex (PFC) (Heine et al., 2007; Heine and Franke, 2014),
nd analyzed gene expression patterns of nimodipine treated sam-
les and control samples.
Our  ﬁndings indicate that nimodipine, at appropriate dosages,
s a promising substance to enhance neurite outgrowth as shown inroscience 40 (2015) 1–11




The solvent ethanol was purchased from AppliChem GmbH (Darmstadt,
Germany)  and VWR  International (Dresden, Germany), respectively. Glutamate,
nerve  growth factor (NGF), and staurosporine were purchased from Sigma–Aldrich
Co.  (St. Louis, MO,  USA). Nimodipine (pure substance) was a gift from Bayer Vital
GmbH (Leverkusen, Germany). 1000-fold stock solutions of nimodipine were pre-
pared in absolute ethanol and ﬁnally added to 1 ml  of incubation medium (resulting
ethanol  concentration 0.1%, details see Section 2.3). Untreated cultures (“untreated”)
or  cultures treated with the vehicle ethanol (“ethanol”, resulting end concentration
0.1%)  were used as control groups.
2.2. Animals
Neonatal rat pups (WISTAR RjHan, own breed; animal house of the Rudolf Boehm
Institute  of Pharmacology and Toxicology, University of Leipzig) of postnatal day
1–4 (P1-4) were used for the preparation of the organotypic slice co-cultures. The
animals were housed under standard laboratory conditions of 12 h light–12 h dark
cycle and allowed free access to lab food and water ad libitum.
All  of the animal use procedures were approved by the Committee of Animal
Care  and Use of the relevant local governmental body in accordance with the law of
experimental animal protection. All efforts were made to minimize animal suffering
and to reduce the number of animals used.
2.3. Preparation, culture and treatment of slice co-cultures
Dopaminergic brain slice co-cultures were prepared from P1-4 rats and cul-
tured  according to the “static” culture protocol described previously (Heine et al.,
2007; Heine and Franke, 2014). In brief, coronal sections (300 m)  were cut at mes-
encephalic and forebrain levels using a vibratome (Leica, Typ VT 1200S, Nussloch,
Germany).  For details see also supplementary Fig. S1. After separation of VTA/SN
and  PFC, respectively, the slices were transferred into petri dishes, ﬁlled with cold
(4 ◦C) preparation solution (Minimum Essential Medium (MEM)  supplemented with
glutamine (ﬁnal concentration 2 mM)  and the antibiotic gentamicin (50 g/ml);
all  from Invitrogen GmbH, Darmstadt, Germany). Thereafter, the selected sections
were placed as co-cultures (VTA/SN + PFC, 4 co-cultures per well) on moistened
membrane  inserts (0.4 m, Millicell-CM, Millipore, Bedford, MA,  USA) in 6-well
plates  (Fig. S1.A3), each ﬁlled with 1 ml  incubation medium (50% Minimal Essen-
tial  Medium, 25% Hank’s Balanced Salt Solution, 25% heat inactivated horse serum
(HS), 2 mM glutamine and 50 g/ml gentamicin; all from Invitrogen GmbH supple-
mented  with 0.044% sodium bicarbonate, Sigma-Aldrich; pH was adjusted to 7.2),
referred to as “25% HS incubation medium”.
Supplementary Fig. S1 can be found, in the online version, at http://dx.doi.org/
10.1016/j.ijdevneu.2014.10.005.
The  preliminary gene expression studies (microarray analysis, quantitative
reverse  transcription polymerase chain reaction, qPCR) have been conducted after
culture under serum-free culture conditions. Therefore, after 4 days in vitro (DIV)
the 25% HS incubation medium was replaced by serum-free medium (Neurobasal-A
(NB-A)  medium, 1 mM glutamine supplemented with 2% B27 and 50 g/ml gen-
tamicin; all from Invitrogen GmbH), referred to as “NB-A incubation medium”.
Nimodipine  (ﬁnal concentration 10 M)  or the vehicle ethanol (0.1%), respectively
were  added to the incubation medium at DIV4, 6, 8 and 11.
To  determine the concentration of nimodipine that would be appropriate,
we  ﬁrst analyzed previous published studies and the therein used concentrations
(10  M:  Blanc et al., 1998; Krieglstein et al., 1996; Lecht et al., 2012; Tang et al.,
2003;  20 M:  Martínez-Sánchez et al., 2004; Pisani et al., 1998; Pozzo-Miller et al.,
1999; 50 M:  Bartrup and Stone, 1990, toxic at higher concentrations: Turner et al.,
2007). Second, we  quantiﬁed nimodipine uptake into the co-cultures with applied
nimodipine concentrations ranging from 10 M to 40 M in a preliminary experi-
ment. We  found the lowest dose applied (10 M nimodipine in the culture medium)
yielded a sufﬁciently high concentration in the tissue (unpublished results). There-
fore, the following studies were at ﬁrst conducted with 10 M nimodipine.
The analysis of neurite growth in the organotypic brain slice co-cultures is
a  well-established technique in our lab (Heine et al., 2013; Heine et al., 2007).
Therefore,  the neurite growth analysis has been performed after culture in 25% HS
incubation medium. For the neurite growth quantiﬁcation, slice co-cultures were
divided into different experimental groups and were treated with nimodipine at
different concentrations (ﬁrst 10 M,  later 0.1 M and 1 M)  or the vehicle control
ethanol.  A second control group was left untreated. Nimodipine and ethanol were
added directly after the preparation and at each medium change at DIV1,4,6 and
RESEARCH ARTICLES - Nimodipine8 (Fig. 1). In a second study the effect of 1 M nimodipine alone or in combination
with  50 ng/ml NGF (ﬁnal concentration) was  compared to 50 ng/ml NGF alone. These
culture conditions (25% HS incubation medium, substance application ﬁve times
as indicated in Fig. 1) were also applied for toxicity tests and later gene expression
studies.  In addition, tissue slices of the nimodipine treated groups were dissected
36
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Fig. 1. Culture and treatment schedule. For neurite growth, toxicity and later gene



















































i and 8. Neurite growth was quantiﬁed after biocytin tracing at DIV8 and ﬁxation
t  DIV11, as indicated. For the analysis of toxicity and gene expression, co-cultures
ere  harvested at DIV11.
n nimodipine containing preparation medium. This is in accordance to in vivo
ata of a human study, where prophylactic treatment had the strongest beneﬁcial
ffect  (Scheller et al., 2012). For this reason, 36 nM nimodipine were added to the
reparation solution on the basis of ﬁndings in the literature (Lindsay et al., 2010).
.4. Analysis of gene expression
.4.1.  RNA extraction and quality control
RNA  extraction was performed for microarray analysis and quantitative reverse
ranscription  polymerase chain reaction (qPCR). At the end of culture, both regions
f the co-cultures (PFC and VTA/SN) were separated with a scalpel and all PFC-
nd  VTA/SN-slices from one well, containing four co-cultures, were pooled to one
ample, respectively. Afterwards total RNA was  isolated using TRIzol reagent (Life
echnologies, Gaithersburg, MD,  USA) according to the manufacturer’s instructions.
he  total RNA was alcohol precipitated for a second time with addition of ammo-
ium  acetate and GlycoBlue (Life Technologies) for optimal recovery of the nucleic
cids. RNA integrity and concentration for each sample that was later on applied to
he microarray, was  examined on an Agilent 2100 Bioanalyser (Agilent Technolo-
ies,  Palo Alto, CA, USA) using the RNA 6.000 LabChip Kit (Agilent Technologies)
ccording  to the manufacturer’s instructions. RNA integrity and concentration of
amples, that were investigated by qPCR, were examined on a 1.5% agarose gel and
ith NanoDrop1000 (NanoDrop Technologies, Wilmington, DE, USA), respectively.
.4.2. Microarray analysis
Microarray measurements were conducted at the microarray core facility of
he Interdisziplinäres Zentrum für klinische Forschung (IZKF) Leipzig (Faculty of
edicine, University of Leipzig). Biotin labeled probes were prepared from 250 ng
f total RNA using the TargetAmpTM-Nano Labeling Kit for Illumina® Expression
eadChip  (Biozym, Hessisch Oldendorf, Germany) according to the manufacturer’s
nstructions.  Hybridization of labeled probes to an Illumina Rat Ref12 BeadChip
Illumina  Inc., San Diego, CA, USA) using the respective BeadChip kit (Illumina)
as  done according to the protocol of the manufacturer. Bead level data was
reprocessed  using standard Illumina software resulting in background-corrected,
uantile-normalized expression estimates which were used for further analysis.
anked  lists of differentially expressed genes were obtained in treatment-vs.-control
omparisons  and judged using the Welch’s t-test and subsequent False Discovery Rate
djustment (Opgen-Rhein and Strimmer, 2007). Gene Set Z-scoring (Törönen et al.,
009) was used to perform gene set analysis using gene-ontology terms (Wirth et al.,
012).
.4.3. qPCR
Reverse transcription was  performed using the RevertAidTM H Minus First Strand
DNA  Synthesis Kit (Fermentas, St. Leon-Rot, Germany) with 1 g total RNA and
ligo(dT)18 primer. qPCR was conducted using a LightCycler (Roche Diagnostics,
annheim,  Germany) in a total volume of 10 l per capillary containing 5 l Quan-
iTect  SYBR Green 2× Master Mix  (Roche), 0.4 l cDNA, 1 l primer (5 M, each)
peciﬁc  for the different target genes or the reference genes (mitochondrial ribo-
omal protein L32, MrpL32 and ubiquitin, Ubc) and 3.6 l water. The oligonucleotide
rimer  sequences are listed in Table A.1. The Hot Start Polymerase was  activated by
 15 min  pre-incubation at 95 ◦C, followed by 55 ampliﬁcation cycles at 95 ◦C for
◦ ◦0 s, 60 C for 10 s and 72 C for 10 s. The obtained crossing point (CP) values were
etween  15 and 28 for the different target genes. A melting curve analysis was per-
ormed to verify correct qPCR products. The following appropriate controls have
een used: no template control (water) and “reverse transcription-minus control”,
n order to exclude the presence of genomic DNA in the samples. Quantiﬁcation ofroscience 40 (2015) 1–11 3
gene  expression was performed by the CP method with MrpL32 and Ubc serving
as reference housekeeping genes.
2.5. Neurite quantiﬁcation
2.5.1. Tracing and neurite visualization
To  quantify neurite outgrowth between the two slices of the co-cultures,
biocytin-tracing (detailed time schedule in Fig. 1) was performed according to a
previously described protocol (Franke et al., 2003; Heine et al., 2007). At DIV8,
small biocytin-crystals of similar size were placed onto the VTA/SN slice of the
co-cultures. Co-cultures were left in contact with the crystals for 2 h to allow the
uptake of biocytin. Afterwards they were reincubated with medium containing
the  respective nimodipine concentrations for 48 h. At DIV11, the cultures were
ﬁxed  and cut into 50 m vibrosections. Afterwards, the anterograde tracer biocytin
was  labeled using the avidin–biotin-complex (1:50, ABC-Elite Kit, Vector Labora-
tories,  Inc., Burlingame, CA, USA), in combination with nickel/cobalt-intensiﬁed
3.3′-diaminobenzidine hydrochloride (DAB; Sigma–Aldrich) as a chromogen. After
mounting on glass slides, all stained sections were dehydrated in a series of graded
ethanol, processed through n-butylacetate and covered with Entellan (Merck, Darm-
stadt, Germany).
2.5.2.  Automated image quantiﬁcation
The  quantiﬁcation of outgrowing biocytin-traced neurites was  performed as
previously described (Heine et al., 2013; Heine and Franke, 2014). Brieﬂy, micro-
scopic images were taken at 40-fold magniﬁcation in the border region (where the
two initially separated brain slices were grown together, for details see also Fig.
S1.B1) using an usual transmitted light bright ﬁeld microscope (Axioskop 50; Zeiss
Oberkochen, Germany) equipped with a CCD camera (DCX-950P, SONY Corporation,
Tokyo, Japan). The following criteria were used for the selection of the biocytin-
traced  slices: (a) the tracer was correctly placed on the VTA/SN, (b) the major part of
the VTA/SN was  characterized by a dense network of biocytin-traced structures and
(c) no traced cell bodies had been observed in the target region PFC (in more detail
described in Heine et al., 2007). During image acquisition, preceding treatments of
the observed tissue slices were hidden from the experimenter.
After  pre-processing of the images (for details see Heine et al., 2013), neurite
structures  appeared as well-deﬁned bright regions. Subsequently, the image area
occupied by the neurites was measured to obtain a reasonable estimate of the under-
lying neurite density of the analyzed specimens. Precisely, the ratio of the number
of  foreground pixels (neurites) against the total number of pixels in the images was
taken, giving the percentage of area occupied by neurites in the focal plane. Neurite
density was  subsequently normalized to the median values of the untreated controls
of each individual experiment.
2.6.  Analysis of cell death
2.6.1.  Lactate dehydrogenase (LDH) activity in conditioned culture medium
LDH  release into the 25% HS incubation medium was quantiﬁed after treatment
with  0.1 M,  1 M and 10 M (time schedule according to Fig. 1). Medium samples
were  collected at every medium exchange (DIV1, 4, 6, 8) and before ﬁxation (DIV11),
and stored at −20 ◦C until further analysis.
When the samples reached room temperature after thawing, LDH  activity was
measured by the method of Koh and Choi (1987) applied to 96-well plate format
using  ﬁlter-based plate reader device (Polarstar Omega von BMG  Labtech, Offenburg,
Germany) measuring the absorption at 340 nm.  Brieﬂy, the LDH substrate pyru-
vate and the coenzyme NADH (both Sigma–Aldrich) were added to the conditioned
medium  samples and the decrease of NADH due to LDH activity was measured over
the time (every 10 s for 3 min).
To  exclude variations due to temperature changes between individual sets of
measurements, LDH activity of all samples has been normalized to the control sam-
ple (untreated) at DIV1 of the respective preparation.
2.6.2. Active caspase 3 immunolabeling and propidium iodide (PI) uptake
For  the active caspase 3 immunolabeling and PI (Invitrogen GmbH) uptake quan-
tiﬁcation, nimodipine was applied at 0.1 M,  1 M and 10 M as described above
for  the neurite quantiﬁcation study. As positive controls for caspase 3 activation
and  the induction of necrosis, 5 M staurosporine (for 4 h) and 10 mM glutamate
(for  48 h), respectively, have been added to the incubation medium prior to ﬁxation
of the co-cultures at DIV11. PI (7.5 M)  was added 3 h before the ﬁxation to every
culture  well.
After  ﬁxation, co-cultures were cut into 50 m slices as described above and
stained.  In detail, slices were blocked with Tris buffered saline (TBS, 0.05 M; pH
7.6) containing fetal calf serum (FCS, 5%) and Triton X-100 (0.3%) for 30 min. Then,
the slices were incubated with a primary antibody directed against active caspase
3  (produced in rabbit, 1:50, MBL  International, Inc., Woburn, MA,  USA) for 48 h at
4 ◦C. After washing with TBS, the secondary antibody (donkey anti rabbit Alexa488
RESEARCH ARTICLES - Nimodipineconjugated  IgG, 1:400, Jackson ImmunoResearch, West Grove, PA, USA), diluted
in  TBS supplemented with 5% FCS and 0.3% Triton X-100, was  applied for 2 h at
room temperature. For further characterization of active caspase 3 positive cells,
multiple ﬂuorescence labeling was performed. The slices were incubated with a
mixture of primary antibodies (rabbit anti-active caspase 3, 1:50, MBL  International,
37































































Fig. 2. Results of qPCR validation experiments. (A–F) Expression levels of the IEGs,
which were found to be upregulated in the PFC in the microarray study: Arc, activity-
regulated cytoskeleton-associated protein; Egr1,2 and 4, early growth response
protein 1, 2 and 4; Fos, proto-oncogene c-Fos; Junb, transcription factor jun-B are
expressed as CP, normalized to untreated control (y-axis), while x-axis repre-
sents  the different treatments (application of 0.1% ethanol (in the ﬁgure: eth) or
10 M nimodipine (in the ﬁgure: Nim), respectively at DIV4, 6, 8 and 11). Statistical
analysis  was  done in comparison to vehicle control ethanol. (A–E) Treatment with
RESEARCH ARTICLES - Nimodipine
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n combination with mouse anti-microtubule associated protein-2 (MAP2), 1:1000,
illipore, Temecula, CA, USA and goat anti-GFAP, 1:1000, Santa Cruz Biotechnol-
gy,  Inc., Santa Cruz, CA, USA) for 48 h at 4 ◦C. After washing with TBS, the secondary
ntibodies  (donkey anti rabbit Cy3 conjugated IgG, 1:1000 and donkey anti mouse
lexa488 conjugated IgG, 1:400 and donkey anti goat Dyelight 647 conjugated IgG,
ll Jackson ImmunoResearch, West Grove, PA, USA), diluted in TBS supplemented
ith  5% FCS and 0.3% Triton X-100, was  applied for 2 h at room temperature. In
ddition, slices were stained with the nucleic acid probe Hoechst 33342 (40 g/ml,
olecular Probes, Leiden, Netherlands), to identify the cell nuclei. After mounting
n  glass slides, all stained sections were dehydrated and covered as described above.
.6.3. Image analysis
Fluorescence labeled specimens were imaged with a confocal laser scanning
icroscope  (LSM 510 Meta; Zeiss, Oberkochen, Germany). Excitation wavelengths
ere  633 nm,  543 nm,  488 nm and 351 nm/364 nm to evoke the Dyelight 647, PI,
lexa488 and Hoechst ﬂuorescence, respectively. Microscopic images were taken
t 20-fold magniﬁcation. For each group, 6 slices were analyzed within the PFC and
TA/SN, (3 pictures per slice and region, resulting in 18 pictures per group and
egion). During image acquisition and manual cell counting preceding treatments
f the observed tissue slices were hidden from the experimenter. Cells positive for
ctive caspase 3 were counted manually with the help of ImageJ cell counter plugin
http://rsb.info.nih.gov/ij/; http://rsbweb.nih.gov/ij/plugins/cell-counter.html). PI
ptake quantiﬁcation was  conducted with an algorithm implemented in Wolfram
athematica  9.0.1. To assess the number of PI positive cell nuclei, a global threshold
or  binarization was  chosen to divide the image in PI positive nuclei and background.
urthermore, a maximal particle size was deﬁned to estimate the number of cell
uclei in regions where the segmentation could not separate single nuclei. In those
ases, the area of the region was divided by the mean cell size (which was  deter-
ined  from a visually veriﬁed image), to obtain a rough estimate of the number of
ells which are connected in this region.
.7. Statistics
All quantitative data (except microarray analysis) has been analyzed with
igmaPlot  12 statistical analysis program. Details referring to the applied tests are
peciﬁed in the respective result section and in the ﬁgure legends.
. Results
.1. Upregulation of immediate early genes (IEGs) in the PFC after
reatment with 10 M nimodipine
To elucidate the mode of action of nimodipine, we  conducted
 microarray study to preliminarily identify the genes whose
xpression is modulated by nimodipine application. After sub-
tance application (4 times 10 M,  for details regarding the chosen
oncentration see Section 2.3), co-cultures were separated into
FC and VTA/SN. The two regions were analyzed individually.
ene expression patterns of untreated, vehicle control ethanol, or
imodipine treated samples were compared. There were no differ-
ntially expressed genes in the VTA/SN, but we found upregulated
enes in the nimodipine treated PFC samples. Therefore, we focused
n the PFC samples for further gene expression analyses.
Self-organizing map  (SOM) analysis of the microarray data was
sed to visualize the expression patterns of each sample that
as been applied to the microarray. The comparison of the SOMs
evealed that the expression patterns of both controls (untreated
nd ethanol) were very similar to each other. Therefore, the sam-
les of the two groups were combined to a single control group
or further analysis of the microarray study. Differential expression
nalysis of nimodipine versus control group within the PFC yielded
even genes with log fold changes > 2 (log2 FC, p-value Welch’s t-
est): Arc (activity-regulated cytoskeleton-associated protein, log2
C 3.487, p = 0.018), Egr1 (early growth response protein 1, log2
C 2.466, p = 0.06), Egr2 (log2 FC 3.568, p = 0.095), Egr4 (log2 FC
.844, p = 0.177), Fos (proto-oncogene c-Fos, log2 FC 2.05, p = 0.219),
unB (transcription factor jun-B, log2 FC 2.069, p = 0.280), and Pmch
pro-MCH precursor, log2 FC 2.853, p = 0.499). The transcripts of the
EGs (Arc, Egr1,2,4, Fos and JunB) were quantiﬁed by qPCR of ﬁve
ndependent preparations. With the exception of JunB, signiﬁcantly
igher gene expressions were conﬁrmed after nimodipine treat-
ent, with median values ranging from 5-fold to 36-fold compared10 M nimodipine increased expression of the investigated genes of interest signiﬁ-
cantly. Data are shown as box plots, n(independent samples) = 5, *p < 0.05, **p < 0.01,
Mann–Whitney rank sum test.
to vehicle control ethanol, Mann–Whitney rank sum test, p < 0.05,
p < 0.01 (Fig. 2). All of these validated upregulated genes belong to
the group of IEGs. The transcriptional activation of these genes after
nimodipine treatment, which are involved in neurite growth and
plasticity (reviewed in Pérez-Cadahía et al., 2011; Shepherd and
Bear, 2011) strongly suggested a nimodipine induced enhancement
in neurite growth in our test system under the applied conditions.
3.2.  No enhanced neurite growth after treatment with 10 M
nimodipine
In parallel to preliminary gene expression analysis, we inves-
tigated whether nimodipine may  enhance neurite growth in the
dopaminergic system. Therefore a treatment study with 10 M
nimodipine in comparison to untreated and vehicle ethanol treated
control co-cultures was  performed, following a well-established
treatment schedule for neurite growth analysis (Fig. 1 and Heine
et al., 2007, 2013). Surprisingly, treatment with nimodipine at this
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for details see Fig. S1) of the co-cultures. Automated image quan-
iﬁcation of at least 60 analyzed pictures per group revealed that
he median value for neurite density in 10 M nimodipine treated
o-cultures was even lower than neurite density in the vehicle
ontrol (10 M nimodipine was 85% of ethanol group, p = 0.283;
ann–Whitney rank sum test, data not shown).
.3. 10 M nimodipine induces an increase in active caspase 3
ositive cells, but has no inﬂuence on PI uptake, LDH release and
ax/bcl-2  ratio
We  wanted to clarify whether the application of 10 M
imodipine to the co-cultures induces (neuro-)toxic effects. Dif-
erent toxicological methods have been used after application of
.1 M,  1 M,  and 10 M nimodipine (according to the treatment
chedule shown in Fig. 1) to quantify apoptotic and necrotic cell
eath: (i) measurement of LDH release into the incubation medium,
ii) PI uptake quantiﬁcation, (iii) analysis of caspase 3 activation
n immunostained co-culture slices, and (iv) calculation of the
ax/bcl-2 ratio.
The  highest LDH activity was detected at DIV1 (Fig. 3A ). It
ecreased during the culture period without a signiﬁcant difference
etween the differently treated groups. These ﬁndings are substan-
iated by the analysis of PI uptake into the PFC and the VTA/SN,
here no signiﬁcant changes were observed after the different
reatments, except in the positive control treated with glutamate
10 mM,  48 h). Data are shown in Fig. 3B.
Moreover, the number of the active caspase 3 positive cells was
uantiﬁed after immunoﬂuorescence labeling (exemplary micro-
copic images are shown in Fig. 3D–F). We  found a slightly but
igniﬁcantly increased number of cells being positive for active cas-
ase 3 staining after treatment with nimodipine (10 M)  in the
ortical part of the cell culture compared to the vehicle ethanol
reated control (p < 0.05). In comparison, the positive control stau-
osporine, which is known to induce apoptosis, was characterized
y an obviously much higher number of active caspase 3 pos-
tive cells (p < 0.01); n(analyzed images) = 18, ANOVA on ranks
ollowed by all pairwise multiple comparison procedures (Dunn’s
est) (Fig. 3C). To assess apoptosis with a second method, expression
evels of bax and bcl-2 were quantiﬁed and bax/bcl-2 ratio was  cal-
ulated for all different treatments (untreated, ethanol, nimodipine
0.1–10 M))  in PFC and VTA/SN samples. In contrast to active cas-
ase 3 immunoreactivity, no signiﬁcant changes were detected
etween the different groups (data not shown).
With multiple ﬂuorescence labeling, we further aimed to char-
cterize the identity of the cells being apoptotic after application of
0 M nimodipine. Active caspase 3 positive cells are often sur-
ounded by GFAP positive structures (Fig. 3G). Additionally, we
ound active caspase 3 immunoreactivity and apoptotic fragmen-
ation of cell nuclei (Fig. 3G, insert) located in areas where MAP2
taining is less deﬁned (Fig. 3H,I), indicating a locally restricted loss
f MAP2 immunoreactivity during apoptosis.
.4. Signiﬁcant enhancement of neurite growth after treatment
ith  0.1 M and 1 M nimodipine
After  having shown that 10 M nimodipine induces caspase
 activation in the organotypic brain slice co-cultures whereas
.1 M and 1 M do not, the neurite growth promoting potential
f nimodipine was investigated again by applying these lower con-
entrations to the co-cultures (according to the time schedule of
reatment in Fig. 1). After application of nimodipine at both con-
entrations (0.1 M,  1 M),  a visible increase in biocytin-traced
utgrowing neurites in the border region of the co-cultures was
bserved in comparison to control conditions (untreated control,
thanol; Fig. 4A). In contrast, neurite density after the application ofroscience 40 (2015) 1–11 5
10 M nimodipine is as low as in the images of the controls (Fig. 4A).
These qualitative observations have been conﬁrmed by automated
image quantiﬁcation, revealing a signiﬁcant augmentation of the
neurite density in co-cultures which had been treated with 0.1 M
and 1 M nimodipine (116% and 127% of vehicle control ethanol,
respectively), n(analyzed images) > 225, p < 0.01, ANOVA on ranks
followed by all pairwise multiple comparison procedures (Dunn’s
test) (Fig. 4B).
For  a better estimation of the neurite growth promoting impact
of nimodipine in our co-culture system, the effect of 1 M nimodip-
ine was compared to the well-known growth factor NGF. To check
additionally for potential synergistic action, both compounds were
also applied together. The strongest effect was observed for the
combination of both compounds (138% of vehicle control ethanol),
followed by 1 M nimodipine (127% of vehicle control ethanol) and
NGF alone (119% of vehicle control ethanol), (see supplementary
Fig. S2). All of these treatments were signiﬁcantly higher than the
vehicle control ethanol (p < 0.01). The combination of nimodipine
(1 M)  and NGF was signiﬁcantly higher than NGF alone (p < 0.05)
but not signiﬁcantly higher than 1 M nimodipine, n(analyzed
images) > 173, ANOVA on ranks followed by all pairwise multiple
comparison procedures (Dunn’s test).
Supplementary Fig. 2 can be found, in the online version, at
http://dx.doi.org/10.1016/j.ijdevneu.2014.10.005.
3.5. Expression levels of CBPs, IEGs and myelin constituents are
not  altered by 0.1 M and 1 M nimodipine
With  neurite density quantiﬁcation, we did show a neurite
growth promoting effect of nimodipine (0.1 M,  1 M)  in the
dopaminergic projection system. Nevertheless, the mode of action
remained unclear and we  wanted to address this issue. After cul-
ture under the conditions, where enhanced neurite outgrowth was
found, we  quantiﬁed the changes in expression levels of several
genes in PFC and VTA/SN separately (Fig. 5 exemplarily shows the
results for the PFC, treatment according to Fig. 1): (i) The CBPs Pvalb
and S100b have been reported to be upregulated after nimodipine
treatment (Buwalda et al., 1994; Luiten et al., 1994). Our results
revealed no signiﬁcant changes in gene expression in our model in
response to nimodipine application. (ii) It was shown that nimodip-
ine treatment causes an increase in the thickness of the myelin
sheath (Mattsson et al., 2001). Therefore, we quantiﬁed expression
levels of the myelin constituents myelin and lymphocyte protein
(Mal), myelin oligodendrocyte glycoprotein (Mog) and myelin pro-
teolipid protein 1 (Plp1). Again, no signiﬁcant changes in gene
expression were found. (iii) Guntinas-Lichius et al. (1997) described
a nimodipine induced increase in transcripts of GFAP. We quan-
tiﬁed GFAP in our experimental model, detecting no signiﬁcant
change in expression levels. (iv) Furthermore, we tested if the IEGs
that were found to be up-regulated in the microarray will also be
up-regulated under the conditions that lead to enhanced neurite
growth. The ﬁndings from the microarray and subsequent qPCR
validation (with 10 M nimodipine) were not conﬁrmed after cul-
ture under neurite growth conditions. We found that the expression
of Arc, Egr1, Egr2, Fos and Junb was  not signiﬁcantly changed after
treatment with nimodipine (0.1 M,  1 M). Nevertheless, there is
a tendency of a concentration dependent reduction of expression
levels of the above mentioned genes, which was signiﬁcant for Egr4
after application of 1 M nimodipine, n(independent samples) = 6
for all analyzed transcripts (Fig. 5).
RESEARCH ARTICLES - Nimodipine4. Discussion
We  investigated the effects of nimodipine in an organotypic
co-culture model of the dopaminergic system and we  found
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Fig. 3. Toxicity testing. (A) LDH release into 25% HS incubation medium. Data have been normalized to the control value at DIV1 of the respective preparation. Being maximal
at  DIV1, LDH activity decreased during the culture period without signiﬁcant differences between the differently treated groups. (B) Propidium iodide uptake quantiﬁcation
in the co-cultures, shown as percentage of maximal damage after treatment with 10 mM glutamate. No signiﬁcant changes were found after nimodipine (in the ﬁgure:
Nim) application in comparison to the vehicle control ethanol (in the ﬁgure: eth). Data are shown as means, error bars indicate standard error, n(analyzed pictures) = 18,
except  glutamate: n = 9, **p < 0.01, ANOVA followed by all pairwise multiple comparison procedures (Holm–Sidak test). (C) Quantiﬁcation of active caspase 3 positive cells
RESEARCH ARTICLES - Nimodipine
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Fig. 4. Neurite outgrowth quantiﬁcation. (A) Representative microscopic images of biocytin positive neurites in the border region, as they were used for neurite density
quantiﬁcation. For comparison and reference, an image of neurites treated with 10 M nimodipine is included, (scale bar: 50 m).  (B) Neurite growth is signiﬁcantly increased


















RESEARCH ARTICLES - Nimodipinefter treatment with 0.1 M and 1 M nimodipine (in the ﬁgure: Nim) in compariso
edian value of the untreated control group of each individual preparation. Data ar
ll  pairwise multiple comparison procedures (Dunn’s test).
ncreased density of neurites in the border region of the co-cultures
fter application of nimodipine at certain concentrations (0.1 M,
 M).  The application of 10 M nimodipine did not enhance
eurite density. In contrast, we observed a moderate caspase
 activation following application of 10 M nimodipine. More-
ver, we quantiﬁed the expression of several genes (CBPs, IEGs,
in the graph: active caspase 3+ cells) in the cortical parts of the co-cultures detected by im
ells  found after application of 10 M nimodipine, but not as pronounced as after applic
or the induction of apoptosis. Data are shown as box plots, n(analyzed pictures) = 18, *p <
thanol. (D–F) Confocal ﬂuorescence microscopic images of the cortical part of the co-cul
ehicle control ethanol. The number of active caspase 3 positive cells after treatment with
aspase 3 positive cell after treatment with 10 M nimodipine; the active caspase 3 po
oechst staining exhibits the fragmentation of the nucleus, typical for apoptotic cells, hi
as  been found, probably due to reduced immunoreactivity in apoptotic neurons (I). Activ
rrowheads. (Scale bars: D–F = 50 m;  G–I = 20 m)he vehicle control (0.1% ethanol). Neurite density data have been normalized to the
n as box plots, n(analyzed pictures) > 225, **p < 0.01, ANOVA on ranks followed by
GFAP and myelin constituents) in the co-cultures after incuba-
tion under the conditions, where enhanced neurite growth has
been found. The expression of the investigated genes did not
change signiﬁcantly after treatment, indicating that other mech-
anisms are involved in the observed nimodipine mediated neurite
growth.
munoﬂuorescence staining. There are signiﬁcantly more active caspase 3 positive
ation of 5 M staurosporine (in the ﬁgure: sts), which served as a positive control
 0.05, **p < 0.01, ANOVA on ranks followed by Dunn’s multiple comparison against
tures after application of (E) 1 M and (F) 10 M nimodipine in comparison to (D)
 10 M nimodipine is markedly increased. (G–I) Higher magniﬁcation of an active
sitive cell body (red, arrow) is surrounded by GFAP positive structures (green, G).
ghlighted in the insert in (G). No clear co-localization with MAP2 (green, H and I)
e caspase 3 negative neurons with well-deﬁned cell bodies are indicated by empty
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Fig. 5. Gene expression analysis in the PFC after treatment under “neurite growth promoting conditions”. (A–E, G) Expression levels of immediate early genes decrease
after application of 0.1 M and 1 M nimodipine. (F, H–L) Expression levels of GFAP, myelin constituents (Mal, Mog, Plp1) and Ca2+ binding proteins (Pvalb, S100b) are not
signiﬁcantly altered by nimodipine treatment under the applied conditions. Results are expressed as CP, normalized to the untreated control (y-axis), while the x-axis
























RESEARCH ARTICLES - Nimodipineollowed by multiple comparisons vs. vehicle control ethanol (in the ﬁgure: eth), 
xpression levels were not signiﬁcant.
.1. Calcium and neurite growth
Axon outgrowth occurs within optimal levels of intracellular
a2+. If levels rise above or fall below a narrow optimal level
rowth is decelerated or inhibited (Kater et al., 1988). This sug-
ests that nimodipine at concentrations of 0.1 M and 1 M – the
oncentrations that enhanced neurite density in our study – inﬂu-
nces intracellular Ca2+ concentrations in a way that is optimal
or neurite outgrowth in the used model. Even though it is not
roven by our experiments, based on the published literature it
eems very likely that Ca2+ is the causative agent in our model:
VCC play an active and speciﬁc role in mediating the effects of
a2+ on growth cone motility and morphology, and different stud-
es reported that Ca2+ inﬂux through these channels affect axonal
rowth (Nishiyama et al., 2003; Schmitz et al., 2009; Tang et al.,
003). In addition, process extension is not only regulated by pro-
onged shifts in Ca2+ inﬂux or intracellular baseline changes, but
lso by temporal intracellular Ca2+ ﬂuctuations (Gomez and Zheng,
006). Transient elevations of intracellular Ca2+ levels, either spon-
aneous or electrically stimulated, are known to affect neurite
xtension. It was shown that the incidence, frequencies, and ampli-
udes of Ca2+ transients are inversely related to the rate of axon
utgrowth (Gomez et al., 1995; Gomez and Spitzer, 1999; Gu and–Sidak test). (I, J, L) Data are shown as box plots, ANOVA on ranks; differences of
Spitzer,  1995). This is consistent with our observations and the
results of other studies, which have shown that partial blocking
or silencing of Ca2+ inﬂux by LVCC blockade accelerated axonal
sprouting and outgrowth (Angelov et al., 1996; Lindsay et al., 2010;
Mattsson et al., 2001).
As  already mentioned above, the concentration of the applied
LVCC blockers seems to be crucial. Daschil and Humpel (2014) have
shown a dose-dependent effect of LVCC blockers on the survival
of SN pars compacta neurons in dopaminergic brain slices. Among
the tested concentrations (0.1 M,  1 M and 10 M),  only 1 M
and 10 M nifedipine and 1 M nimodipine markedly enhanced
the survival of SN neurons. In addition, after blockade of LVCC
with nifedipine at increasing concentrations (5–30 M),  Tang et al.
(2003) observed increased axon lengths of cortical neurons in
cell culture experiments. They also applied nimodipine (10 M)
and found neurite growth enhancement. In contrast, we  did not
ﬁnd growth promotion, but rather toxic effects with nimodipine
used at this concentration. This discrepancy likely relates to dif-
ferences between the two model systems and application schemes
(single versus repeated long-term application). The latter is espe-
cially likely to be a relevant difference as Koh and Cotman (1992)
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.2. Neuroprotection and neurotoxicity
In this study, we focused on the regenerative and growth
romoting potential of nimodipine in the dopaminergic system.
owever, parameters of neuroprotection have also been analyzed.
he absence of a reduction of LDH release in the nimodipine
0.1 M,  1 M,  10 M)  treated samples after the preparation of the
rain slices (representing a mechanical insult with deterioration
f neuronal connections) does not suggest a neuroprotective effect
f nimodipine in the used experimental model. In contrast, quan-
iﬁcation of active caspase 3 after nimodipine (10 M)  application
evealed the induction of apoptosis.
Recently, it was reported that 10 M nimodipine is toxic to cul-
ured hippocampal neurons (Sendrowski et al., 2013). Additionally,
igh concentrations and prolonged administration of LVCC block-
rs like nimodipine have been reported to be toxic in primary cell
ultures (Koh and Cotman, 1992) and in vivo (Turner et al., 2007).
here is an increased vulnerability to Ca2+ deprivation especially
ithin a tight time window during postnatal neuronal develop-
ent (around P7) (Turner et al., 2007).
Moreover, Puopolo et al. (2007) have found that nimodipine
3 M)  completely blocks spontaneous ﬁring in acutely dissoci-
ted SN pars compacta neurons, and Mercuri et al. (1994) did show
n mesencephalic brain slice cultures that spontaneous electrical
ctivity of dopaminergic neurons is blocked by the application of
0 M nimodipine. It is widely accepted that electrical activity is a
rerequisite for neuronal survival and its blockade leads to pro-
rammed cell death (as reviewed by Mennerick and Zorumski,
000). Therefore, we suggest that the observed caspase 3 activation
nd the absence of enhanced neurite growth in the co-cultures after
pplication of 10 M nimodipine could be a result of the reduced
lectrical activity (due to the LVCC blockade).
With multiple ﬂuorescence labeling after application of 10 M
imodipine, we found active caspase 3 immunoreactivity located
n areas where MAP2 staining is less deﬁned compared to the
urroundings where MAP2 staining is distinctly demarcated.
herefore, our interpretation of the multiple immunoﬂuorescence
abeling is that presumably neurons undergoing apoptosis follow-
ng LVCC blockade by 10 M nimodipine. This is in line with other
eports, indicating that disappearance of MAP2 can be used as a
arker for neurotoxic events (Koczyk, 1994). Moreover, earlier
tudies demonstrated that only neurons – not glial cells – are vul-
erable to higher concentrations of nimodipine (Koh and Cotman,
992). We  suggest that the GFAP positive structures surrounding
ctive caspase 3 positive cell bodies most likely belong to reactive
strocytes, which envelop apoptotic neurons and thereby isolate
he dying cells from the environment.
.3. Nimodipine’s mode of action and target cells
To elucidate the mechanism leading to the reported beneﬁcial
ffects of nimodipine, gene expression has been analyzed using
xpression microarrays. We  found a group of genes belonging to
EGs to be upregulated in the nimodipine treated PFC samples.
iven that (i) the PFC is the target region of the dopaminergic neu-
ite processes and therefore the region where new connections are
stablished; (ii) the PFC is supposed to produce guiding signals
hat trigger neurite ingrowth (Gomez-Urquijo et al., 1999; Plenz
nd Kitai, 1996) and (iii) changes in gene expression in the VTA/SN
ollowing nimodipine application were not found in the applied
odel, we focused on the PFC samples for further gene expression
nalyses.
Applying qPCR after culture under the conditions promot-
ng enhanced neurite growth, we pursued the leads from other
ublished investigations and interpreted our own preliminary
icroarray analysis as discussed below:roscience 40 (2015) 1–11 9
Transient  upregulation of Pvalb and S100b until P10 was
observed in the neocortex and the hippocampus after mater-
nal perinatal nimodipine administration in rats (Buwalda et al.,
1994). This upregulation of CBPs was  supposed to be one of the
mechanisms that lead to the observed neuroprotective effect of
nimodipine after perinatally occurring ischemic insults. We  did
not ﬁnd such an increase in transcripts encoding for the cho-
sen CBPs (Pvalb, S100b) in response to nimodipine treatment
in the cortical part of the co-cultures at the end of the culture
period.
LVCC are also present on glia (D’Ascenzo et al., 2004; Latour
et al., 2003; Westenbroek et al., 1998). It was  shown that long-term
treatment with nimodipine (in vivo, >42 days) led to enhanced and
prolonged astroglial ensheathment of axotomized, target deprived
neurons in an in vivo model of facial and hypoglossal nerve
resection, (Guntinas-Lichius et al., 1997). It was  further shown that
nimodipine reduced cell loss and increased GFAP immunoreac-
tivity in a model of traumatic brain injury (Thomas et al., 2008).
However, quantiﬁcation of GFAP encoding mRNA transcripts did
not reveal changes of gene expression levels in our model at
DIV11.
In addition, application of nimodipine increased not only the
number and size of myelinated axons of the facial nerve but also
increased the degree of myelination, both in lesioned and non-
lesioned facial nerves (Mattsson et al., 2001). In order to explore
whether nimodipine application affects myelination and thereby
stabilizes axonal growth in our model, we quantiﬁed the transcripts
of the myelin components Mal, Mog  and Plp1. No signiﬁcant gene
expression changes have been found, suggesting that this aspect is
not relevant for the enhanced neurite growth observed in dopami-
nergic brain slice co-cultures.
In  the microarray and qPCR analysis, we  found IEGs to be upre-
gulated after 10 M nimodipine application. We  wanted to conﬁrm
this upregulation under the conditions that enhanced neurite out-
growth. IEGs are closely related to neuronal growth and plasticity
and therefore are interesting candidates for the regulation of neu-
rite growth (reviewed in Pérez-Cadahía et al., 2011; Shepherd
and Bear, 2011). However, the ﬁndings from the microarray anal-
ysis were not reproduced after application of 0.1 M or 1 M
nimodipine. In contrast, we found a decrease in expression levels
after nimodipine (0.1 M,  1 M)  treatment. The down-regulating
effect of a dihydropyridine LVCC blocker on the expression of IEGs
(e.g. c-Fos, JunB, Egr1 and others) is in line with the results of
Murphy et al. in cultured cortical neurons (Murphy et al., 1991)
and with the ﬁndings reviewed by Sheng and Greenberg, which
demonstrated an upregulation of these genes not only after stim-
ulation with growth factors (NGF and Epidermal Growth Factor,
EGF) but also after Ca2+ inﬂux and depolarization (Sheng and
Greenberg, 1990). This study further corroborates the notion that
blockade of Ca2+ inﬂux inhibits IEG expression rather than induces
it.
In summary, the results of the gene expression analysis
indicate that the regulation of the expression of the investi-
gated genes cannot clearly explain the observed nimodipine
mediated neurite growth in the applied model of the dopami-
nergic projection system. Therefore, referring to the investigated
genes, nimodipine-induced neurite outgrowth does not seem to
depend on mRNA synthesis. In contrast, mechanisms including
non-coding RNA or nimodipine-induced protein modiﬁcations
should be considered and examined in further investiga-
tions.
RESEARCH ARTICLES - Nimodipine4.4. Conclusion and translational outlook
Nimodipine – at certain concentrations (0.1 M, 1 M)  –
seems to inﬂuence the intracellular Ca2+ concentration in a way
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Table  A.1
Sequences of primers for quantitative polymerase chain reaction (qPCR).
Target Accession ID Forward primer Reverse primer
Genes of interest
Arc  NM 019361.1 GCCAGTCTTGGGCAGCATAG CACTGGTATGAATCACTGCTGG
Bax  NM 017059.2 ACCCGGCGAGAGGCAG CTCGATCCTGGATGAAACCCT
Bcl-2  NM 016993.1 GACTGAGTACCTGAACCGGC AGTTCCACAAAGGCATCCCAG
Egr1  NM 012551.2 ACCTGACCACAGAGTCCTTTTC GCAACCGGGTAGTTTGGCT
Egr2  NM 053633.1 CTACCCGGTGGAAGACCTCG GATCATGCCATCTCCAGCCAC
Egr4  NM 019137.1 TATCCTGGAGGCGACTTCTTG TCCAGGAAGCAGGAGTCTGTT
Fos  NM 022197.2 TACTACCATTCCCCAGCCGA CTGCGCAAAAGTCCTGTGTG
Junb  NM 021836.2 AGGCAGCTACTTTTCGGGTC TTGCTGTTGGGGACGATCAA
Gfap  NM 017009.2 AGCTTACTACCAACAGTGCCC TCATCTTGGAGCTTCTGCCTC
Mal  NM 012798.1 CTGCAGTGGTGTTCGCCTAT GCTCCCAATCTGCTGTCCTA
Mog  NM 022668.2 TGTGTGGAGCCTTTCTCTGC TGAACTGTCCTGCGTAGCTG
Plp1  NM 030990.2 CTGCAAAACAGCCGAGTTCC AGGGAAACTAGTGTGGCTGC
Pvalb  NM 022499 AAGAGTGCGGATGATGTGAAGA CAGAATGGACCCCAGCTCATC
S100b(eta)  NM 013191.1 AGAGGGTGACAAGCACAAGC TTCCTGCTCTTTGATTTCCTCCA
Housekeeping genes
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hat is advantageous for neurite outgrowth. Thereby nimodipine
nhances neurite density in organotypic co-cultures of the dopa-
inergic projection system, as demonstrated for the ﬁrst time in
his study.
In  addition, we did show that a set of genes whose expression
evels were quantiﬁed are not changed by nimodipine application,
uggesting that other mechanisms are involved in the observed
imodipine mediated effects.
The here presented data support previous clinical observations
f the beneﬁcial effect of nimodipine e.g. on the preservation of
ranial nerve functions following vestibular schwannoma surgery
Scheller et al., 2007). Regarding the use of nimodipine against
iseases affecting especially the dopaminergic system, primarily
urther in vivo data and eventually clinical studies will have to be
onducted. In general, nimodipine is a usually well-tolerated drug
Castanares-Zapatero and Hantson, 2011). Therefore no barriers in
he use of nimodipine for neurite outgrowth in clinical situations
re expected. The elucidation of the detailed mode of action of
imodipine as a neuroprotective and neuroregeneration promoting
ubstance – especially within the dopaminergic projection system
 will help to foster its application and the identiﬁcation of new tar-
ets and therapy options also within the dopaminergic projection
ystem.
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dopaminergic projection  system.  (A1) Photograph of a neonatal  rat brain. The  regions containing ventral 
tegmental area/substantia nigra (VTA/SN) and prefrontal cortex (PFC) are highlighted in dark and bright red. 
(A2)  Coronal  sections  of  the  rat  brain;  additional  cuts  are made  as  indicated  by  dashed  lines  to  isolate 
VTA/SN (#) and PFC (*), respectively. (A3) Coronal sections of 300µm thickness were placed side by side on 
membrane inserts as co‐cultures. (B1) Schema of a co‐culture consisting of PFC and VTA/SN; the transparent 
box  indicates  the border  region, where  the  two  initially separated slices were grown  together and where 
neurite density was quantified  after biocytin‐tracing  and histochemical processing  (described  in detail  in 
section  2.5.1).  (B2)  Microscopic  image  of  a  biocytin‐traced  co‐culture  slice  after  treatment  with  1µM 
nimodipine. Biocytin‐traced  cell bodies are  located  in  the VTA/SN. Outgrowing neurites  cross  the border 
region between VTA/SN and PFC and grow into the PFC. (Scale bar: 500µm) 




Nim)  and  50ng/ml  nerve  growth  factor  (NGF)  alone  or  in  combination.  (A)  Representative microscopic 
images  of  biocytin  positive  neurites  in  the  border  region  as  they  were  used  for  neurite  density 
quantification, (scale bar: 50µm). (B) Neurite density data has been normalized to the median value of the 
untreated  control  group  of  each  individual  preparation.  Neurite  growth  is  significantly  increased  after 
treatment with 1µM nimodipine, 50ng/ml NGF and the combination of both  in comparison to the vehicle 
control (0.1% ethanol). No significant increase in neurite density has been observed among the Nim‐, NGF‐ 
and  Nim+NGF‐treated  groups.  Neurite  density  data  have  been  normalized  to  the median  value  of  the 
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ORIGINAL RESEARCH REPORT
Mesenchymal Stem Cells Support Neuronal Fiber Growth
in an Organotypic Brain Slice Co-culture Model
Katja Sygnecka,1,2 Andreas Heider,1 Nico Scherf,3 Ru¨diger Alt,1,4
Heike Franke,2,* and Claudia Heine1,2,*
Mesenchymal stem cells (MSCs) have been identiﬁed as promising candidates for neuroregenerative cell
therapies. However, the impact of different isolation procedures on the functional and regenerative charac-
teristics of MSC populations has not been studied thoroughly. To quantify these differences, we directly
compared classically isolated bulk bone marrow-derived MSCs (bulk BM-MSCs) to the subpopulation Sca-
1 +Lin -CD45 - -derived MSCs - (SL45-MSCs), isolated by ﬂuorescence-activated cell sorting from bulk BM-
cell suspensions. Both populations were analyzed with respect to functional readouts, that are, frequency of
ﬁbroblast colony forming units (CFU-f), general morphology, and expression of stem cell markers. The SL45-
MSC population is characterized by greater morphological homogeneity, higher CFU-f frequency, and sig-
niﬁcantly increased nestin expression compared with bulk BM-MSCs. We further quantiﬁed the potential of
both cell populations to enhance neuronal ﬁber growth, using an ex vivo model of organotypic brain slice co-
cultures of the mesocortical dopaminergic projection system. The MSC populations were cultivated under-
neath the slice co-cultures without direct contact using a transwell system. After cultivation, the ﬁber density
in the border region between the two brain slices was quantiﬁed. While both populations signiﬁcantly en-
hanced ﬁber outgrowth as compared with controls, puriﬁed SL45-MSCs stimulated ﬁber growth to a larger
degree. Subsequently, we analyzed the expression of different growth factors in both cell populations. The
results show a signiﬁcantly higher expression of brain-derived neurotrophic factor (BDNF) and basic ﬁbroblast
growth factor in the SL45-MSCs population. Altogether, we conclude that MSC preparations enriched for
primary MSCs promote neuronal regeneration and axonal regrowth, more effectively than bulk BM-MSCs, an
effect that may be mediated by a higher BDNF secretion.
Introduction
Studying neuronal regeneration and regrowth isimportant in potentially treating neurological diseases as-
sociated with the loss of neurons and their corresponding ﬁber
projections. In this context, stem cells that positively inﬂuence
neuronal regeneration and axonal regrowth are of great interest
for the development of cell therapeutic strategies.
Mesenchymal stem cells (MSCs) are multipotent precur-
sors, which are capable of differentiation into bone, cartilage,
and adipose tissues. They can be obtained easily from, for
example, adult bone marrow (BM), adipose tissue, or um-
bilical cord blood. Conventionally, MSCs are isolated from
human or animal tissue through plastic adhesion and culture
procedures [1–3].
Recent reports and reviews suggest a beneﬁcial role of
MSCs in recovery after neuronal injury and in neurode-
generative diseases like Parkinson’s disease [4–8]. For
example, positive effects of MSCs on ﬁber regeneration
have been shown under various experimental condi-
tions, such as cell cultures [9,10], organotypic slice culture
models [11–13] and also in vivo [14,15]. Besides the
synthesis of extracellular matrix molecules, stabilization
of the microenvironment, and immune modulatory prop-
erties, the production of humoral factors appears to be one
of the relevant processes for the observed regenerative
effects of MSCs [16,17]. In this context, the expression
and secretion of growth factors such as brain-derived
neurotrophic factor (BDNF), nerve growth factor (NGF),
glial cell-derived neurotrophic factor (GDNF), or basic
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ﬁbroblast growth factor (bFGF, also known as FGF2) have
been elucidated [9,13,14,18–20].
MSCs are intrinsically heterogeneous and are comprised
of a diverse repertoire of distinct subpopulations (for review
see Phinney [21]). It is accepted that methods used to iso-
late, expand, and cultivate MSCs signiﬁcantly affect their
overall composition and therefore their therapeutic potential
[22–25]. Current limitations in the use of MSCs underline
the need to identify speciﬁc surface markers that can be used
to investigate the physiological functions and biological
properties of MSCs [26]. Morikawa et al. have recently
shown that MSCs need not necessarily be isolated by culture
expansion, but can be prospectively isolated from primary
tissue, yielding a highly enriched homogeneous subpopu-
lation [3]. These PaS cells are a subpopulation of the very
small embryonic-like stem cell population described earlier
by Kucia et al. that have shown a broad differentiation po-
tential beyond the mesenchymal lineage in vitro [27,28].
The prospective isolation of MSCs will certainly have to be
considered for safer and more effective clinical treatments
in the future [26]. Therefore, gaining knowledge about the
different MSC populations and the use of standardized
protocols for the preparation of homogenous cell popula-
tions and their expansion is integral.
We set out to investigate the impact of the isolation pro-
cedure on the functional and regenerative characteristics of
MSC populations. In this study, bulk BM-derived MSCs (bulk
BM-MSCs), directly expanded from cell suspensions of iso-
lated BM of 8-week-old mice, were compared to Sca-1+
Lin-CD45- -derivedMSCs (SL45-MSCs), which were sorted
from lineage depleted BM suspensions via ﬂuorescence-
activated cell sorting (FACS) from mice of the same age. The
properties of both populations were analyzed in regards to their
(i) ability to form ﬁbroblast colony-forming units (CFU-f), (ii)
general appearance and morphology, (iii) expression of stem
cell markers and growth factors, and (iv) neuronal ﬁber growth
promoting potential. To examine ﬁber growth, an organotypic
brain slice co-culture model of the mesocortical dopaminergic
projection system consisting of brain slices of the ventral
tegmental area/substantia nigra (VTA/SN) and the prefrontal
cortex (PFC) of newborn mice was employed. Fiber density in
the border region between the two slices was quantiﬁed after co-
cultivation with either BM-MSCs or sorted SL45-MSCs
underneath the slice co-cultures using biocytin tracing and
subsequent automated image analysis. The growth factor BDNF
was applied to the co-culture medium as a positive control for
ﬁber growth enhancement. The co-cultures serve as a model of
both development and regeneration, as the growth of ﬁber
connections under ex vivo conditions strongly correlates with
the development of neuronal circuits in vivo, and the dopami-
nergic projections in the neonatal mouse brains are cut during
preparation. Therefore, this model is suitable to analyze growth
promoting effects of substances and cells in a context that is




For the preparation of the organotypic brain slice co-cultures,
neonatal mouse pups of postnatal day 2 (P2) were used (C57BL/
6, own breed; animal house of the Rudolf Boehm Institute of
Pharmacology and Toxicology, University of Leipzig, Leipzig,
Germany). For the isolation of the MSC populations, 8-week-
old C57BL/6 mice were used (Medizinisch-Experimentelles
Zentrum, University of Leipzig, Leipzig, Germany). Both
genders were used for the preparation of the organotypic brain
slice co-cultures and the isolation of both MSC populations. No
gender-speciﬁc differences between male or female mice were
observed. The animals were housed under standard laboratory
conditions, under a 12 h light–12h dark cycle and allowed ac-
cess to lab food and water ad libitum.
All of the animal use procedures were approved by the
Committee of Animal Care and Use of the relevant local
governmental body in accordance with the law of experi-
mental animal protection.
Isolation and expansion of investigated cells
Isolation of murine BM. BM was isolated following a
method modiﬁed fromMorikawa et al. [3]. Tibiae and femura
were dissected out of 8– 1-week-old C57BL/6 mice. After
cleaning, the bones were crushed with a pestle, and marrow
was ﬂushed out with 5mL of wash buffer [phosphate buffered
saline (PBS) with 0.3% citrate phosphate dextrose buffer
(both Sigma-Aldrich, Taufkirchen, Germany) and 1% bovine
serum albumin (BSA; SERVA, Heidelberg, Germany)]. The
resulting solution was passed through a 0.45mm cell strainer
(Greiner Bio-One GmbH, Frickenhausen, Germany) before
proceeding. The remaining bone chips were further minced
using scissors and digested at 37C using an enzyme solu-
tion: Accutase containing penicillin/streptomycin (Pen/Strep
100U/mL and 100mg/mL, respectively; both PAA Labora-
tories GmbH, Co¨lbe, Germany), 2mM calcium chloride
(Sigma-Aldrich), and 1mg/mL collagenase IV (SERVA).
Afterward, the pooled cell fractions were then washed once
with wash buffer and manually counted using a Neubauer
counting chamber (Carl Roth GmbH andCo. KG, Karlsruhe,
Germany).
Derivation of MSCs from murine BM. About 107 bulk BM
cells were seeded in 75 cm2 culture ﬂasks (Greiner Bio-One
GmbH) and cultivated in bulk BM-MSCs maintenance medium
[alpha-modiﬁcation of Eagle’s minimal essential medium with
10% fetal bovine serum (FBS), supplemented with Pen/Strep
(100U/mL and 100mg/mL, respectively; all from PAA La-
boratories)] to derive MSCs. After 2 days, an initial washing
step with PBS was performed to remove nonadherent cells.
Afterward, fresh bulk BM-MSCs maintenance medium was
applied. For further expansion the medium was changed every
2–3 days. Cells were passaged via trypsinization (using trypsin;
PAA Laboratories) when reaching 80% conﬂuency. Passages
3–5 have been used for all experiments in this study except for
the colony forming unit-ﬁbroblast (CFU-f) assay (see below).
Isolation of SL45-MSCs. The isolation procedure was
adapted from Kucia et al. and Morikawa et al. [3,28]. Ma-
ture blood cells were removed from BM preparations via the
magnetic activated cell sorting lineage depletion kit (bio-
tinylated antibody cocktail; Miltenyi Biotech, Bergisch
Gladbach, Germany). Lineage negative (Lin - ) cells were
stained with anti-Sca-1-phycoerythrin(-PE) and anti-CD45-
PE-carbocyanine(-Cy)7 in addition to Streptavidin-Alexa-
Fluor-488 to label and exclude any remaining Lin + cells (all
from eBiosciences, Frankfurt a.M., Germany), for 30min at
4C using saturation concentrations recommended by the
2 SYGNECKA ET AL.
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manufacturer. To discriminate living cells from dead
cells and debris, Hoechst (5 mg/mL) and propidium iodide
(PI; 2 mg/mL) stains (all Sigma-Aldrich) were employed.
Sca-1 +CD45 -Lin -Hoe +PI- (SL45)-MSCs were sorted by
FACS in FACS sort buffer (PBS with 1% FBS, 1mM eth-
ylenediaminetetraaceticacid, and 25mM HEPES; all Sigma-
Aldrich; 0.2 mm sterile ﬁltered) using a BD FACS Vantage
SE cell sorter (BD Biosciences, Heidelberg, Germany).
Cultivation of SL45-MSCs. Sorted SL45-MSCs were cul-
tivated in 25 cm2 culture ﬂasks (Greiner Bio-One GmbH) in
bulk BM-MSCs maintenance medium until passage 2.
Afterward, cells were cultivated in SL45-MSCs maintenance
medium [alpha MEM with 30% FBS, Pen/Strep (100U/mL
and 100 mg/mL, respectively); PAA Laboratories] and 50 ng/
mL recombinant human FGF2 (Peprotech, Hamburg, Ger-
many). The administration of FGF2 and additional serum to
the medium was needed for the prolonged in vitro growth of
SL45-MSCs, as the cells would stop growing after 3 pas-
sages without additional FGF2. For further expansion, the
medium was changed every 2–3 days. Upon reaching 80%
conﬂuence the cells were passaged using Accutase (PAA
Laboratories). Passages 3–5 have been used for all experi-
ments in this study except for the CFU-f assay (see below).
CFU-f assay
To empirically determine the frequency of CFU-f in cell
suspensions, freshly isolated cells, either sorted SL45-MSCs
(starting with 1,000 cells) or bulk BM-MSCs (starting with
107 cells), were cultivated for 14 days in Ø 3 cm culture
dishes or in 75 cm2 culture ﬂasks, respectively (both Greiner
Bio-One GmbH). The cell numbers are a consequence of
intrinsic differences in availability of the cells and their
respective colony frequencies. The frequency of colony
forming cells in bulk BM-MSCs is far lower than in the
SL45 population. Plating the same number of cells would
therefore generate either too many SL45-derived colonies or
too few BM-MSC-derived colonies for reliable quantiﬁca-
tion. For this reason, we adjusted the input cell number to
yield quantiﬁable numbers of colonies.
The CFU-f assays were performed for both MSC popu-
lations in bulk BM-MSC maintenance medium. The cells
were ﬁxed using methanol (AppliChem GmbH, Darmstadt,
Germany) and stained using Giemsa stain (Sigma-Aldrich).
The resulting primary colonies were counted using a bin-
ocular microscope.
Immunoﬂuorescence staining
The two MSC preparations from either bulk BM or SL45
cells were characterized by applying immunoﬂuorescence
staining after cultivation under maintenance conditions. When
the cultures reached 80% conﬂuency, cells were ﬁxed for
10min with 4% paraformaldehyde (PFA; Merck, Darmstadt,
Germany) in PBS at room temperature (RT). After the ﬁxation
step, cells were washed with PBS with 0.5% Tween 20 (PBS-
T; both Sigma-Aldrich). Reactive PFA endings were saturated
in a 30min incubation step with 20mM glycine (Carl Roth
GmbH and Co. KG) in PBS. After permeabilization with
0.1% Triton-X 100 (Applichem GmbH) for 5min, cells were
washed and incubated over night at 4C in blocking solution
[PBS-T with addition of 3% FBS (PAA Laboratories), 1%
BSA (SERVA)] and primary antibodies: mouse anti-bIII tu-
bulin (1:500; Promega, Mannheim, Germany) and rabbit anti-
nestin (1:400; Chemicon, Temecula, CA). Cells were washed
again and stained for 1.5 h at RT in blocking solution con-
taining secondary antibodies: donkey anti-mouse and donkey
anti-rabbit conjugated with Cy2 or Cy3 (1:400/1:800, re-
spectively; both Jackson Immunoresearch, West Grove, PA)
followed by washes with Tris-buffered saline with 0.5%
Tween 20 (Sigma-Aldrich). Finally, staining of the cell nuclei
was performed using Hoechst 33342 (Sigma-Aldrich) at
concentration of 5mg/mL for 10min. Then cells were washed
again, embedded in ﬂuorescence mounting medium (Dako
Deutschland GmbH, Hamburg, Germany), and immunoﬂuo-
rescence labeling was analyzed using an inverted microscope
(Nikon Eclipse Ti) equipped for the detection of Cy2, Cy3 and
Hoechst.
RNA extraction and quantitative real-time
polymerase chain reaction
Quantitative real-time polymerase chain reaction (qPCR)
was conducted to quantify the expression of (i) stem cell
markers nestin and bIII tubulin under maintenance condi-
tions and (ii) growth factors: BDNF, ciliary neurotrophic
factor (CNTF), FGF2, GDNF, hepatocyte growth factor
(HGF), insulin-like growth factor 1 (IGF1), NGF, and
neuregulin 1 (NRG1) after cultivation in maintenance me-
dium or in brain slice culture medium (for composition see
section ‘‘Preparation and cultivation of slice co-cultures’’)
in both bulk BM-MSCs and SL45-MSCs.
For gene expression analysis under co-culture cultivation
conditions (meaning in brain slice culture medium, rather than
in co-culture with brain slices), 1 day after seeding of the bulk
BM-MSCs or SL45-MSCs, respectively, into 25 cm2 culture
ﬂasks,maintenance mediumwas changed to brain slice culture
medium. Corresponding to the duration of cultivation of cells
underneath the co-cultures, after 3.5 days cells were harvested
for RNA-extraction. Total RNA was isolated using TRIzol
reagent (Life Technologies, Gaithersburg, MD) according to
the manufacturer’s instructions. RNA concentration was mea-
sured with NanoDrop1000 (NanoDrop Technologies, Wil-
mington, DE).
Reverse transcription was performed using the RevertAidTM
HMinus First Strand cDNASynthesisKit (Fermentas, St. Leon-
Rot, Germany) with 0.1mg total RNA and oligo(dT)18 primer
in 20mL total reaction volume. qPCR was conducted using a
LightCycler (Roche Diagnostics, Mannheim, Germany) in a
total volume of 10mL per capillary [LightCycler Capillaries
(20mL); Roche Applied Science, Mannheim, Germany] con-
taining 5mL QuantiTect SYBR Green 2·Master Mix (Roche
Applied Science), 0.4mL cDNA, 1mL primer (5mM each)
speciﬁc for the different target genes or the reference genes
[mitochondrial ribosomal protein L32 (MrpL32) and ubiquitin
(Ubc)], and 3.6mL water. Sequences of all used primers are
listed in the Supplementary Table S1 (Supplementary Data
are available online at www.liebertpub.com/scd). The Hot
Start Polymerase (contained in the QuantiTect SYBRGreen 2·
Master Mix) was activated by a 15min preincubation at
95C, followed by 55 ampliﬁcation cycles at 95C for 10 s, 60C
for 10 s, and 72C for 10 s. A melting curve analysis was per-
formed to verify correct qPCR products. The following appro-
priate controls have been used: no template control (water) and
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‘‘reverse transcription-minus control,’’ to exclude the presence
of genomic DNA in the samples. Quantiﬁcation of gene ex-
pression was performed by the DCP method with MrpL32 and
Ubc serving as reference housekeeping genes.
Determination of the BDNF concentration
in the conditioned media
To further investigate growth factor production and se-
cretion on the protein level, the concentration of BDNF has
been quantiﬁed in conditioned brain slice culture medium.
Conditioned medium of cells that were used for RNA ex-
traction (see above) was collected and kept at - 80C until
analysis. BDNF levels were measured using a multiplexed
particle-based ﬂow cytometric cytokine assay [32]. Assay
kits were purchased from Millipore (Zug, Switzerland). The
procedures closely followed the manufacturer’s instructions.
The analysis was conducted using a conventional ﬂow
cytometer (Guava EasyCyte Plus; Millipore).
Preparation and cultivation of slice co-cultures
Slice co-cultures consisting of a prefrontal and a mes-
encephalic slice were prepared from P2 mice and culti-
vated according to the ‘‘static’’ culture protocol using a
transwell system as described previously for rats [29,33].
After decapitation of the pups, the brains were removed
from the skull and immersed into low melting agar. Fore-
brain- and mesencephalon-containing brain parts were
separated with coronal cuts and the resulting tissue blocks
were ﬁxed onto the specimen stage of a vibratome (Leica,
Typ VT 1200S, Nussloch, Germany). Coronal sections
(thickness 300 mm) were cut at mesencephalic and fore-
brain levels to obtain slices of the VTA/SN and the PFC,
respectively. A scheme to illustrate the preparation pro-
cedure is shown in Fig. 1. Four co-cultures were placed on
one membrane insert (0.4 mm, Millicell-CM; Millipore) in
a six-well plate (NuncTM Multidish; Thermo Scientiﬁc via
VWR International GmbH, Dresden, Germany), ﬁlled with
1mL of the brain slice culture medium [25% MEM, 25%
Basal Medium Eagle without glutamine, 25% horse serum,
glutamine to a ﬁnal concentration of 2mM, gentamicin
50 mg/mL (all from Invitrogen GmbH, Darmstadt, Ger-
many), and 0.6% glucose (Hospital Pharmacy, University
of Leipzig, Leipzig, Germany), pH adjusted to 7.2].
Twenty-four hours before the preparation of the orga-
notypic co-cultures, 105 bulk BM-MSCs or SL45-MSCs,
respectively were seeded on poly-l-lysine (Sigma-Aldrich)-
coated glass slides (Carl Roth GmbH and Co. KG) and were
cultivated in the respective maintenance medium (see
above). After the completion of the preparation these glass
slides were transferred underneath the membrane inserts
with the organotypic co-cultures. Co-cultures were kept at
37C and 5% CO2. Culture medium was changed every 2–3
days and glass slides were changed at days in vitro (DIV)4
and DIV7. The cells used for the exchange were derived
from continuing cultures of the original input cells, ensuring
that cells of the same batch and age were used throughout
each experiment. Control cultures were cultivated without
any additional cells or substances. As a reference for the
growth promoting potential, BDNF (75 ng/mL; Peprotech)
was added to the brain slice culture medium with every
medium exchange in an additional experimental group
(BDNF group). For detailed information see also Fig. 2.
Tracing procedure, ﬁxation, and visualization
of ﬁbers
Biocytin tracing, ﬁxation, and subsequent processing of
the co-cultures were performed as previously described
[29,31,33]. At DIV8, small biocytin crystals (Sigma-
Aldrich) were placed on the VTA/SN part of the co-cultures
FIG. 1. Preparation of brain slice co-cultures of the me-
socortical dopaminergic projection system [(A), black ar-
row]. After decapitation of the mouse pups, the brain was
removed from the skull under sterile conditions. Coronal
cuts were made at the level of forebrain and mesencephalon
[(A), dashed lines]. The brain parts were ﬁxed on the
specimen stage of a slicer and cut as indicated [(B), dashed
lines] to isolate PFC (*) and VTA/SN (#), respectively.
Coronal sections of 300 mm thickness were cut and resulting
sections were placed as co-cultures on the moistened
membranes (C) and inserted in six-well plates ﬁlled with
brain slice culture medium. After DIV10 the slices were
ﬁxed and the biocytin tracing was visualized. (D) Schematic
co-culture slice to illustrate the localization of the PFC, the
border region and the VTA/SN in greater magniﬁcation.
PFC, prefrontal cortex; VTA/SN, ventral tegmental area/
substantia nigra; DIV, days in vitro.
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under binocular control. After 2 h, the co-cultures were
rinsed carefully with brain slice culture medium. To allow
the anterograde transport of the tracer, the co-cultures were
reincubated for 48 h.
At DIV10, the co-cultures were ﬁxed in a solution con-
sisting of 4% PFA, 0.1% glutaraldehyde (SERVA), and 15%
picric acid (Sigma-Aldrich) in phosphate buffer (PB, 0.1M,
pH 7.4) for 2 h and were subsequently washed with PB.
Afterward, co-cultures were cut into 50mm thick slices with
the vibratome and collected in PB.
Biocytin was visualized with the avidin-biotin-horserad-
ish peroxidise complex (1:50, ABC-Elite Kit; Vector La-
boratories, Inc., Burlingame, CA) and ammonium nickel (II)
sulfate hexahydrate/Cobalt (II) chloride hexahydrate (Ni/
Co; both Sigma-Aldrich) intensiﬁed 3,3¢-diaminobenzidine
hydrochloride (Sigma-Aldrich). Stained slices were moun-
ted on glass slides and embedded with Entellan (Merck)
when completely dried.
Quantiﬁcation of ﬁber density
Microscopic images from the whole border region were
obtained with a transmitted light bright ﬁeld microscope
(Axioskop 50; Zeiss, Oberkochen, Germany) equipped with a
CCD camera at 40·magniﬁcation. The border region of the
co-culture is the part where the two initially separated brain
slices were grown together (for illustrations see also Figs. 1D
and 3A, B2). Slices were used for analysis only if they ful-
ﬁlled the following criteria: (i) the tracer was correctly placed
on the VTA/SN, (ii) the major part of the VTA/SN was
characterized by a dense network of biocytin-traced structures
and (iii) no traced cell bodies had been observed in the target
region PFC (previously described in more detail in [30]).
A tailored image analysis procedure had been designed to
quantify the ﬁber density in an automated manner, described
previously in detail [31]. After preprocessing and image
binarization, the ratio of the number of foreground pixels
(ﬁbers) to the total number of pixels in the images was
taken, yielding an estimate of the percentage of area occu-
pied by ﬁbers (ﬁber density) in the focal plane.
Statistics
Statistical signiﬁcance of the frequency of CFU-f and of
the expression level of nestin and bIII tubulin between the
different cell populations was assayed by Student’s t-test.
Statistical analysis of the ﬁber growth promoting effect of the
different MSC populations was performed using Kruskal–
Wallis analysis of variance on Ranks followed by Dunn’s test
for multiple comparisons against the control group and
against the BDNF group. Statistical signiﬁcance of the ex-
pression of various growth factors (mRNA-level; BDNF ad-
ditional protein-level) was determined by Student’s t-test or
Mann–Whitney Rank Sum Test, as indicated. All quantitative
data have been analyzed with SigmaPlot 12 statistical analysis
program, all signiﬁcant differences were considered at a P-
level below 0.05 (*P< 0.05, **P< 0.01, ***P< 0.001).
Results
Characterization of bulk BM-MSCs and sorted
SL45-MSCs under maintenance conditions
Primary CFU-f are 10,000-fold enriched in SL45-MSCs versus
bulk BM-MSCs. While bulk BM-MSCs were directly ex-
panded from cell suspensions of freshly isolated BM of
8-week-old mice, SL45-MSCs were sorted from lineage
depleted BM suspensions via FACS-sorting from mice of
the same age (for details see Fig. 4A1–A4).
FIG. 2. Time schedule indicating
preparation at DIV0 and subse-
quent medium changes, exchange
of glass slides with bulk BM-MSCs
and SL45-MSCs, tracing at DIV8
and ﬁxation at DIV10. BDNF was
applied after every medium ex-
change to the ‘‘BDNF group.’’
BM-MSCs, bone marrow-derived
mesenchymal stem cells; BDNF,
brain-derived neurotrophic factor;
SL45-MSCs, Sca-1 +Lin -CD45 - -
derived MSCs.
FIG. 3. Biocytin labeling. (A) Overview of a biocytin-
traced co-culture slice (after cultivation with bulk BM-
MSCs). (B1–B3) Microscopic images of traced cell bodies
in the VTA/SN (B3), traced ﬁbers in the border region of the
co-culture (B2) and in the PFC (B1) at higher magniﬁcation.
Scale bars: (A) 500mm, (B1–B3) 100mm. PFC, prefrontal
cortex; VTA/SN, ventral tegmental area/substantia nigra.
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Primary sorted SL45-MSCs (1,000 cells) and bulk BM-
MSCs (107 cells) were subjected to a CFU-f assay. These
cell numbers are a consequence of intrinsic differences in
availability of the cells and their respective colony fre-
quencies (for details see section ‘‘CFU-f assay’’ in ‘‘Mate-
rials and Methods’’). Two weeks after inoculation, both
unsorted and sorted cells gave rise to newly formed colonies
comprising spindle-shaped, ﬁbroblast-like cells. As an ex-
ample, sorted SL45-MSCs are shown in Fig. 4C1 at day 0
and in Fig. 4C2 at day 14 after sorting, respectively. The
frequency of CFU-f was 5.3 · 10 - 6 – 4.1 · 10 - 6 (n = 8) in
bulk BM-MSCs and 5.3 · 10 - 2 – 3.3 · 10 - 2 (n = 5) in SL45-
MSCs (Fig. 4B). Primary CFU-f were 10,000-fold enriched
in prospectively isolated SL45-MSCs compared to bulk
BM-MSCs. This suggests that SL45-MSCs are a more ho-
mogeneous cell population not only with respect to surface
marker expression but also in terms of functional properties.
Higher expression of nestin in SL45-MSCs versus bulk BM-
MSC. Nestin and bIII tubulin are markers for immature
neuronal cells. Nestin on its own, however, has been shown to
mark precursor cells of both neuronal and mesenchymal lines
[34–36]. bIII Tubulin on the other hand is co-expressed in
some mesenchymal cells together with nestin before any
neuronal differentiation takes place [37]. A characterization of
the nestin and bIII tubulin protein expression in both unsorted
bulk BM-MSCs and sorted SL45-MSCs was performed using
immunoﬂuorescence staining with antibodies against these
markers. We observed a difference in nestin and bIII tubulin
expression between classically isolated MSCs and those de-
rived from sorted SL45 cells (Fig. 5A, B). While almost all
SL45-MSCs expressed nestin, the population of bulk BM-
MSCs was heterogeneous and also contained many cells that
did not express nestin. This observation was compatible with
our general impression that bulk BM-MSCs are generally
more heterogeneous, with some cells showing a classical
spindle-shaped MSC morphology, others appearing broader
and less well deﬁned in shape. In contrast, in SL45-MSCs the
predominant cell type shows a smaller spindle-shaped or oli-
gopolar morphology with rather small or condensed nuclei, a
clearly deﬁned cell body, and a prominent expression of
nestin. bIII Tubulin-positive cells occurred with similar fre-
quency in both cell populations.
Furthermore, the expression of nestin and bIII tubulin in
both populations was determined on a mRNA level. The
FIG. 4. Primary CFU-f and representative illustration of the isolation of SL45 cells. (A1–A4) SL45-MSCs were sorted from
suspensions of murine bone marrow of 8-week-old mice. For this purpose, cells were stained with Hoechst, PI, lineage markers
(Lin), and a combination of Sca-1 and CD45. (A1) All events plotted with regard to forward scatter (FSC) and Hoechst signal
intensity. (A2) Histogram showing PI staining of Hoechst+ cells from (A1). (A3) Hoechst+ , PI- cells were stained for Lin
expression. (A4)The dot plot showsHoechst+ , PI- , andLin- cells thatwere analyzed for expression ofCD45andSca-1. Sca-1+ ,
Hoechst+ , PI- , Lin- , andCD45- cells (SL45-MSCs)were found at a frequency of 3.75%. (B)After 2weeks of cultivation,CFU-
f contained in both bulk BM-MSCs and SL45-MSCs and both cell populations gave rise to newly formed colonies comprised of
spindle-shaped, ﬁbroblast-like cells. TheCFU-f frequencywas far higher in SL45-MSCs than in bulkBM-MSCs.Data are shown
as box-whisker plots; SL45-MSCs: n= 5, bulk BM-MSCs: n= 8; Student’s t-test, ***P< 0.001. (C1,C2) Sorted SL45-MSCs are
shown in themicrographs at day 0 (d0) and 14 (d14) after sorting. Scale bars: (C1) 100mm, (C2) 250mm.CFU-f, ﬁbroblast colony
forming units; PI, propidium iodide. Color images available online at www.liebertpub.com/scd
6 SYGNECKA ET AL.
RESEARCH ARTICLES - MSCs
55
qPCR-results conﬁrmed our qualitative observations from
the immunostaining experiments. Nestin was detectable in
both MSC populations with a signiﬁcant higher expression
in the sorted SL45-MSCs (mean DCP= 13.793) compared
with the bulk BM-MSCs (mean DCP = 0.0318) (Fig. 5C).
The mRNA expression of bIII tubulin was comparable in
both MSC populations. There was no signiﬁcant difference
in the number of bIII tubulin-transcripts between the two
analyzed cell populations (Fig. 5D).
MSCs derived from enriched SL45-MSCs
were more potent in stimulating ﬁber
growth than classically isolated bulk BM-MSCs
After ﬁxation of the dopaminergic co-cultures at DIV10
and visualization of the biocytin tracing, the target orien-
tated ﬁber outgrowth of cell bodies originating from the
VTA/SN could be observed. Neuronal processes sprouting
from the black labeled cell bodies of the VTA/SN sur-
mounted the border region between the initially separated
slices and grew into the target region PFC. An example of a
VTA/SN +PFC co-culture after cultivation with bulk BM-
MSCs is shown in Fig. 3.
We compared the ﬁber growth promoting potential of
MSCs derived from sorted SL45 cells and bulk BM-MSCs
to BDNF-treated and untreated controls, respectively. Ex-
amples of biocytin traced ﬁbers within the border region are
shown for all groups in Fig. 6A. The quantiﬁcation of the
ﬁber density in the border region revealed a signiﬁcant
growth promoting effect for both MSC preparations. The
corresponding box-whisker plots are shown in Fig. 6B. Both
SL45-MSCs and bulk BM-MSCs exhibit a signiﬁcantly
stronger growth promoting effect compared with control. As
expected, BDNF also enhanced ﬁber growth in comparison
to untreated control conditions. However, the effect was
signiﬁcantly less pronounced than that of the co-cultures
with SL45-MSCs, suggesting a greater neurosupportive
stimulus of these mesenchymal cells.
Sorted SL45-MSCs expressed signiﬁcantly higher
levels of the growth factors BDNF and FGF2
We assessed the expression of growth factors that could be
responsible for the observed ﬁber growth promoting effect of
bulk BM-MSCs and sorted SL45-MSCs. The mRNA of the
growth factors BDNF, CNTF, FGF2, GDNF, HGF, IGF1,
NGF, and NRG1 was detected by qPCR in cell samples both
after cultivation in maintenance medium and in brain slice
culture medium, respectively. Under maintenance conditions,
the mRNA of BDNF, FGF2, and NGF was signiﬁcantly
higher expressed in SL45-MSCs than in bulk BM-MSCs
(Student’s t-test, P< 0.05, data not shown). Consistent with
this observation, BDNF and FGF2 were expressed to a sig-
niﬁcantly greater extent in the SL45-MSC population (Fig.
7A, B) after cultivation in brain slice culture medium. Under
this condition, the median DCP for NGF transcripts was also
higher in SL45-MSCs, but the difference between the two
groups was not signiﬁcant (Fig. 7C).
Additionally, secreted BDNF protein has been quantiﬁed in
the conditioned brain slice culture medium of both cell popu-
lations. The BDNF concentration in SL45-supernatants was
signiﬁcantly higher (median value: 0.487 fg/mL/cell) than in
bulk BM-MSC supernatants (median value: 0.026 fg/mL/cell),
P< 0.01, n= 6.However, the resultingBDNFconcentrations in
the incubation media with SL45 or bulk BM-MSCs (mean
values: 288 and 17pg/mL, respectively) were lower than in the
BDNF-positive control, where 75ng/mL BDNF was added.
Taken together, these measurements show a production of
important growth factors by both cells types. This might be one
of the major reasons for the observed effect on ﬁber growth in
those cultures, which could explain the additional cell-speciﬁc
beneﬁt of the MSCs over the BDNF-treated control.
Discussion
The present study conﬁrms the previously reported neu-
rosupportive and regenerative features of MSCs, and addi-
tionally highlights the importance of isolation and expansion
FIG. 5. Nestin and bIII tubulin expression. (A, B) Im-
munoﬂuorescence staining against nestin (red), bIII tubulin
(green), and Hoechst (blue) of (A) unsorted bulk BM-MSCs
and (B) sorted SL45-MSCs expanded nondifferentiated
cells growing in maintenance medium: (A) Only some bulk
BM-MSCs show immunoreactivity for nestin, whereas
(B) almost all SL45-MSCs were positive for nestin. bIII
Tubulin-positive cells occurredwith similar frequency in both
cell populations. (C,D)mRNAexpression levels of nestin and
bIII tubulin (Tubb3) in the two cell populations after culti-
vation under maintenance conditions are expressed as DCP
(relative expression normalized to the housekeeper genesUbc
andMRPL32, y-axis). (C)Nestin expressionwas signiﬁcantly
higher in SL45-MSC samples (mean > 400-fold compared to
bulk BM-MSCs, P< 0.05). (D) No signiﬁcant difference in
the expression of bIII tubulin was detected by quantiﬁcation
of the mRNA transcripts (P= 0.63). Data are shown as
mean – standard error of the mean, n > 4 independent cell
preparations, *P < 0.05, Student’s t-test. Scale bars: (A, B)
100 mm. MrpL32, mitochondrial ribosomal protein L32; n.s.,
not signiﬁcant; Ubc, ubiquitin. Color images available online
at www.liebertpub.com/scd
MESENCHYMAL STEM CELLS SUPPORT NEURONAL FIBER GROWTH 7
RESEARCH ARTICLES - MSCs
56
conditions. We provided evidence that sorted SL45-MSCs
differ from bulk BM-MSCs in certain aspects: SL45-MSCs
were enriched for primary CFU-f, were more homogeneous,
expressed higher protein- and mRNA-levels of nestin, and
expressed higher amounts of the growth factors BDNF and
FGF2 compared with the more heterogeneous bulk BM-
derived cell population. Moreover, utilizing organotypic
dopaminergic slice co-cultures, we have shown that both
BM-MSC populations signiﬁcantly enhanced neuronal ﬁber
growth in comparison with control conditions. The growth
promoting effect of the cells was more pronounced than the
effect of the growth factor BDNF. Interestingly, sorted
SL45-MSCs were more potent in stimulating ﬁber growth in
our co-culture system, indicating that this cell population is
enriched for cells that are responsible for the observed re-
generative and trophic effects.
FIG. 6. Quantiﬁcation of ﬁber density in the border region of organotypic brain slice co-cultures after application of
different BM-derived stem cell populations. (A)Microscopic images of traced ﬁbers in the border regions of the co-cultures
after cultivation with (A2) classically isolated bulk BM-MSCs, (A3) SL45-MSCs in comparison to (A4) BDNF-treatment
and to (A1) control conditions. (B) Fiber quantiﬁcation revealed that SL45-MSCs showed the highest beneﬁt for ﬁber
growth, followed by bulk BM-MSCs. The effect of BDNF was less pronounced than after co-cultivation with any of the
MSC preparations. Data are shown as box-whisker plots and represent the empirical distribution of ﬁber densities of the
investigated groups, control: n = 50 images, bulk BM-MSCs: n = 111 images, SL45-MSCs: n = 186 images, BDNF: n = 93
images; **P< 0.01 in comparison to control, #P < 0.01 in comparison to BDNF, Kruskal–Wallis analysis of variance on
Ranks followed by Dunn’s test for multiple comparisons. Scale bar: (A1–A4) 50 mm.
FIG. 7. The expression of BDNF, FGF2, and NGF in bulk BM-MSCs and sorted SL45-MSCs, quantiﬁed by quantitative
real-time polymerase chain reaction. (A–C) Expression levels of BDNF, FGF2, and NGF in the two cell populations are
expressed as DCP (relative expression normalized to the housekeeper genes Ubc and Mrpl32, y-axis). Signiﬁcantly higher
expression levels of (A) BDNF and (B) FGF2 were revealed in the SL45-MSC population. No signiﬁcant difference in the
expression of (C) NGF between the two cell populations was detected, but there is a tendency to higher expression in the
SL45-MSC samples. Data are shown as box-whisker plots, n > 4 independent cell preparations, *P< 0.05, **P < 0.01,
Mann–Whitney Rank Sum Test. FGF2, basic ﬁbroblast growth factor; NGF, nerve growth factor; n.s., not signiﬁcant.
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Conventionally cultured MSCs yield heterogeneous pop-
ulations that often contain contaminating cells due to the
signiﬁcant variability in the isolation method, the tissue
origin, and the lack of speciﬁc MSC markers [21,23,26].
Moreover, experimental artifacts introduced by inconsistent
cell culture protocols or following extensive culture ma-
nipulation may result in changes of the MSCs’ properties or
in the aging processes of the cells, both causing complica-
tions in the utilization of MSCs as therapeutic tools (for
review see Wang et al. [25]). As an example, the number of
passages was shown to greatly inﬂuence the survival rate,
migration, and neuroprotective capacities of MSCs [38].
With regard to the use of MSCs in clinical medicine, it is
anticipated that more homogeneous cell preparations will
yield more consistent clinical outcomes that exhibit both
dose responsiveness and more reproducible outcomes [21].
Collectively, these studies underline the importance of pre-
paring adequate homogenous cell populations of MSCs.
In our study, we found a higher frequency of nestin-
positive cells and signiﬁcantly more mRNA transcripts of
nestin in SL45-MSCs compared with classically isolated
bulk BM-MSCs. This is in accordance with results of other
studies, where the heterogeneity of primary MSC cultures
and an increase in the percentage of nestin-positive MSCs as
a function of the number of passages were observed [39].
This further implicated the superior proliferative capacity of
nestin-positive MSCs.
The expression of nestin and bIII tubulin in undifferenti-
ated cells has been reported previously and has been taken as
evidence for proliferative and progenitor potential [35,40–
42]. Furthermore, nestin has been described as a marker for
MSCs in the recent literature [34,37,43]. In this context, it
was shown that nestin-positive MSCs contain all the CFU-f
activity of the BM, can self-renew in serial transplantation,
and are able to differentiate toward mesenchymal lineages
[34,37]. Indeed, we could conﬁrm multilineage differentia-
tion capacity into adipogenic, chondrogenic, and osteogenic
lineages in both bulk BM-MSCs and SL45-MSCs (Supple-
mentary Fig. S1).
Several ﬁndings point to an active role of MSCs in ex-
perimental in vitro and in vivo models of different diseases of
the CNS, including Parkinson’s disease, stroke, multiple
sclerosis, traumatic brain or spinal cord injury [8,44–48]. As
an example, animal studies in traumatic brain injury have
shown improved functional outcome when MSCs were in-
jected intracerebrally or intravenously [49,50]. Human MSCs
were beneﬁcial after spinal cord injury due to the increase in
axonal sprouting and in the number of surviving rat cortical
neurons in vivo [51]. Further underlining the importance of
MSCs, there are 77 clinical trials registered using MSCs in
neuropathological conditions (www.clinicaltrials.gov, website
of the National Institutes of Health, Bethesda, MD, search for
‘‘mesenchymal stem cells and CNS,’’ October 2014, eg, re-
garding Parkinson’s disease: NCT01446614).
The regeneration of injured neuronal cells and the cor-
responding ﬁber projections are of great interest with respect
to the described neurological diseases. Organotypic brain
slices that can be maintained in culture for several weeks
facilitate the study of cellular interactions and mechanisms
in this context. Furthermore, this technique represents a
powerful tool for the development of ex vivo models of
neurological disorders and to investigate approaches for
potential stem cell therapies (for review see Daviaud et al.
[52]). For example, MSCs revealed a signiﬁcant neuropro-
tective effect in ischemia models of organotypic hippo-
campal slices [19,53]. In organotypic spinal cord slices,
topically applied MSCs survived, migrated into the slice,
and promoted host neurite extension [11,12] and axonal
outgrowth from the cortex to the spinal cord [13]. Here, we
describe a beneﬁcial effect of BM-MSC preparations with a
particular focus on the clinically relevant parameter of ax-
onal outgrowth in the dopaminergic system. Our data indi-
cate that SL45-MSCs are more potent than bulk BM-MSCs.
Therefore, SL45-MSCs appear to be particularly well suited
to promote neuro(re)generation ex vivo.
Our ﬁndings show that MSC preparations derived from a
deﬁned cell population enriched for primary MSCs are ad-
vantageous in different aspects. (i) SL45-MSCs have a
higher ﬁber growth promoting potential compared to con-
ventional bulk BM-MSCs. (ii) A more homogenous MSC
population can be obtained much faster starting from pre-
enriched CFU-f, allowing for a shorter expansion phase in
vitro, and hence a lower risk of culture prone alterations or
mutation accumulations on the MSC population. (iii) Due to
the more homogeneous population derived from enriched
primary MSCs, the risk of contamination with alloreactive
immune cells might potentially be lower. Summarizing, we
suggest the use of cell material that is more homogeneous
and highly enriched in CFU-f activity as a starting point for
cell therapeutic development. This is in line with previously
published studies and their conclusions [1,3,26,28,54].
Earlier studies were based on the assumption that the neu-
roregenerative effects ofMSCs are caused by the replacement of
damaged cells by differentiation into neurons or glia [55,56].
However, the current opinion favors a model of regeneration
induced by the release of soluble factors, such as trophic factors.
Thus, the capacity of MSCs to actively alter the microenvi-
ronment via these factors may contribute more signiﬁcantly to
tissue repair than their plasticity [16,24,47]. Our ﬁndings also
suggest a stimulating effect mediated via soluble secreted fac-
tors as the main reason for the observed impact on ﬁber growth,
as the cells where plated underneath the co-cultures without
direct contact to the brain slices in our study. This hypothesis is
in line with ﬁndings by other groups, demonstrating the secre-
tion of trophic factors byMSCs, includingBDNF,NGF,GDNF,
FGF2, and the vascular endothelial growth factor [9,18,57–59].
We detected the mRNA of the growth factors BDNF,
CNTF, FGF2, GDNF, HGF, IGF1, NGF, and NRG1 by qPCR
in all assessed cell samples. The signiﬁcantly higher ex-
pression of BDNF and FGF2 in the SL45-MSC population,
which has exemplarily been conﬁrmed on the protein level
for BDNF, could be a reason for the more pronounced effect
evoked by the sorted SL45-MSC population as compared to
the classically isolated bulk BM-MSCs. This might result
from the homogeneity of the populations with SL45-MSCs
where the cells express similar levels of growth factors, while
the more heterogeneous bulk BM-MSCs consist of a mixture
of both secreting and non-secreting cells.
The observed growth promoting effect of the growth
factor producing MSC populations in the dopaminergic
projection system is not surprising, taking into account that
previous studies have shown the beneﬁcial effects of BDNF,
GDNF, and FGF2 on mesencephalic dopaminergic neurons
[60–62]. These growth factors are considered to mediate
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dopaminergic neuronal survival and neuroprotection. Thus,
they had become potential candidates for the therapy of
Parkinson’s disease [63–66]. For example, BDNF provides
support for both developing and adult dopaminergic neurons
[67–70]. So BDNF resulted in enhanced survival of tyrosine
hydroxylase-positive neurons and increased growth of ty-
rosine hydroxylase-positive ﬁbers into striatal tissue [71].
GDNF, which is especially important for the development of
embryonic dopaminergic neurons [72], induced neuronal
survival and promoted the innervation of target areas [73–
76]. FGF2 stimulated the proliferation of dopaminergic
progenitor cells, promoted survival and neurite outgrowth of
dopaminergic neurons, and participated in nigrostriatal
pathway formation and target innervation [66,77,78].
The impact of the BDNF application to the brain slice
culture medium was less pronounced than the growth fa-
cilitating properties of both MSC populations under study.
This is in agreement with previous studies showing that the
combined application of neurotrophins (eg, BDNF and
NGF) elicited greater axon growth than treatment with each
neurotrophin alone [79]. Moreover, Crigler et al. revealed
that MSCs express potent neuroregulatory molecules in a
restricted manner in addition to growth factors like BDNF
and NGF. These growth factors may further contribute to
MSC-induced effects on neuronal survival and nerve re-
generation [9].
Conclusion
In conclusion, both MSC preparations exerted highly
beneﬁcial effects on ﬁber outgrowth in organotypic brain
slices of the dopaminergic system well above the level of
untreated controls, and had also a stronger effect than the
positive control BDNF. Thus, MSCs appear to be very well
suited to promote neuro(re)generation. The outcome was
dependent on the isolation and expansion conditions and we
could show that the more homogeneous sorted SL45-MSCs
were more potent in stimulating ﬁber growth, indicating an
enrichment of cells that are responsible for the observed re-
generative and trophic effects. The higher expression levels
of nestin, BDNF, and FGF2 in SL45-MSCs compared to
classically isolated BM-MSCs may serve as an explanation
for the higher potential in stimulating ﬁber growth as dem-
onstrated in this study.
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Adipogenesis. Five thousand cells/cm2 were seeded in
maintenance medium and expanded. At a conﬂuency of
80%, medium was replaced by adipogeneic differentiation
medium [Dulbecco’s modiﬁed Eagle’s medium (DMEM)/
F12 (1:1; PAA Laboratories, GmbH, Co¨lbe, Germany), 5%
rabbit serum, 3.925mg/L dexamethasone, 10mg/L insulin,
111.1mg/L 3-isobutyl-1-methylxanthin, 35.76mg/L in-
domethacine, and 10mM HEPES (all from Sigma-Aldrich)
supplemented with Pen/Strep (100U/mL and 100 mg/mL,
respectively; all from PAA Laboratories)]. This medium
was partly (50%) changed every 2–3 days. After 7 days,
cells were ﬁxed and adipogenesis was analyzed.
Chondrogenesis. About 250,000–500,000 cells were
centrifuged in 1mL maintenance medium in a 15mL-falcon
tube at 270 g for 3min. After 24 h incubation at 37C, me-
dium was replaced by chondrogeneic differentiation medium
[DMEM/F12 (1:1; PAA Laboratories), 10% fetal calf serum
(FCS; PAA Laboratories), 39.25mg/L dexamethasone, 1%
ITS-Premix, 37.84mg/mL l-ascorbic acid 2-phosphate (all
from Sigma-Aldrich, Taufkirchen, Germany), 46.24mg/mL
proline, and 10 ng/mL transforming growth factor beta 1
(Peprotech) supplemented with Pen/Strep (100U/mL and
100mg/mL, respectively; all from PAA Laboratories)]. This
medium was partly (50%) changed every 2–3 days. After 21
days, chondrogenesis was analyzed.
Osteogenesis. Five thousand cells/cm2 were seeded in
maintenance medium and expanded. At a conﬂuency of
80%, medium was replaced by osteogenic differentia-
tion medium [DMEM/F12 (1:1; PAA Laboratories), 10%
FCS (PAA Laboratories), 39.25 mg/L dexamethasone,
2.16 mg/mL b-glycerophosphate, and 25.61 mg/mL l-
ascorbic acid (all from Sigma-Aldrich) supplemented with
Pen/Strep (100U/mL and 100mg/mL, respectively; all from
PAA Laboratories)]. This medium was partly (50%)
changed every 2–3 days. After 21 days, osteogenesis was
analyzed.
Analysis of differentiation
Adipogenesis. Cells were ﬁxed with 3.7% paraformalde-
hyde (PFA) for 30min, washed with propylene glycol
(Sigma-Aldrich), and incubated in Oil Red O solution
(0.5%; Sigma-Aldrich in propylene glycol) for 10min at
room temperature. Afterward, cells were washed with pro-
pylene glycol until washing reagent remained colorless.
Cells were analyzed with a usual light microscope (Nikon).
Chondrogenesis. Processing of the cell aggregates: Cells
were ﬁxed with 3.7% PFA for 120min and washed twice
with phosphate-buffered saline (PBS) followed by histo-
logical processing: dehydration in graded series of ethanol,
xylole, and melted parafﬁn (Vogel GmbH and Co. KG,
Giessen, Germany), embedding in parafﬁn, hematoxyline/
erythrosine staining [10–15 s in Mayer’s hematoxylin solu-
tion (Merck, Darmstadt, Germany), 10–15 s in 0.6% eryth-
rosine solution (Merck) in 35% ethanol, four drops of acetic
acid/200mL added directly before use], sectioning with a
microtome (Leica RM 2165, 4 mm), mounting on glass
slides, rehydration in series of xylole and graded ethanol,
washing in water, and staining.
Masson’s Trichrome staining: After postﬁxation at 60C for
60min with Bouin’s ﬂuid (Sigma-Aldrich), slices were wa-
shed under running tap water for 10 min at room temperature
(RT). All followed steps were conducted at RT. Slices were
incubated for 10min in Weigert’s iron hematoxylin solution
(Sigma-Aldrich) followed by washing with water for 10min.
Then, slices were stained with ponceau fuchsine solution
[0.75 g/L ponceau de xylidin, 0.25 g/L acid fuchsine (both
Sigma-Aldrich) 1% acetic acid] for 30min, followed by a
rinsing step with 1% acetic acid. Incubation in phospho-
tungstic acid (2%; Sigma-Aldrich) for 2min was conducted
followed by a rinsing step with 1% acetic acid. Finally, slices
were incubated in Fast Green solution (0.2% Fast Green FCF;
Supplementary Table S1. Sequences of Primers for Quantitative Polymerase Chain Reaction
Target Accession ID Forward primer Reverse primer
Bdnf NM_007540.4 GGCTGACACTTTTGAGCACG CAAGTCCGCGTCCTTATGGT
Cntf NM_170786.2 ACCTCTGTAGCCGCTCTATCT AGGCCTTGATGTTTTACATAAGATT
Fgf2 NM_008006.2 CGACCCACACGTCAAACTAC GTTGGCACACACTCCCTTGA
Gdnf NM_010275.2 CTGAAGACCACTCCCTCGG TCTTCAGGCATATTGGAGTCAC
Hgf NM_010427.4 TCAGGACCATGTGAGGGAGAT ACATCCACGACCAGGAACAA
Igf1 NM_010512.4 GGACCGAGGGGCTTTTACTT TCCGGAAGCAACACTCATCC
Mrpl32 NM_029271.2 CAGAGCTGGAGTCGCTTTGT TGAGGATGGATGGTCTCTGGA
Nes NM_016701.3 AGAGGACCCAAGGCATTTCG TGCCTTCACACTTTCCTCCC
Ngf NM_013609.3 GGGGGAGTTCTCAGTGTGTG CACCTCCTTGCCCTTGATGT
Nrg1 NM_178591.2 ACTGGCATCTGTATCGCCCT CTGCCGCTGTTTCTTGGTTTT
Tubb3 NM_023279.2 TTCGTCTCTAGCCGCGTGAA CTCCCAGAACTTGGCCCCTATC
Ubc NM_019639.4 CCCACACAAAGCCCCTCAAT AAGATCTGCATCGTCTCTCTCAC
Bdnf, brain-derived neurotrophic factor; Cntf, ciliary neurotrophic factor; Fgf2, basic ﬁbroblast growth factor; Gdnf, glial cell-derived
neurotrophic factor; Hgf, hepatocyte growth factor; Igf-1, insulin-like growth factor 1; Mrpl32, mitochondrial ribosomal protein L32; Ngf,
nerve growth factor; Nrg1, neuregulin 1; Ubc, ubiquitin.
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Sigma-Aldrich in 1% acetic acid) for 5min, followed by a
last rinsing step with 1% acetic acid.
Safranin O staining: Slices were incubated with Safranin
O solution (0.2%; Sigma-Aldrich in 1% acetic acid) for
10min, followed by a washing step with aqua dest.
Thereafter, slices were stained with Fast Green solu-
tion [0.04% Fast Green (Chroma, Stuttgart, Germany) in
0.2% acetic acid] for 15 s. Slices were then washed with
aqua dest. and embedded when dried. All steps were
conducted at RT.
Embedding of stained slices: After the staining, slices
were washed with 96% ethanol for 3min and rinsed with
xylole. After having dried, slices were embedded with Roti
Histokit (Carl Roth GmbH and Co. KG, Karlsruhe, Germany).
Osteogenesis. Cells were ﬁxed with 3.7% PFA for
30min, washed with PBS and incubated in 1% Alzarin Red
solution (Sigma-Aldrich) for 5min at room temperature.
Afterwards, cells were washed with PBS until washing re-
agent remained colorless. Cells were analyzed, after having
dried with a usual light microscope.
SUPPLEMENTARY FIG. S1. In vitro differentiation assays showing tri-lineage potential of bulk bone marrow-derived
mesenchymal stem cell (BM-MSC) (A–C) and Sca-1 +Lin -CD45 - -derived MSC (SL45-MSC) (D–F) populations starting
from ﬁbroblast colony forming units. (A, D) Adipogenesis was demonstrated by Oil red O staining of lipid globules. (B, E)
Chondrogenesis was conﬁrmed by (B1, E1) Masson’s Trichrom staining (collagene appears green; nuclei are blue-black;
cytoplasm is stained red); (B2, E2) Safranin O staining (proteoglycans appear orange-red; nuclei are blue-black; cytoplasm
is stained gray-green). (C, F) Osteogenesis of bulk BM-MSCs (C1, C2) and SL-45-MSCs (F1, F2) was indicated by
Alizarin Red staining of depositions of calcium mineralized matrix. Micrographs of representative experiments are shown.
Scale bars: (A–E) 100 mm, (F) 200mm.
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The  loss of neurons and  their projections,  is a common  feature of mechanical  injuries of  the brain 
and of neurological diseases. This  loss  results  in  the disturbance of  the affected neuronal  circuits. 
Due  to  their  importance  in  the  regulation of many physiological and psychological  functions  in  the 
CNS, the impairment of dopaminergic projections, resulting in disorders like e.g. Parkinson’s disease, 
depression  and  schizophrenia,  is  especially  severe.  The most  important  dopaminergic  projections 
originate  in  the ventral mesencephalon  (VM)  containing among others  the ventral  tegmental area 
(VTA) and the substantia nigra  (SN) pars compacta. Cell bodies of most of the brains dopaminergic 
cells, which are characterized by the expression of the key enzyme of dopamine (DA) synthesis: the 
tyrosine hydroxylase  (TH), are  located  in the VM. Mesostriatal projections  innervating  the striatum 
(STR), mesocortical  projections  targeting  cortical  regions  such  as  the  prefrontal  cortex  (PFC),  and 
mesolimbic  projections  innervating  in  limbic  regions,  are  distinguished  according  to  their  target 
regions. 





the  complex  cytoarchitecture  in  the  brain  tissue  under  ex  vivo  conditions. Moreover,  the  specific 
innervation of target regions within slice co‐cultures of projection systems corresponds to the in vivo 




mesocortical  (VTA/SN+PFC)  co‐cultures. Furthermore,  it was  intended  (ii)  to analyze possible  toxic 






SUMMARY - Introduction, aim and methods
73
cell  populations  to  be  tested  were  seeded  on  coated  glass  slides  and  placed  underneath  the 
membrane  inserts without direct contact to the co‐cultures. The glass slides were replaced by new 
ones when cells were confluent. 
For  the  analysis of neuroregenerative  processes within  the  co‐cultures, newly built neurites were 





taken,  following biocytin  tracing or  TH  labeling, were used  for  the quantification of  fiber density, 
applying  automated  image  processing  procedures.  The  percentage  of  pixels  belonging  to  fibrous 
structures was determined using this procedure.  
In  addition  to  fiber  growth  analysis,  toxicological  effects  and  the  effects  on  gene  expression 
potentially exerted by the tested substances or cells were analyzed. Necrotic cell death was assessed 
by the quantification of (a) the activity of the lactate dehydrogenase (LDH) released from the tissue, 
and  (b)  propidium  iodide  (PI)  uptake  by  the  cells.  Apoptotic  events  were  detected  by  the 
immunostaining of active caspase 3 in tissue sections and subsequently quantified by the counting of 
active  caspase  3‐positive  cell  bodies.  Further,  gene  expression  in  co‐cultures  and  cells  has  been 




Cyclic  adenosine/guanosine monophosphates  (cAMP/cGMP)  are  second messengers  that mediate 
many important signaling pathways within a cell. The degradation of cAMP and cGMP by 3’,5’‐cyclic‐
nucleotide phosphodiesterases  (PDEs)  inactivates  these pathways.  In  the work presented here, we 
focused  on  two  PDE  families:  PDE2  and  PDE10.  As  there  is  only  one  gene/isoform  (PDE2A  and 
PDE10A,  respectively)  belonging  to  each  of  these  two  families,  I will  refer  to  them  as  PDE2  and 
PDE10, in the following. Both PDE2 and PDE10 are strongly expressed in the STR. 
With  the  first experiments,  IC50 values of  the  tested PDE  inhibitors  (PDE‐I) were determined, using 
human purified proteins from each PDE family. It was shown that both the inhibitors of PDE2 (BAY60‐
7550, ND7001) and of PDE10 (MP‐10) are highly potent and highly specific for the respective isoform. 
In addition,  the  cGMP  level was measured  following  the PDE2‐I application  to HEK293  cells  stably 








PDE2 and PDE10  in the co‐cultures was of  interest. Both PDE  isoforms were detected on fibers and 
cell bodies  in VTA/SN and STR,  respectively. No co‐localization of  the PDE2 or PDE10 with TH was 
found. 
Following  the  characterization  of  substances  and  co‐cultures  as  described  above,  the  co‐cultures 
were treated with BAY60‐7550, ND7001 and MP‐10. The biocytin tracing and  immunohistochemical 





The  dihydropyridine  derivative  nimodipine  is  a  specific  inhibitor  of  L‐type  voltage  gated  calcium 
channels with a vasodilatory effect, preferentially on cerebral blood vessels. Additionally, nimodipine 
was shown to inhibit calcium channels that are expressed by neurons. Studies in animal models and 








growth  quantification  following  treatment  with  10 µM  nimodipine  revealed  that  there  was  no 
significant  change  in  fiber  density  in  the  border  region  between  the  two  brain  slices  of  the  co‐
cultures in comparison to vehicle control co‐cultures (0.1% ethanol). Instead, it was found that 10 µM 
nimodipine induced the activation of caspase 3. In contrast, the number of active caspase 3‐positive 






To  get  some  insight  into  the mechanisms,  underlying  the  observed  enhanced  neurite  outgrowth 
induced by 0.1 µM and 1 µM nimodipine,  the expression  levels of  selected genes were quantified 
with  qPCR,  following  cultivation  and  treatment.  The  genes  were  coding  for  (a)  glial  (Gfap)  and 
oligodendrocytic structure proteins (Mal, Mog, Plp1), (b) calcium binding proteins (Pvalb, S100b) and 
(c)  immediate  early  genes  (Arc,  Egr1,  Egr2,  Egr4,  Fos  and  JunB). With  one  exception  (Egr4),  the 
expression  of  the  genes  of  interest was  not  significantly  altered  by  nimodipine  treatment, when 
compared to the vehicle control samples. 
In conclusion, besides the well‐described indications of nimodipine application (inhibition of delayed 
cerebral  ischemia  caused  by  vasospasms  following  subarachnoid  hemorrhage;  perioperative 
application during  surgery of vestibular  schwannoma),  this  study demonstrates  the  concentration‐




diseases,  research  on  cell  therapies  has  attracted  enormous  attention  in  the  last  decades with  a 
special focus on mesenchymal stromal/stem cells (MSCs). An enhancement of neurite outgrowth by 
MSCs  has  been  shown  in  many  in  vitro  and  in  vivo  studies.  These  findings  indicate  a 
neuroregenerative  potential  of  these  cells  that  seems  to  result  from  the  release  of 
immunomodulatory and trophic factors.  
Bulk MSCs, classically obtained by plastic adhesion, are generally heterogeneous. Different  isolation 
and  cultivation  protocols  yield  MSC  cultures  with  different  proportions  of  the  respective 
subpopulations,  resulting  in  varying  compositions of  the above‐mentioned  secreted  factors. There 
have  been  efforts  to  isolate  and  characterize  homogeneous  subpopulations,  e.g.  with  regard  to 





forming units  (CFU‐f),  (b)  the morphological appearance of  the  rather  small  SL45‐MSCs was more 
homogeneous,  (c)  nestin  was  significantly  higher  expressed  in  SL45‐MSCs,  while  there  was  no 
difference  in βIII‐tubulin expression between  the cell populations  (both proteins are considered as 
markers for mesenchymal cells as well as for progenitors of the mesenchymal and neuronal lineage) 








induced  by  both  bulk  BM‐MSCs  and  SL45‐MSCs, when  compared  to  untreated  and  BDNF‐treated 










and  extrinsic orchestrating  factors.  The  growth‐promoting  effects of  (i)  the modulation  of  second 
messenger  (cAMP,  cGMP)  turnover  with  PDE‐Is,  (ii)  the  partial  blockade  of  calcium  currents  by 





cell  types  of  the  CNS  contribute  to  the  beneficial  effects  of  the  applied  treatments  during  the 
different  phases  of  regeneration. A  better  understanding  of  the  intracellular  signaling  events  and 
their  interactions would  allow  to make use of potential  synergistic  effects of different  treatment, 
more efficiently. 
   





des Gehirns  als  auch  ein  gemeinsamer Aspekt  vieler  neurologischer  Erkrankungen. Dieser  Verlust 
führt zur Störung betroffener Projektionsbahnen. Bedingt durch die große Bedeutung dopaminerger 
(DAerger)  Projektionen  für  physiologische  und  psychologische  Funktionen,  wie  die  gezielte 
Ausführung  von  Bewegungsabläufen,  Belohnung  und  Kognition;  sind  Beeinträchtigungen  dieser 
Projektionssysteme  besonders  schwerwiegend  und werden  in  Krankheitsbildern, wie  zum Beispiel 
Morbus  Parkinson,  Depression  oder  Schizophrenie  deutlich.  Die  wichtigsten  DAergen 
Projektionsbahnen haben ihren Ursprung im ventralen Mesencephalon (VM), das unter anderem das 
ventrale  tegmentale  Areal  (VTA)  und  die  Substantia  nigra  (SN)  pars  compacta  enthält.  In  diesen 
Regionen des Gehirns befindet sich ein Großteil der DAergen Zellkörper des Gehirns, die sich durch 
die  Expression  des  Schlüsselenzyms  der  Dopamin  (DA)‐Synthese,  der  Tyrosin‐Hydroxylase  (TH), 
auszeichnen.  Die  einzelnen  Projektionsbahnen  werden  nach  den  Zielgebieten  unterschieden: 




nach  Schädel‐Hirn‐Traumen,  adäquat  behandeln  zu  können,  müssen  neue  Therapieformen 
entwickelt  und  geprüft  werden.  Dafür  sind  geeignete  Modellsysteme  notwendig.  In  den  letzten 
Jahrzehnten  wurden  organotypische  Hirnschnittkulturen  als  vielseitige  und  effektive  Modelle 
etabliert. Ein entscheidender Vorteil dieser Modelle gegenüber Primärzellkulturen  ist der Erhalt der 
komplexen Cytoarchitektur des Gehirngewebes unter Kulturbedingungen. Darüber hinaus wurde  in 
Co‐Kulturen  aus  zwei  oder  mehreren  Hirnschnitten  gezeigt,  dass  das  zielgerichtete  Auswachsen 
neuronaler  Fortsätze  unter  ex  vivo‐Bedingungen  den  in  vivo‐Mustern  entsprechend  erfolgt. 
Gegenüber klassischen in vivo‐Versuchen bieten organotypische Kulturen eine bessere Zugänglichkeit 
zum Probenmaterial und erlauben die genaue Kontrolle des extrazellulären Milieus.  
Ziel  der  hier  dargestellten  Arbeit  war  die  Charakterisierung  verschiedener  Substanzen  und 
Zellpopulationen  hinsichtlich  ihrer  Wirkung  auf  das  neuronale  Faserwachstum  (auch  als 
Neuritenwachstum  bezeichnet)  unter  Verwendung  von  mesostriatalen  (VTA/SN+STR)  und 
mesokortikalen  (VTA/SN+PFC) Gewebe‐Co‐Kulturen. Mögliche  toxische  (Neben‐)Wirkungen  an den 
Co‐Kulturen sollten mit geeigneten Methoden erfasst werden. Weiterhin sollten im Anschluss an die 
Kultivierung eventuelle Einflüsse der Behandlung auf die Genexpression untersucht werden. 
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Überblick über die angewandten Methoden 
Auf  die  Präparation  der  oben  beschriebenen  Co‐Kulturen  aus Hirngewebsschnitten  neugeborener 
Ratten oder Mäuse (P0‐3) folgte die Kultivierung auf semipermeablen Membraneinsätzen für einen 
Zeitraum  von  10‐11  Tagen.  Die  Substanzen  wurden  bei  jedem  Medienwechsel  über  das 
Kulturmedium  appliziert.  Die  zu  testenden  Zellen  wurden  auf  Glasplättchen  unterhalb  der 
Membraneinsätze  ohne  direkten  Kontakt  zu  den  Co‐Kulturen  platziert  und  bei  Konfluenz 
ausgetauscht. 
Zur  Analyse  neuroregenerativer  Prozesse  in  den  Co‐Kulturen  wurden  die  neu  auswachsenden 
Neuriten  mittels  Biocytin‐Tracing  dargestellt  bzw.  die  DAergen  Strukturen  durch 
immunohistochemische  Färbung  von  TH  nachgewiesen.  Für  die  erstgenannte  Methode  wurden 
Biocytinkristalle auf die VTA/SN aufgebracht. Der Tracer wurde von den Zellen aufgenommen und 
anterograd  in die Fortsätze transportiert. Nach Fixierung der Co‐Kulturen wurden die so markierten 
Zellkörper  und  Fortsätze  mit  immunhistochemischen  Methoden  sichtbar  gemacht.  Die 
Quantifizierung  der  Faserdichte  nach  Tracing  oder  TH‐Färbung  erfolgte  an  mikroskopischen 
Aufnahmen  der  Grenzregion  zwischen  den  zwei  Hirnschnitten  einer  Co‐Kultur  mittels  digitaler 
Bildverarbeitung. Dabei wurde der Anteil der Pixel im Bild, der Neuriten zuzuordnen ist, bestimmt.  
Darüber hinaus kamen Methoden zur Untersuchung toxischer Eigenschaften der Substanzen und der 
Wirkung  auf  die Genexpression  in  den  Co‐Kulturen  zum  Einsatz: Die Quantifizierung  nekrotischer 
Zelluntergänge  erfolgte  durch  (a)  die  Aktivitätsbestimmung  der  aus  dem  Gewebe  freigesetzten 
Laktatdehydrogenase  (LDH)  und  (b)  die  Quantifizierung  der  Propidiumiodid  (PI)‐Aufnahme  durch 
beschädigte  Zellen.  Apoptotische  Vorgänge  infolge  der  Substanzapplikation  wurden  mittels 
Immunfluoreszenz‐Markierung  und  Quantifizierung  des  frühen  Apoptose‐Markers,  der  aktivierten 
Caspase 3, in den Gewebeschnitten erfasst. Weiterhin war die Analyse der Expression verschiedener 
Gene  in  den  Co‐Kulturen  und  Zellen  Gegenstand  der  experimentellen  Arbeiten.  Verwendete 
Methoden  waren  auf  RNA‐Ebene  Microarray‐Untersuchungen  und  quantitative  Echtzeit‐Reverse‐





sind  second  messenger,  über  die  viele  wichtige  Vorgänge  in  der  Zelle  vermittelt  werden.  Die 
„Abschaltung“ des Signals erfolgt enzymatisch durch Phosphodiesterasen (PDEs). In der vorliegenden 
Arbeit  lag der Fokus auf PDE2A und PDE10A. Da dies jeweils die einzigen Isoformen der PDE2‐ bzw. 
ZUSAMMENFASSUNG - Methoden und Ergebnisse
79
PDE10‐Familie  sind,  werde  ich mich  im  Folgenden mit  PDE2  bzw.  PDE10  auf  sie  beziehen.  Eine 
deutliche Expression von beiden PDEs, PDE2 und PDE10, ist im STR gezeigt worden. 




vollständigen  Sequenz  der  humanen  PDE2  transfeziert  war,  führte  zu  einer 
konzentrationsabhängigen Erhöhung von cGMP.  
Mit  weiteren  Versuchen  wurden  organotypische  Co‐Kulturen  (VTA/SN+STR)  im  Anschluss  an  die 
Kultivierung  immunhistochemisch charakterisiert. Neben der Untersuchung der Expression DAerger 




Nach  den  oben  beschriebenen  Charakterisierungen  der  PDE‐Is  und  der  Co‐Kulturen  erfolgte  die 
Behandlung der Co‐Kulturen mit BAY60‐7550, ND7001 und MP‐10, gefolgt von der Quantifizierung 
des neuronalen Faserwachstums mittels Biocytin‐Tracing und nach immunhistochemischer Detektion 
der  TH.  BAY60‐7550  und  ND7001  verstärkten  das  Auswachsen  der  Neuriten,  ähnlich  dem 
Wachstumsfaktor  NGF  (engl.  nerve  growth  factor).  MP‐10  bewirkte  hingegen  keinen 




Das  Dihydropyridinderivat  Nimodipin  ist  ein  spezifischer  Inhibitor  des  spannungsgesteuerten 
Calciumkanals  vom  L‐Typ mit  gefäßerweiternder Wirkung  ‐  vorwiegend  auf  zerebrale  Blutgefäße. 
Zudem ist eine Wirkung der Substanz auf die Calciumkanäle von Neuronen bekannt. Präklinische und 
klinische Studien konnten eine neuroregenerative bzw. neuroprotektive Wirkung von Nimodipin  im 
peripheren  Nervensystem  zeigen,  wobei  der  zugrunde  liegende  Wirkmechanismus  bisher  nicht 
bekannt ist. In der vorliegenden Arbeit sollte in mesokortikalen Co‐Kulturen der Ratte eine mögliche 
Regulation  der  Genexpression  mittels  Microarray‐Untersuchungen  sowie  ein  Einfluss  auf  das 
Auswachsen von Neuriten durch Nimodipin geprüft werden. Die Analyse der Genexpressionsmuster 
in VTA/SN und PFC, die nach der Kultivierung und Behandlung der Co‐Kulturen getrennt voneinander 




Nimodipin  behandelten  Gruppe.  Die  nachfolgende  Quantifizierung  des  Neuritenwachstums  nach 
Behandlung  mit  10 µM  Nimodipin  ergab  jedoch,  dass  diese  Konzentration  der  Substanz  die 
Neuritendichte  in der Grenzregion  zwischen VTA/SN und PFC  im Vergleich  zu Kontroll‐Co‐Kulturen 
nicht  signifikant  veränderte.  Stattdessen  ergaben  toxikologische  Untersuchungen,  dass  10 µM 
Nimodipin  die  Aktivierung  der  Caspase  3  induzierte.  Nach  Behandlung  mit  0,1 µM  und  1 µM 
Nimodipin wurde keine Veränderung der Anzahl aktiver Caspase 3‐positiver Zellen beobachtet. Ein 
Einfluss auf die Freisetzung von  LDH bzw. der Aufnahme von PI wurde bei  keiner der applizierten 
Nimodipin‐Konzentrationen  (0,1 µM‐10 µM)  gefunden.  Eine  erneute Neuritenwachstumsstudie mit 
0,1 µM und 1 µM Nimodipin zeigte eine Erhöhung der Neuritendichte, ähnlich der nach Applikation 
des Wachstumsfaktors NGF. Um Einblick  in den molekularen Wirkmechanismus zu bekommen, der 
dem  verstärkten  Auswachsen  der Neuriten  zu Grunde  liegen  könnte, wurde  im  Anschluss  an  die 
Kultivierung  und  die  Behandlung  mit  0,1 µM  und  1 µM  Nimodipin  die  Expression  von  Genen 
kodierend für (a) Strukturproteine von Gliazellen (Gfap) und Oligodendrozyten (Mal, Mog, Plp1), (b) 
Calcium‐bindende Proteine (Pvalb, S100b) und (c) „Frühe‐Antwort‐Gene“ (Arc, Egr1, Egr2, Egr4, JunB 
und  Fos) mittels  qPCR  untersucht. Mit  einer Ausnahme  (Egr4) wurden  durch  die  Behandlung mit 
Nimodipin  keine  signifikanten  Veränderungen  der  Expression  der  betrachteten  Gene  im  PFC  im 
Vergleich zu den Kontrollgruppen (unbehandelt und Lösungsmittelkontrolle: 0,1% Ethanol) gefunden.  
Mit  dieser  Studie  konnte  am  Beispiel mesokortikaler  Co‐Kulturen  erstmals  gezeigt  werden,  dass 
Nimodipin neben den bisher bekannten Anwendungen (z.B. Verhinderung von verzögerter zerebraler 
Ischämie  durch  Vasospasmen  infolge  von  Subarachnoidalblutung,  perioperative  Applikation  bei 







eine  Verstärkung  des  neuronalen  Faserwachstums  zeigte,  scheint  auf  die  Sezernierung 
immunmodulatorischer  und wachstumsfördernder  Faktoren  zurückzuführen  zu  sein.  Bei  klassisch 
durch  Adhäsion  auf  Plastikoberflächen  gewonnenen  MSCs  handelt  es  sich  um  eine  heterogene 
Zellpopulation (bulk MSCs), wobei die Anteile der entsprechenden Subpopulationen in Abhängigkeit 
von  Isolierungs‐  und  Kultivierungsprotokollen  variieren  können. Daraus  ergeben  sich  voneinander 
abweichende  Zusammensetzungen  der  freigesetzten  Faktoren.  In  der  Vergangenheit  gab  es 
Bemühungen,  einzelne  Subpopulationen  zu  isolieren  und  zu  charakterisieren.  Dies  erfolgt  zum 
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Beispiel  anhand  der  exprimierten  Zelloberflächenmarker  mittels  Fluoreszenz‐aktivierter 
Zellsortierung ausgehend von bulk MSCs. Eine der bisher beschriebenen Subpopulationen  sind die 
Sca‐1+Lin‐CD45‐(SL45)‐MSCs.  
In  der  vorliegenden  Studie  sollten  aus  dem  Knochenmark  (engl.  bone  marrow,  BM)  von  adulten 
Mäusen  gewonnene  bulk  BM‐MSCs mit  der  daraus  isolierten  SL45‐MSC‐Subpopulation  verglichen 
werden. Die Grundcharakterisierung der beiden Zellpopulationen zeigte, dass sich die SL45‐MSCs von 
den  bulk  BM‐MSCs  durch  einen  105‐fach  höheren  Anteil  an  kolonieformenden  Einheiten  (CFU‐f) 
unterschieden. Zudem waren sie von gleichmäßigerer Morphologie, mit vorwiegend kleineren Zellen. 
Die Expression von Nestin war in den SL45‐MSCs signifikant höher, während es keinen Unterschied in 
Bezug  auf  die  Expression  von  βIII‐Tubulin  gab.  Beide  Proteine  gelten  als  Marker  sowohl  für 





Zur  Bestimmung  wachstumsfördernder  Eigenschaften  der  MSC‐Populationen  auf  Neuriten  in 
mesokortikalen  Co‐Kulturen  der  Maus  wurden  bulk  BM‐MSCs  und  SL45‐MSCs  jeweils  auf 
Glasplättchen ohne direkten Kontakt  zu den Gewebe‐Co‐Kulturen unterhalb der Membraneinsätze 
eingebracht. 
Beide  untersuchten  Zellpopulationen  steigerten  das  Neuriten‐Wachstum  in  den  Co‐Kulturen 
signifikant,  wobei  der  Effekt  der  SL45‐MSCs  stärker  (signifikant  höhere  Neuritendichte  als  nach 
Behandlung mit BDNF) ausfiel als der der bulk BM‐MSCs. Eine mögliche Erklärung dafür könnte u.a. 







Das  erneute  Auswachsen  von  Neuriten  infolge  mechanischer  Schädigung  oder  neurologischer 
Erkrankungen umfasst ein komplexes Zusammenspiel verschiedener extrinsischer und  intrinsischer 
Faktoren. Die wachstumsfördernden Wirkungen  (i) der PDE‐Is, die  in die Deaktivierung der  second 
messenger cAMP/cGMP eingreifen, (ii) der teilweisen Blockade von Calciumströmen durch Nimodipin 
und (iii) der parakrinen Effekte von MSCs, z.B. durch die Freisetzung von Wachstumsfaktoren; wie es 




Die molekularen Mechanismen,  die  den  beschriebenen  Effekten  zugrunde  liegen, müssen  jedoch 
Gegenstand  zukünftiger  Studien  sein. Darüber hinaus  ist bisher nicht  vollständig  verstanden, über 
welche  Zelltypen  des  ZNS  die  Effekte  der  Behandlungen  in  den  verschiedenen  Phasen  der 
Regeneration vermittelt werden. Mit einem umfassenden Verständnis der intrazellulären Signalwege 
und  deren  Wechselwirkungen  könnten  mögliche  synergistische  Effekte  von  verschiedenen 
Behandlungen effizient genutzt werden. 
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